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In 2017, the U.S. Department of Health and Human Services acknowledged the 
U.S. opioid epidemic, although the first wave was traced to the 1990s. As each year 
passed, the overall incidence and prevalence of opioid misuse, as well as the human and 
economic costs, increased. Current conventional misuse interventions targeting opioid 
prescription incidence have provided little amelioration to the public health burden and 
are projected to have a negligible impact in the coming years. Although current analytic 
approaches have been instrumental in identifying the risk factors associated with opioid 
misuse, these analytic approaches have been limited. The majority of these analytic 
approaches have been variable-centered, which help identify risk factors by estimating 
relationships on variables, not persons at risk. Person-centered approaches provide the 
ability to not only identify risk factors but also identify previously unobserved risk 
profiles. To identify opioid misuse risk factors and at-risk groups, I first performed a 
systematic literature review. I identified all known risk factors associated with opioid 
misuse from January 1999 to January 2019 from the review. I then used a variable-
centered approach on the 2017 National Survey on Drug Use and Health (NSDUH) 
among noninstitutionalized U.S. adults aged 18 and older to test the associations of 
known risk factors by means of logistic regression. The logistic regression findings 
indicated that age, residence, employment, criminality, overall health, mental health, and 
other substance dependences/abuses were significant population-level risk factors. The 




opioid misuse subgroups: (1) single opioid users (25.7% of sample); (2) prescription or 
combination opioid user (4.7% of sample); (3) prescription opioid user (14.5% of 
sample); and (4) mixed opioid use (55.2% of sample). Prescription or combination 
opioid users were considered to be the highest risk subgroup because they had the 
highest conditional probability of using a combination of heroin and prescription 
opioids. This subgroup represents a possible transition group from purely prescription 
opioids to combinatorial use. Findings revealed that the opioid epidemic is multifaceted 
and should use both targeted variable-centered and person-centered approaches to tailor 
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Characterizing the U.S. Opioid Epidemic 
The U.S. Department of Health and Human Services (2019) declared a public 
health opioid emergency in 2017, although the first wave of the epidemic can be traced 
to the early 1990s. Currently, estimates indicate that 21 to 29% (approximately 11.4 
million) of U.S. patients medically prescribed opioids for chronic pain misuse them 
(National Institute on Drug Abuse, 2019; U.S. Department of Health and Human 
Services, 2019). Of those misusing, 8 to 12% develop a misuse disorder (U.S. 
Department of Health and Human Services, 2019). This misuse can lead to opioid 
dependence and abuse in medical users, as well as nonmedical users (Jones, 2017).  
Opioid misuse is defined as taking prescription pain relievers in a manner not 
indicated by a health professional. This type of misuse includes using another 
individual’s prescription, acquiring pain relievers illegally (i.e., without a prescription; 
drug dealer), or taking the pain reliever for a desired psychological and/or physiological 
effect (i.e., to get high; National Institute on Drug Abuse, 2019; U.S. Department of 
Health and Human Services, 2019). Misuse also involves the use of illicit opioid 
substances like heroin. In 2017, 886,000 people reported using heroin, with 81,000 using 
for the first time (National Institute on Drug Abuse, 2019) and 652,000 estimated to 
have a use disorder (Center for Behavioral Health Statistics and Quality, 2018). 




opioids (U.S. Department of Health and Human Services, 2019), and 4 to 6% of 
individuals misusing prescription opioids transitioned to heroin (U.S. Department of 
Health and Human Services, 2019). Regardless of which was used first, opioids have a 
highly addictive nature, with various health consequences that become more apparent 
year to year. 
Opioid use affects multiple organ systems, and with continuous use has been 
shown to deteriorate these systems, as well as cause various negative health outcomes. 
General health issues include constipation, sleep apnea, bone fractures, and 
hypothalamic-pituitary-adrenal axis dysregulation (U.S. Department of Health and 
Human Services, 2019). Other health risks associated with intravenous opioid use are an 
increase in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection 
(U.S. Department of Health and Human Services, 2019). An indirect health risk, but one 
of note, is the rising incidence of children born with withdrawal syndrome because of the 
mother’s opioid use and misuse (National Institute on Drug Abuse, 2019). The ultimate 
consequence of misuse is death by overdose, which is increasing in the United States. 
Costs and Projections of Opioid Misuse 
Human Cost of Opioid Misuse 
A 30% upsurge in opioid overdose was reported from July 2016 through 
September 2017 in 45 states (U.S. Department of Health and Human Services, 2019). 
Related deaths have increased 345% from 2001 to 2016 (i.e., from 33.3 to 130.7 deaths 
per million population), with more than 42,000 overdose deaths reported in 2016—




Opioid misuse led to more than 1.68 million years of life lost in 2016 (Gomes, Tadrous, 
Mamdani, Paterson, & Juurlink, 2018). Of all opioid overdoses, 40% of deaths involved 
prescription opioids (National Institute on Drug Abuse, 2019). Current estimates indicate 
that over 130 people die every day from opioid overdose (National Institute on Drug 
Abuse, 2019), and the public health burden will only grow since projections estimate a 
61% increase by 2025 (Chen et al., 2019). A projected status quo model—that is, a 
model based on if current misuse and overdose death trajectories continue unabated—
estimated that there will be 235,000 opioid-related deaths (i.e., 85,000 from prescriptions 
and 150,000 from heroin) from 2016 to 2020 (Pitt, Humphreys, & Brandeau, 2018). 
Furthermore, the same status quo model projected 510,000 opioid-related deaths (i.e., 
170,000 from prescriptions and 340,000 from heroin) from 2016 to 2025 (Pitt et al., 
2018). The cost in human life of opioid abuse is heavy and may be underreported (Seth, 
Rudd, Noonan, & Haegerich, 2018). 
Economic Costs of Opioid Misuse 
The economic burden of opioid misuse was estimated to have cost the U.S. over 
$78.5 billion in 2013, which included both nonfatal and fatal costs (Florence, Zhou, Luo, 
& Xu, 2016). These estimates include amounts calculated from healthcare, substance use 
treatment, justice system, and lost productivity costs. The aggregate societal cost was 
higher in nonfatal costs ($56.990 billion) than in fatal costs ($21.513 billion) (Florence 
et al., 2016). Moreover, while opioid misuse and overdose deaths are projected to 




of the opioid epidemic because mainstream universal interventions targeting opioid 
misuse have had mixed results. 
Projected Trajectories of Opioid Misuse Interventions 
Current predictive models for interventions targeting the decrease of prescription 
opioid misuse are bleak; they project a decrease of overdose deaths by only 3.0 to 5.3% 
(Chen et al., 2019). If frontrunner interventions designed to decrease the incidence of 
misuse continue on a modest trajectory, they would have a minimal impact on the 
projected course of overdose deaths between 2016 and 2025 when compared to a 
constant-incidence model (Chen et al., 2019). The modest-incidence-decrease model 
projected an overall reduction of 3.8%, which is a 2.0% decrease in illicit opioid deaths 
and 10.7% decrease in prescription opioid deaths (Chen et al., 2019). The worst-case 
scenario model, in which opioid fatality and incidence would stabilize by 2025, 
projected a continuous increase of overdose deaths for which any level of intervention 
would have no decreasing effect (i.e., bend the curve) on overdose deaths (Chen et al., 
2019). The majority of deaths (88%) in this model would be assignable to illicit opioids 
(Chen et al., 2019). The cumulative effect on the number of overdose deaths from 2016 
to 2025 from misuse interventions in the worst-case scenario model would be 3.0% to 
4.3% (Chen et al., 2019). The best-case scenario model, in which the decrease in 
incidence of prescription opioid misuse would be at a 50% higher rate than historical 
trends, would decrease overdose deaths by 5.3%—a 2.8% decrease in illicit opioid 
deaths and 14.9% decrease in opioid prescription deaths (Chen et al., 2019). 




prevention and intervention programs will have minimal effects on opioid misuse 
overdose deaths.  
Pitt et al. (2018), in a similar modeling study, projected how 11 interventions 
under a status quo trajectory would change overdose deaths, life years, and quality-
adjusted life years. Over a projected 5-year intervention, the promotion of naloxone 
availability, needle exchange programs, medication-assisted treatment, and psychosocial 
treatment were found to increase life years and quality-adjusted life years, as well as 
reduced opioid deaths. In the same projection, reduced prescribing for pain patients and 
surfeit opioid management increased life years and quality-adjusted life years as it 
reduced opioid prescriptions and related deaths. However, in this model, prescription 
users with dependence switched to heroin use. The switch to heroin among patients with 
reduced prescriptions for pain and excess opioid management interventions were found 
to increase heroin-related deaths. The largest projected reduction of deaths was 4%, 
accomplished by increasing the availability of naloxone. Similar to Chen et al.’s (2019) 
projections, Pitt et al. (2018) found that no single policy in their 5- and 10-year 
projections substantially intervened on opioid-related deaths. 
Overall, the findings by Chen et al. (2019) and Pitt et al. (2018) suggest that 
current intervention strategies must be tailored to have a meaningful impact on the 
opioid epidemic and allude to the multidimensional and dynamic nature of the epidemic. 
Targeted interventions and policies are needed to improve on misuse outcomes, as well 
as mitigate the associated public health burden. Usually, this improvement is 




characteristics, socioecological indicators, general and mental health status, as well as 
co-substance dependence and abuse. In this manner, the most successful public health 
strategies identify the salient factors that can be hidden in the epidemiological data to 
address unique, high-risk subgroups.  
Risk Factors Associated with Opioid Misuse 
Critical to curbing the impact of the opioid epidemic is gaining an understanding 
of the etiology of misuse—that is, the factors leading to dependence and abuse. Of 
importance is understanding overdose risk profiles and deaths across demographic 
characteristics, such as age, race/ethnicity, biological sex, sexual identity, educational 
attainment, and employment. Epidemiological, descriptive, and variable-centered 
approaches—methods to describe the associations between variables—have used various 
demographic characteristics to independently and collectively assess their relationship to 
opioid misuse that leads to dependence and abuse. When analyzing these 
epidemiological studies, the media has primarily focused on middle-income, non-
Hispanic Whites; however, misuse and overdose deaths occur in other groups depending 
on risk and protective factors. Non-Hispanic Whites and Native Americans/Alaska 
Natives are the groups most likely to be impacted by opioid overdose deaths; 
nevertheless, affected groups increase or decrease in rates of overdose death from year to 





Current Epidemiological Trends in the U.S. Opioid Epidemic 
Scholl et al. (2019) reported that from 2016 to 2017, opioid-involved overdose 
deaths increased among both sexes and among those over the age of 25. The largest 
increase reported was among males aged 25 to 44 years old (i.e., increase of 4.6 per 
100,000). During this same time span, overdose deaths increased in non-Hispanic 
Whites and Blacks, as well as Hispanics, with the largest relative change occurring 
among non-Hispanic Blacks. Prescription opioid-related death rates remained stable 
across all racial/ethnic groups in most states. At the same time, heroin-related overdose 
deaths declined among males and the 15-24 age group. While heroin-related overdose 
death rates declined overall in 2017 compared to 2016, death rates increased among 
older adults ages 55 and above. Those over 65 had the largest relative rate increase. 
Death rates also increased among racial/ethnic groups, and non-Hispanic Blacks had the 
largest relative rate increase.  
Studies Examining Opioid Misuse Risk Factors 
The epidemiological findings presented by Scholl et al. (2019) revealed a 
complex relationship between sociodemographic factors and opioid misuse. Age was a 
significant indicator, particularly among younger age groups. Older adults, previously 
overlooked, have presently become a major focus. Among older adults, the younger age 
groups of 50-64 have been found to be most at-risk of opioid misuse when in chronic 
pain (Chang, 2018) and when using emergency department services (Choi, DiNitto, 
Marti, & Choi, 2018). Age has generally been a definitive risk factor in opioid misuse, as 




epidemiological studies, race/ethnicity had a similarly tenuous relationship with opioid 
misuse as did age. The relationship of race/ethnicity to opioid misuse must be 
contextually addressed, as myriad other health disparity studies on any given outcome 
have demonstrated. The current opioid misuse literature has found that race/ethnicity 
alone is not a strong predictor for misuse when considered in the context of other 
biopsychosocial factors. 
For instance, race/ethnicity must be considered in conjunction with other 
sociodemographic factors like sex/gender. Nicholson and Vincent (2018) observed that 
the prevalence of prescription opioid misuse varied among Black women and men. 
Nicholson and Vincent found that among Black women, lower socioeconomic status 
(SES) increased the probability of misuse, while older age, higher educational 
attainment, and rural residence lowered the probability. Substance diversion from “drug 
dealers,” illicit substances, marijuana, nicotine use, other prescription misuse, and poor 
self-reported health increased the probability of misuse among Black men. Sex/gender 
independently was less clear in its relationship with opioid misuse (Nicholson & 
Vincent, 2018). Although men have been found to be more likely to misuse opioids at 
the population level, women in certain cases have been found to be at higher odds of 
misusing (Huhn, Tompkins, Campbell, & Dunn, 2019; Serdarevic, Striley, & Cottler, 
2017). For example, women catastrophizing pain—perceiving pain in a more intense and 
exaggerated manner compared to others—were more likely to misuse opioids (Huhn, 
Tompkins, Campbell, & Dunn, 2019). Other studies have found women to have higher 




Nonmedical prescription opioid use among females 24 and older were also found to use 
other illicit substances at 1.9 higher odds compared to males (Tetrault et al., 2008).  
Other socioecological and sociodemographic variables (although understudied), 
like criminality and sexual identity, have been associated with misuse. Individuals with 
criminality or involvement with the legal system had a prevalence of 22.4% for 
prescription opioid use, 33.2% for prescription opioid misuse, 51.7% for prescription 
opioid use disorder, and 76.8% for heroin use (Winkelman, Chang, & Binswanger, 
2018). Winkelman et al. (2018) suggested that individuals using opioids have high levels 
of criminal justice system involvement, as well as complex health profiles. Similarly, 
Pierce et al. (2017) found that, when adjusting for cocaine use, sex/gender, age, and birth 
cohort, individuals testing positive for opioid use had higher rates of criminality. Gender 
differences were observed in females, with a larger rate ratio increase compared to males 
in opioid use initiation. Though findings appear clearly defined, both studies adjusted 
their models to account for multiple sociodemographic characteristics.  
Sexual minorities, such as those identifying as gay/lesbian or bisexual, have been 
situationally reported to be at risk of misusing opioids (Duncan, Zweig, Hambrick, & 
Palamar, 2019; Kecojevic, Wong, Corliss, & Lankenau, 2015; Schuler, Rice, Evans-
Polce, & Collins, 2018). For instance, Duncan et al. (2019) found that those identifying 
as bisexual or gay/lesbian were at 78% or 115% increased odds for opioid misuse than 
heterosexuals, respectively. Stratifying analyses by sex, Duncan et al. observed that 
these associations became limited to females only. Inversely, Kecojevic et al. (2015) 




suffered physical abuse and high levels of perceived stress during childhood were more 
likely to report opioid misuse. Schuler et al. (2018) took a more holistic approach to 
understand the disparities between sexual minorities and those identifying as 
heterosexual, accounting for not only sexual identity and sex/gender but also age and 
other substance dependence/abuse. Similar to Duncan et al. (2019), Schuler et al. (2018) 
found that, when compared to heterosexual women, bisexual women had high odds at all 
ages in all substance dependence/abuse outcomes. Those identifying as gay/lesbian 
individuals between the ages of 18 and 25 had elevated odds for substance use when 
compared to same-sex/gender heterosexuals.  
General health and its role in opioid misuse is also not clearly understood. Most 
individuals who are prescribed opioid medications are attending to some type of physical 
pain. In some cases, in adjusted models, those who identified as being in poor health 
were more likely to misuse opioids (Nicholson & Vincent, 2018). Opioid misuse in light 
of mental health issues is also unclear because epidemiological studies have not focused 
on the role of mental health outcomes such as depression, anxiety, or suicidality. 
However, some mental health prevalence on opioid misuse and the interplay of mental 
health issues—such as negative emotions from chronic pain (Garland et al., 2018), 
mental illness (Novak, Feder, Ali, & Chen, 2019; Prince, 2019), and suicidality 
(Ashrafioun, Heavey, Canarapen, Bishop, & Pigeon, 2019; Conroy & Bjork, 2018; 
Prince, 2019)—have been found to have mixed associations to opioid misuse. 
Health insurance has also been identified as a having a role in opioid misuse, 




profiteering nature of insurance companies, there is a perpetuation of suboptimal pain 
management that facilitates opioid misuse. Thus, having health insurance actually 
encourages opioid misuse, regardless of the larger macroeconomic motivations that lead 
to the facilitation of opioid access to patients. Wettstein (2019), for instance, observed a 
dose-response relationship with access to insurance on opioid overdose deaths. 
However, the young adult provision of the Affordable Care Act was found to reduce 
opioid death among 19- to 25-year-olds. Specifically, for every 1% more coverage, there 
is a 19.8% reduction of opioid deaths among young adults (Wettstein, 2019).  
The use of other substances, whether legal, illicit, or prescribed, has also been 
linked to misuse. Most concurrent substances have been positively associated with 
opioid misuse (Degenhardt et al., 2013; Grigsby & Howard, 2019), such as nicotine and 
tobacco dependence (John et al., 2019; Rajabi, Dehghani, Shojaei, Farjam, & 
Motevalian, 2019), alcohol overdose (Fernandez et al., 2019), sedatives (Kelley et al., 
2019), methamphetamines (Ellis, Kasper, & Cicero, 2018), tranquilizers (Jones, Mogali, 
& Comer, 2012; Maree, Marcum, Saghafi, Weiner, & Karp, 2016), and other analgesics 
(Peckham et al., 2018). Marijuana tends to have a tenuous relationship; use has been 
associated with both increased and decreased opioid use (Campbell, Hall, & Nielsen, 
2018). Regardless of the findings, to determine the various risk factors that provide 
context for opioid misuse, two methodological approaches predominate: variable-




Variable-Centered Versus Person-Centered Approaches 
The literature is unclear regarding the contributing patterns of opioid misuse and 
patterns of biopsychosocial characteristics associated with increased likelihood of opioid 
use. Although variable-centered approaches clarify the relationship of variables to 
variables based on averages (Howard & Hoffman, 2017; Laursen & Hoff, 2006; Morin, 
Gagne, & Bujacz, 2016), it is generally acknowledged that these approaches cannot 
easily examine outliers (Gunver, Senocak, & Vehid, 2017; Prykhodko, Prykhodko, 
Makarova, & Pugachenko, 2017; Rousseeuw & Hubert, 2011). In addition, variable-
centered approaches assume linear additive relationships between variables, which at 
times can be limiting since behavioral health risk factors are dynamic and do not 
accumulate in an additive fashion (Bámaca-Colbert & Gayles, 2010; Meeusen, 
Meuleman, Abys, & Bergh, 2018). Furthermore, regressive approaches are also often 
limited by variation or the lack thereof. If variables are collinear, the variation is 
decreased, and the relationship becomes tenuous. Often, the approach requires a more 
parsimonious model whereby important indicators are dropped from the model (Howard 
& Hoffman, 2017). Some of these indicators may be critical to determine salient risk 
profiles but will often be overlooked as outliers in public health research—although not 
so much in social sciences research. 
A critical aspect to understanding risk in context is to identify and examine how 
combinations of behavioral and biopsychosocial factors co-occur. Using a person-
centered approach provides a methodological platform to answer questions regarding the 




can then lead to dependence or abuse. Person-centered approaches such as latent class 
analysis (LCA) allow the researcher to identify and examine co-occurring risk profiles 
that are not possible in variable-centered approaches because LCAs, rather than relying 
on traditional linear regressive methods, rely on a mixture analysis (Laursen & Hoff, 
2006; Howard & Hoffman, 2017; Muthén & Muthén, 2000). Relationships are 
determined by classes or groups in which inclusivity or exclusivity of variables do not 
hinder the analysis as much as it would in a regression. LCA uses observed and 
measured indicators of various risk factors on latent outcomes, or an unobserved variable 
(Laursen & Hoff, 2006). It can identify various risk profiles from classes that can then be 
used to categorize individuals at differential risk (Howard & Hoffman, 2017; Muthén & 
Muthén, 2000). As such, the individual is not reduced to a sole variable but can be 
accounted for in greater complexity by analyzing a constellation of variables to identify 
their possible risk profile. For example, John et al. (2019) used LCA to assess the 
prevalence of opioid misuse and use disorder by sociodemographic indicators and past-
year polysubstance use focusing on tobacco use among primary care patients.  
Dissertation Purpose 
To my knowledge, no person-centered approaches have been used to identify 
generalizable risk profiles of opioid dependence and abuse. Person-centered approaches 
(e.g., LCA) in public health research are burgeoning due to their ability to identify risk 
groups for targeted interventions. The goals of this dissertation were to fill the associated 
gaps in the opioid misuse literature and to expand person-centered analyses in public 




variable-centered and person-centered approaches and to scrutinize the use of these 
approaches in addressing the current opioid epidemic. Aim 1 was a systematic review of 
the opioid misuse literature to identify the existing associations of demographic, 
socioecological, health, and substance co-use risk and protective factors on opioid 
dependence and abuse. Next, for Aim 2, I tested the findings/gaps from the systematic 
literature review by examining the risk and protective factors of opioid misuse using a 
variable-centered approach on a nationally representative sample. Biopsychosocial 
factors such as demographic characteristics, socioecological factors, health status, and 
other substance dependences or abuse status identified in the review were significant in 
developing the variable-centered model. The final aim (Aim 3) was to extend the 
previous findings/gaps from the literature review of Aim 1 and the variable-centered 
approach from Aim 2 by identifying and examining risk groups of opioid dependence or 
abuse using a person-centered approach. Biopsychosocial factors such as demographic 
characteristics, socioecological factors, health status, and heroin and/or pain reliever 
dependence or abuse were used to assess risk group/class membership. Covariates used 
were other substance dependences or abuse. Overall, biopsychosocial indicators were 
used to identify important risk factors for opioid misuse in the variable-centered model, 
while they provided a comprehensive risk profile in the person-centered model.  
Last, for the purposes of this dissertation, I methodologically compared and 
contrasted the variable-centered and person-centered approaches used to identify opioid 
misuse risk. I synthesized the findings within and across methods, as well as suggested 




address the U.S. opioid epidemic. Using both approaches, I provided methodological 
context to best address the issues where current, conventional interventions are failing. 
For instance, the findings from the systematic literature review elucidated the quality of 
findings concerning opioid misuse risk factors. Using the latest nationally representative 
dataset of opioid dependence and abuse to test both variable-centered and person-
centered approaches, I also elucidated the strengths and weaknesses of both variable-
centered and person-centered methodologies in addressing the growing public health 
crisis in order to identify the population-level risk factors to opioid misuse, as well as 
identify risk subgroups currently dependent on or abusing opioids. By applying this 
process, prevention strategies and intervention programs can be designed to efficiently 
and efficaciously intervene in opioid misuse and overdose death. 
Dissertation Overview 
My dissertation is formatted into three publishable works and consists of five 
chapters. In Chapter I, I provided a brief overview of the opioid epidemic, the human 
and economic burdens, and the general risk factors associated with opioid misuse and 
overdose. I also provided an overview of variable-centered and person-centered 
approaches and their strengths and weaknesses. The focus of the introduction was to 
discuss the public health burden of opioid misuse and the merits of the two approaches 
in addressing the public health crisis and health disparities. Chapter II (Aim 1) is a 
systematic literature review that provides a reference frame for the known risk factors of 
opioid misuse. Specifically, the review addresses what is known about the impact of 




and protective factors related to the opioid public health crisis. I highlight the findings of 
the opioid epidemic by the variable-centered and the person-centered approach and 
discuss how they have been applied to examine opioid dependence and abuse. Chapters 
III and IV describe the methodological applications of both the variable-centered 
approach (using a logistic regression) and the person-centered approach (using an LCA), 
respectively, on the 2017 National Survey on Drug Use and Health (NSDUH), which 
contains a nationally representative sample of noninstitutionalized U.S. adults. Chapter 
III (Aim 2) discusses a logistic regression to extend previous findings and gaps in the 
systematic literature review by examining the risk and protective factors of opioid 
dependence or abuse. In Chapter IV (Aim 3), I explore the use of an LCA to extend 
previous findings and gaps in the literature from Aim 1 and findings of the variable-
centered approach from Aim 2 to identify at-risk groups. The person-centered approach 
helped identify risk subgroups in opioid misuse and key risk indicators and factors 
among subgroups. A design similar to John et al. was used to create a comprehensive 
assessment of opioid misuse. In the conclusion, Chapter V, I discuss and synthesize the 
relevant findings of Chapters III and IV. Chapter V highlights the strengths and 
weaknesses of each approach and the public health impact each has in addressing the 
opioid epidemic. This study was reviewed by the Texas A&M University Institutional 
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 The main objective of the systematic literature review was to identify reports of 
biopsychosocial characteristics as risk factors on opioid misuse from U.S. representative 
samples in the peer-reviewed and gray literature (e.g., conference proceedings, 
organizational reports, clinical trials, dissertations, theses). The secondary objective was 
to evaluate the findings on biopsychosocial characteristics as predictors of risk on opioid 
misuse. Biopsychosocial characteristics identified as risk factors included 
sociodemographic, socioecological, and health indicators, as well as other substances 
used. The studies eligible for inclusion provided the biopsychosocial characteristic risk 
factors that could be tested at the population-level and group-level on opioid misuse. 
Protocol will be registered under the PROSPERO International prospective register of 
systematic reviews. 
Methods 
Selection Criteria  
All studies that reported the biopsychosocial characteristics of (a) only 
prescription opioid misuse, (b) only illicit opioid heroin misuse, or (c) prescription 
opioid and heroin misuse met the inclusion criteria. Studies conducted from January 




when the opioid epidemic can be traced to according to the National Institute on Drug 
Abuse (2019). Findings from the literature needed to be completed using (a) a variable-
centered approach (e.g., regressive methods) or (b) a person-centered approach (i.e., 
latent class analysis). Only studies conducted using a representative U.S. adult 
population were included. Any research conducted on non-U.S. groups or populations 
were excluded.  
Factors  
The biopsychosocial characteristic predictors of opioid misuse were gleaned 
from sociodemographic indicators (e.g., age group; race/ethnicity; sexual identity; 
family income; employment status; educational attainment), socioecological indicators 
(e.g., criminality), health indicators (e.g., general self-reported health; mental health 
status; suicidality; access to healthcare), and other substances used (e.g., nicotine; 
alcohol; marijuana; cocaine; methamphetamine; inhalants; tranquilizers; sedatives; 
stimulants). 
Comparators/Control  
Comparison or control groups demonstrated no opioid use or misuse. 
Comparison groups also varied by biopsychosocial characteristics on misuse outcome 
(e.g., sociodemographic-stratified analyses by sex/gender, race/ethnicity, and sexual 
identity). Some comparison groups were based on two categories, while other indicators 




Literature Searches  
The following search engines for the peer-review literature were used: Medline, 
Embase, CINAHL, and Cochrane Central. The gray literature was searched using the 
following engines: Northern Light, WHOCRSP, ClinicalTrials.gov, and ProQuest 
Dissertations & Theses. The search parameters contained the following criteria: (1) exp 
Opioid-Related Disorders/; (2) ((opioid* or opiat*) adj2 (misuse* or abuse* or 
dependenc* or addict*)).ti,ab.; (3) 1 or 2; (4) exp review/ or exp meta analysis/ or exp 
Systematic Review/ or (literature adj3 review$).ti,ab.; (5) RETRACTED ARTICLE/ or 
(medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or 
psychinfo or psycinfo or scisearch or cochrane).ti,ab.; (6) (systematic$ adj2 (review$ or 
overview)).ti,ab.; (7) (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or 
metanal$).ti,ab.; (8) (4 and 5) or 6 or 7; (9) exp cohort analysis/ or exp longitudinal 
study/ or exp prospective study/ or exp follow up/ or cohort$.tw. or exp case control 
study/ or (case$ and control$).tw.; (10) exp regression analysis/; (11) exp health survey/; 
(12) exp cross-sectional study/; (13) (cross sectional or regression analys* or (survey* or 
questionnaire*)).ti,ab.; (14) or/10-13; (15) 3 and 14; (16) limit 15 to yr="1999 -Current"; 
(17) animals/ not humans/; (18) 16 not 17; (19) 8 and 3; (20) exp Risk Factors/; (21) 
(risk adj1 factor*).ti,ab.; (22) exp Models, Statistical/; (23) latent class analy*.ti,ab.; (24) 
or/20-23; and (25) 19 and 24. 
Data Extraction for Selection and Coding  
Paired reviewers (FAMI and CR: undergraduate research assistant) were used to 




for independent assessment. Data collected and reported were on the following: (a) study 
characteristics (e.g., author name, publication year, study design, sample size); (b) 
biopsychosocial characteristics (i.e., sociodemographic, socioecological, and health 
indicators, as well as other substances used) as risk factors of opioid misuse; and (c) 
outcome for opioid misuse (e.g., dependence, abuse, or overdose) and other substances 
concurrently used.  
Strategy for Data Synthesis  
I used Gwet’s AC1 statistic to assess agreement for full-text eligibility and risk of 
bias assessment between myself and CR (research assistant). Agreement of over 0.8, 
which is considered very good, was achieved (Wongpakaran, Wongpakaran, Wedding, 
& Gwet, 2013). Odds ratios with an associated 95% confidence interval were presented. 
When odds ratio were not available, measures were converted to odds ratios. 
Risk of Bias and Quality Assessment  
I independently assessed risk of bias using The Joanna Briggs Institute (JBI) 
critical appraisal tools for use in JBI Systematic Reviews Checklist for Prevalence 
Studies, as detailed in Munn, Moola, Lisy, Riitano, and Tufanaru (2015). The checklist 
includes assessment of (1) sample frame; (2) appropriateness of participant sample; (3) 
adequate sample size; (4) sufficient description of participant sample; (5) data analysis 
undertaken with sufficient sample coverage; (6) validity of methods for identification of 
outcome; (7) outcome measured in a standardized, reliable method; (8) appropriate 





Study Selection  
Of 3,650 reviewed reports, six were included in this systematic review. These six 
studies used nationally representative datasets to assess the prevalence of opioid misuse, 
which included nonmedical prescription opioid dependence or abuse, or heroin 
dependence or abuse. Studies also provided prevalence of biopsychosocial indicators on 
opioid misuse, assessment of nonmedical opioid misuse and/or substance co-use, 
frequency of substance use disorders, and health conditions of opioid users. See Figure 
2.1 for the detailed PRISMA flow chart (available from PRISMA, 2015), which is based 
on the PRISMA Statement (Moher, Liberati, Tetzlaff, & Altman, 2009); see also 
PRISMA Explanation and Elaboration by Liberati et al. (2009). All PRISMA documents 
are distributed under the terms of the Creative Commons Attribution License (i.e., 
permits unrestricted use, distribution, and reproduction in any medium as long as the 










Study Characteristics  
Biopsychosocial characteristics were identified as risk factors to opioid misuse. 
All studies selected for this systematic review could include both nonmedical 
prescription pain relievers and heroin use; however, none included heroin use within 
their classification of opioid misuse. No study came from the same journal or from a 
similar author group. All studies did use a cross-sectional survey study design to report 





























Self-reported past month prescription opioid and other substance 
use: opioid only; opioid and licit, opioid and illicit, or opioid + 














sample)   
DSM-IV criteria for either abuse or dependence: past-year misused 















DSM-IV criteria for either abuse or dependence: past-year 
prescription opioid use w/o misuse; prescription opioid misuse w/o 
use disorder; and prescription opioid use disorder. 
Variable-centered 
(Descriptive) 











DSM-IV criteria for either abuse or dependence and defined as the 
use of substance(s) either without a prescription; in higher amounts, 
more often, or longer than prescribed; or for a reason other than 
prescribed by a health professional. Nonmedical prescription opioid 









SKIP b  
1,983 (national 
sample of opioid 
treatment clients) 
DSM-IV criteria for either abuse or dependence and the most 
frequently misused substance by participant. Method participants 
used for diverted (e.g., “pill mill,” regular doctor, theft, dealer, 















DSM-IV criteria for either abuse or dependence, defined as the use 
of substance(s either without a prescription; in higher amounts, 
more often, or longer than prescribed; or for a reason other than 





Note. DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; MDE = major depressive episode; NSDUH = National Survey on Drug Use and 
Health; NESARC = National Epidemiologic Survey on Alcohol and Related Conditions; SKIP = Survey of Key Informants' Patients. 
a 12 years old and over. 
b 18 years old and over. 
c Not significant in opioid only. 





Study sample frames came from larger nationally representative surveys. Four 
studies came from NSDUH, one from NESARC, and the other from SKIP. Of the six 
studies, five clearly identified using the Diagnostic and Statistical Manual of Mental 
Disorders (Fourth Edition; DSM-IV) to define substance abuse or dependence. While 
Grigsby and Howard (2019) did not mention the use of DSM-IV criteria, the NSDUH 
does use DSM criteria to assess substance abuse or dependence from interview data, 
according to the Center for Behavioral Health Statistics (2018). 
Furthermore, I identified four major categories within biopsychosocial 
characteristics: (1) sociodemographic factors; (2) socioecological factors; (3) health 
factors; and (4) other substance use or misuse. Sociodemographic factors included—at 
minimum—sex/gender, age groups, and race/ethnicity. Socioecological factors included 
some level of criminality. I grouped factors such as theft and sale of illegal substances, 
as well as history of arrest, parole, or probation. Health factors included self-reports of 
physiological health and mental health issues, as well as healthcare access. Physiological 
health issues ranged from sexually transmitted infections, to chronic medical conditions, 
to overall self-reported health. Mental health issues included some variation on reports 
of major depressive episodes, psychological distress, and suicidality. Healthcare access 
included some use of health insurance, state health benefits, or emergency department 
services. Other substance use or misuse included the use of single or multiple licit and/or 






Table 2.2. Study characteristics of identified biopsychosocial factors as risk factors to opioid misuse. 
 Biopsychosocial Characteristics  
Authors Sociodemographic Factors Socioecological Factors Health Factors Other Substance Use/Misuse 
Grigsby &  Sex/gender± Theft† Major dep. ep.† Licit b,f  
Howard  Age group± Selling illegal drugs± STI± Illicit b,g 
(2019) Race/ethnicity±  Suicidal ideation
† Polydrug (licit + illicit)b 
  Family income±   Perc. treatment for subst. use†  
Mojtabai et al. Sex/gender† Any illegal activities†d Chronic med. conditions± Prescription opioids†d 
(2019) Age group† Hist. of arrest, parole, or prob.†d # of chronic med. conditions†   Heroin use disorder†d 
 Race/ethnicity
±  Health ins.
 ± Alcohol use disorder†d 
 Family income
± a  # of healthcare visits
†d Other drug use disorder†d 
 Education
±  ED visits
†d Any subst. use disorder†d 
 Marital status
±  Med. marij. use
†d Benzo. misuse†d 
 Employment status
±   Psych. distress
†d  Nicotine dependence†c 
 Place of residence
±  Major dep. ep.
†  
   Suicidal ideation†d  
   Suicidal plans
†d  
      Suicide attempts†d   
Han et al. Sex/gender  Health ins.  Tobacco use and disorder
h 
(2017) Age group  Overall self-rated health  Alcohol use and disorder
i 
 Race/ethnicity  ED visit
 d Marij. use and disorderi 
 Family income   Chronic medical conditions  Cocaine use and disorder
i 
 Education level  Major dep. ep. Heroin use and disorder
j 
 Marital status   Suicidal ideation Hallucinogen use and disorder
j 
 Employment status    Inhalant use and disorder
j 
 Region of residence   Rx sed./tranq. use and disorder
j 
  Place of residence     Rx stimulant use and disorderj 
Wu et al. Sex/gender⸸    Lifetime subst. abuse treatment
⸸‡ 
(2011) Age group   Family hist. of subst. abuse
⸸ 
 Race/ethnicity    
 Family income     






Table 2.2. Continued. 
Authors 
Biopsychosocial Characteristics 
Sociodemographic Factors Socioecological Factors Health Factors Other Substance Use/Misuse 
Cicero et al. Sex/gender†  Theftb Severe paine Inject primary drug† 
(2011) Age group±    
 Race/ethnicity     
  Yearly income±       
Tetrault et al. Sex/genderb  Overall self-rated health
⸷ Cigarette use⸷ ⸶d 
(2008) Age group⸷ ⸶  Health insurance (w/o
 d)⸷ ⸶ Crack cocaine use ⸷ ⸶d 
 Race/ethnicity
⸶   State sponsored med. asst.
⸷d Alcohol⸷ ⸶d 
 Level of education completed
⸷ ⸶  # of times treated in ED
⸷ ⸶d Marij. use⸷ ⸶d 
 Family income
⸷ ⸶  Needle use ever for drug
⸷ ⸶ Heroin use⸷ ⸶d 
 Marital status
⸷ ⸶  Serious mental illness⸷ ⸶ Cocaine use⸷ ⸶d 
 Employment status
⸷ ⸶   Hallucinogen use
⸷ ⸶d 
 Missed 1+ day of work
⸷ ⸶c    Inhalant use
⸷ ⸶d 
    Nonmed. stimulant
⸷ ⸶d 
        Nonmed tranq. and sed.⸷ ⸶d 
Note. asst. = assistance; benzo. = benzodiazepine; dep. = depressive; ED = emergency department; ep. = episode; hist. = history; ins. = insurance; marij. = marijuana; med. = 
medical; perc. = perceived; prob. = probation; psych. = psychological; Rx = prescription; sed. = sedative; STI = sexually transmitted infection; subst. = substance; tranq. = 
tranquilizer; w/o = without; if text is colored green then at some level is significant based on 95% confidence interval, or p < .05. 
† significant under 95% confidence interval, or p < .05. 
± variable at some level is significant under 95% confidence interval, or p < .05. 
⸸ significant at some level for opioid abuse under 95% confidence interval. 
‡ significant at some level for opioid dependence under 95% confidence interval. 
⸷ significant at some level for female under 95% confidence interval. 
⸶ significant for male at some level under 95% confidence interval. 
a Converted into federal poverty level. 
b Used as a stratification variable, not indicator. 
c In past month or 30 days. 
d Past year or 12 months. 
e Past week or 7 days. 
f Alcohol and cigarettes. 
g Marijuana, cocaine, crack, heroin, LSD, PCP, ecstasy, ketamine, DMT/AMT/FOXY, salvia, inhalants, and methamphetamine. 
h Past-month, past-yr., lifetime w/o past yr. use, or never-use. 
i Past-yr. use dis., past-yr. no use dis., lifetime w/o past yr. use, or never-use. 




Results of Individual Studies 
The prevalence of biopsychosocial characteristics on nonmedical prescription 
opioid misuse, overall, has not been well scrutinized. Past-month comorbid prescription 
opioid misuse and recreational substance use were examined by Grigsby and Howard 
(2019) using the 2016 NSDUH. A multivariate logistic regression was used to examine 
sociodemographic, criminality, health factors, and concurrent substance on opioid use. 
Most prescription opioid misusers in the past-month reported using licit substances like 
nicotine, alcohol, and marijuana, as well as other illicit substances like cocaine, 
methamphetamines, and so on. Males and younger age groups had a substantially higher 
likelihood of past-month prescription opioid misuse with illicit substance or 
polysubstance use. Prescription opioid and polysubstance users had the greatest 
probability of past-year criminality (i.e., theft; selling drugs), mental health issues (e.g., 
suicidal ideations; major depressive episodes), as well as perceived need for treatment 
compared to opioid-only, opioid and licit, and opioid and illicit misusers (Grigsby & 
Howard, 2019).  
Mojtabai et al. (2019) assessed the prevalence of biopsychosocial characteristics 
on nonmedical opioid misuse in the U.S. for individuals reporting opioid use in the past 
year with a weighted sample representing more than 89 million adults. Prevalence of 
prescribed opioids was defined as using a prescription longer than medically advised or 
frequently using larger doses, as well as DSM-IV criteria. Mojtabai et al. used 
multivariate logistic regression models and the machine-learning method of boosted 




associated with concomitant non-prescribed opioid misuse, history of criminality, mental 
health distress, benzodiazepine misuse and other substance abuse or dependence. 
Prescription opioid misuse was also found to be associated with opioid-use disorder 
(Mojtabai et al., 2019).  
Tetrault et al. (2008) focused on expanding the literature on known gender-
related biopsychosocial factors associated with nonmedical prescription opioid use. 
Tetrault et al. used a multivariable logistic regression on the 2003 NSDUH to assess risk 
factors for past-year prescription opioid use stratified by gender. Participants were ages 
12 and older; however, I only focused on findings from 18 and older groups. Females 
and males reported alcohol abuse or dependence, marijuana, and other illicit substance 
use from nonmedical stimulants, cocaine, hallucinogens, sedatives and tranquilizers, all 
of which were associated with past-year prescription opioid use. Among females, for 
first illicit drug use reported at 24 years of age and older, serious psychological distress 
and nicotine use were related to prescription opioid use. Among men, past-year inhalant 
use was related to nonmedical prescription opioid use.  
Wu et al. (2011) had two different analytical samples of abuse or dependence: 
nonmedical prescription opioid users and remission from nonmedical prescription 
opioids. For the purposes of this systematic review, I focused on nonmedical 
prescription use—in particular reports of abuse or dependence. The 2001-2002 
NESARC was used for Wu et al.’s multivariable logistic regression. Approximately 5% 
or participants reported nonmedical prescription opioid use, and 0.3% used heroin. 




and reported heroin use. The mean age for nonmedical prescription opioid and heroin 
use was about 37 and 42 years, respectively. Education level was also similar; 
respondents using prescription opioids and respondents using heroin had about 10 and 9 
years of education, respectively. Those abusing prescription opioids were mainly male, 
White, in the low-SES group, or had a college education. The inverse was found among 
those with a dependence on prescription opioids. They were more likely to be female, 
report a lower family income, be less educated, and have used substance abuse 
treatment. Those using heroin were more likely to be non-White. 
Cicero et al. (2011) technically performed two studies. One was a national 
sample of opioid treatment clients that uses SKIP, while the other was a study in South 
Florida trying to understand opioid abuse in a diverse subpopulation. Only the national 
sample using logistic regression was focused on for this systematic literature review. 
Women were found to be more likely to use a doctor’s prescription and share 
prescription opioids, as well as marginally commit theft. Younger prescription opioid 
abusers (i.e., 18 to 24 year olds) were more likely to obtain opioids through dealers or 
theft, while those 45 and older were more likely to use a clinical purveyor. Lower 
income participants were more likely to acquire opioids through dealers, sharing, and 
theft than the highest income group participants. The highest income group was more 
likely to obtain opioids through a prescription when compared to the lower income 
group participants.  
Han et al. (2017) reported on prevalence using a descriptive weighted analysis. 




prescription opioids, 4.7% misused them, and about .8% had a misuse disorder. More 
than 12.5% of adults reporting prescription opioid use were misusing them. Adults with 
no health insurance, that were unemployed, reported low family income, or had some 
mental health issues were the most common factors reported among those misusing and 
with use disorders. Men were observed to have a lower prevalence of prescription opioid 
use compared to women, and Hispanics had a lower prevalence compared to non-
Hispanic Whites. Similarly, college graduates were found to have a lower prevalence of 
prescription opioid use compared to those not having a high school degree. Adults with 
no health insurance had a lower prevalence than those with insurance. Regarding self-
reported health, participants who described themselves in excellent health had lower 
prevalence than all other lesser self-reports. Conversely, those reporting no major 
depressive episodes nor suicidality had a lower prevalence of opioid use, misuse, and 
misuse with disorder. Table 2.2 also provides the identified biopsychosocial 
characteristics by study that were significant or present in opioid misuse. 
Synthesis of Findings 
Finding from all studies measured the outcome of nonmedical opioid use. 
Although outcomes were measured at different levels and stratifications, there were 
significant biopsychosocial characteristics associated with opioid misuse. Overall, 
sociodemographic, socioecological, and health factors, as well as other substance use or 
misuse were significant or prevalent at one or multiple levels of nonmedical opioid use. 




did not reveal consistent findings by factor. As such, no consistent individual findings 
could be drawn across all studies (see Table 2.2).  
Risk of Bias across Studies  
The JBI critical appraisal tools for Systematic Reviews Checklist for Prevalence 
Studies (Munn et al., 2015) were used to assess all six studies. The first of nine questions 
assessing the risk of bias was the sample frame assessment to address the target 
population. The second assessed if participants were appropriately sampled. The third 
assessed if the sample size was adequate. The fourth assessed if the study subjects and 
setting were adequately described. The fifth assessed if the data analyses of the 
identified sample were conducted with sufficient coverage. The sixth assessed if valid 
methods were used for the identified condition. The seventh assessed if conditions were 
measured in a standard, reliable way for all participants. The eighth assessed if 
appropriate statistical analyses were used. The ninth assessed if the response rate was 
adequate, or if not, whether the responses were managed appropriately (Munn et al., 
2015). 
Five of the six studies used nationally representative data sets that have been 
validated elsewhere. Four of the six studies used the NSDUH, which used a complex 
sampling frame to achieve a representative sample of U.S. noninstitutionalized civilians 
(Center for Behavioral Health Statistics, 2018). Similarly, the NESARC used a complex 
sampling frame of a representative U.S. civilian sample (Grant et al., 2003). As for 
Cicero et al.’s (2011) study, the SKIP used a national sample of opioid treatment clients 




urban treatment centers (Cicero, Ellis, Paradis, & Ortbal, 2010; Cicero, Surratt, & 
Inciardi, 2007). Cicero et al.’s (2011) SKIP study presented the greatest risk of bias. The 
sampling frame, participant sample appropriateness, and adequate response rate were 
unknown and, as such, were uncertain. Half the studies were also conducted without 
sufficient coverage (i.e., Grigsby & Howard, 2019; Han et al., 2017; Cicero et al., 2011). 
Overall, Mojtabai et al. (2019), Wu et al. (2011), and Tetrault et al. (2008) were the 
highest-quality studies, with no risk of bias identified. See Table 2.3 for the full JBI 
critical appraisal checklist of all studies reviewed. 
 















Sample frame to address target population ✓ ✓ ✓ ✓ - ✓ 
Study sampled appropriately ✓ ✓ ✓ ✓ - ✓ 
Adequate sample size ✓ ✓ ✓ ✓ ✓ ✓ 
Subjects and setting described in detail X ✓ ✓ ✓ ✓ ✓ 
Analysis conducted w/ sufficient coverage  X ✓ X ✓ X ✓ 
Valid methods for identification of condition ✓ ✓ ✓ ✓ ✓ ✓ 
Condition measured in standardized manner - ✓ ✓ ✓ ✓ ✓ 
Appropriate statistical analysis ✓ ✓ X ✓ ✓ ✓ 
Adequate response rate  ✓ ✓ ✓ ✓ - ✓ 
Overall Appraisal        
Include ✓ ✓ ✓ ✓  ✓ 





Summary of Evidence 
All studies reviewed in this systematic review used a nationally representative 




The outcome of opioid misuse was measured similarly across all studies, which focused 
on both DSM-IV reports of abuse or dependence, as well as on reports of diversion or 
attainment of opioid. Nevertheless, the outcome of misuse was reported differently 
between studies. Many were stratified—by diversion, by sex/gender, by abuse or 
dependence, or by multiple substance use. Therefore, no clear manner exists in which to 
ascertain the general role of each biopsychosocial characteristic on nonmedical opioid 
misuse. This flaw is a larger symptom of the literature and studies available, which 
consist of descriptive statistics or inconsistent linear models to define nonmedical opioid 
misuse risk factors. 
Limitations 
I conducted a thorough search of the literature with the help of TAMU Libraries 
Systematic Review Services. However, one limitation is that a possibility exists that 
relevant studies may have been missed or overlooked without the use of a trained team 
of systematic researchers. Another limitation is that studies had to be in English and 
constrained to the U.S., which introduces selection bias. Unfortunately, extending the 
search parameters can also introduce bias, both measurement and cultural biases. The 
quality of this systematic review can be strengthened and can limit bias by using a team 
of researchers with access to Cochrane review. While this is the first systematic 
literature review assessing biopsychosocial characteristics on opioid misuse prevalence, 
some weaknesses can be expected. Furthermore, this review also revealed a lack of 
person-centered approaches in opioid misuse research, which introduces a possible 





The systematic review provides a clear and concise summary of findings based 
on the quality of evidence. The comprehensive evaluation of study findings were 
assessed using a variable-centered approach since no person-centered studies were found 
in the systematic literature search. Variable-centered methods like regressions were 
assessed based on strength of associations. The biopsychosocial characteristics identified 
as risk factors to opioid misuse can be used in subsequent variable-centered and person-
centered approaches testing for intervenable factors to opioid misuse. This review also 
helps extend and establish a solid foundation to understand the multidimensional and 
dynamic risk factors associated with opioid misuse and serves to identify the most 
intervenable factors on the opioid epidemic. 
Context of Findings within the Dissertation 
The findings from this systematic literature review revealed multiple 
biopsychosocial characteristic as possible predictors of opioid misuse to examine in this 
dissertation. Biopsychosocial characteristics were divided into four categories: (1) 
sociodemographic indicators; (2) sociological indicators; (3) health indicators; and (4) 
other substance use. Sociodemographic indicators were selected as static variables to 
describe participants and determine the sample’s variation, as well as allow for cross-
sectional survey comparison (Hoffmeyer-Zlotnik & Warner, 2014; Przeworski & Teune, 
1970). Socioecological indicators were defined as dynamic variables that captured 
sociobehavioral outcomes due to human-environment interactions (Glaser, Ratter, 




reviewed and centered on criminality. Criminality has been examined as major 
socioecological indicator elsewhere (see Bottoms, 2007; Burgess, 1923; and Vila, 1994). 
Health, to be represented holistically, was comprised of three factors: (1) physiological 
health; (2) mental health; and (3) access to health services. Lastly, other substance use 
was defined as dependence or abuse of licit and illicit substances. Significant indicators 
from this review were included for both variable-centered and person-centered 
approaches using data from the 2017 NSDUH.  
Sociodemographic factors selected. Four sociodemographic indicators were 
consistent across all studies, although not measured consistently. These indicators were 
age group, sex/gender, race/ethnicity, and income. Age group was used inconsistently 
across the reviewed studies. For the purposes of this dissertation, age groups 18 and 
older were selected and examined by the 2017 NSDUH demarcations. Sex/gender was 
used an indicator or as a stratifying variable in the reviewed studies, but was used as an 
indicator for analytic purposes in this dissertation. Race/ethnicity was also examined 
differently by study, nevertheless race/ethnicity was used in this dissertation by 2017 
NSDUH demarcations. Family income was selected for analysis using the default 2017 
NSDUH categories. Other sociodemographic variables selected were based on the 
findings from this review, which were available in the 2017 NSDUH, included 
educational attainment, employment status, and place of residence. Sexual identity (i.e., 
gay or lesbian; bisexual; heterosexual or straight) was included from the literature 
review in Chapter I, as it was an important indicator to opioid misuse, although not 




  Socioecological variable selected. One socioecological variable was selected 
for analysis based on the systematic literature review. The studies reviewed used various 
indicators (e.g., theft of some kind; any illegal activities; history of being involved in the 
criminal justice system) to capture criminality. The 2017 NSDUH provided a variable 
that encompassed criminality as any illegal action in which the participant was arrested 
and booked. As such, this variable captured criminal behavior and involvement in the 
criminal justice system, which both are associated with opioid misuse. 
Health factors selected. In the studies reviewed, health factors were the most 
inconsistently examined. Using the literature review from Chapter I and the systematic 
literature review, the respective correlates available in the 2017 NSDUH for 
physiological health, mental health, and access to healthcare were selected: (1) self-
reported health status (see Kaplan & Camacho, 1983; and Idler & Benyamini, 1997); (2) 
serious psychological distress and suicidality; and (3) private health insurance (see 
Blackwell, Martinez, Gentleman, Sanmartin, & Berthelot, 2009; and Woolhandler & 
Himmelstein, 2017). 
Substance use factors selected. Studies in the systematic literature review also 
examined substances inconsistently. For the purposes of this dissertation, substances 
either licit or illicit were included if there was a prior association on opioid misuse 
identified in Chapters I or II. Substance dependence or abuse for nicotine/tobacco, 
alcohol, marijuana, cocaine, inhalants, methamphetamine, tranquilizers, stimulants, 




Overall, the literature review from Chapter I and findings of the systematic 
literature review guided the models selected for our variable-centered and person-
centered approaches. Changes were made, however, to the NSDUH especially in the 
2017 cycle (Center for Behavioral Health Statistics, 2018). As such, some variables 
potentially or actually cannot be cross-compared nor are compatible with previous 
versions of the NSDUH; which were reviewed in this dissertation. This may account for 
possible inconsistencies across NSDUH measures used for analysis. In addition, this also 
accounts for differences in the biopsychosocial factors selected, as well as indicator 
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BIOPSYCHOSOCIAL RISK FACTORS ASSOCIATED WITH OPIOID MISUSE IN 
A U.S. REPRESENATIVE SAMPLE: A VARIABLE-CENTERED APPROACH 
 
Introduction 
Estimates indicate that up to 29% of persons misuse prescription pain relievers 
for chronic pain (Vowles et al., 2015), and 8 to 12% of that group develop a misuse 
disorder (Cicero, Ellis, Surratt, & Kurtz, 2014; National Institute on Drug Abuse, 2019). 
The U.S. Department of Health and Human Services (2019) declared a public health 
emergency in 2017, although the first wave of the epidemic can be traced to the 1990s 
(National Institute on Drug Abuse, 2019). In 2016 alone, the record numbers of opioid 
misuse and overdose death provided a stark realization of how the epidemic has become 
a public health crisis (Cicero et al., 2014). Related deaths increased 345% from 2001 to 
2016, with more than 42,000 overdose deaths reported in 2016—higher than any 
previous year on record (U.S. Department of Health and Human Services, 2019). An 
increase of 30% in opioid overdose was reported from July 2016 through September 
2017 in 45 states (Vivolo-Kantor et al., 2018), which means that more than 66% of drug 
overdose deaths in the U.S. involved an opioid—42,249 of 63,632 deaths (Seth, Rudd, 
Noonan, & Haegerich, 2018). 
Projections also revealed that if prevention and intervention programs do not 
change their respective strategies, the rate of misuse and overdose death will increase. 




prescription opioid incidence would have minimal impact, preventing only 3.0% to 5.3% 
of overdose deaths (Chen et al., 2019). Other interventions were projected to have a 
similar negligible impact on overdose death, life years, and quality-adjusted life years, 
with the largest change estimated to bring about a 4% decrease in opioid-related deaths 
(e.g., naloxone increase; Pitt, Humphreys, & Brandeau, 2018). While interventions like 
reduced prescribing for pain patients and excess opioid management can be projected to 
increase life years and quality-adjusted life years, overdose deaths would increase 
among those with opioid dependence due to a move from prescription opioids to heroin 
(Pitt et al., 2018). 
To ameliorate the impact of the opioid epidemic, we must identify and 
understand the risk factors regarding the etiology of misuse to thereby curb dependence 
and abuse. We must understand the biopsychosocial characteristics that underpin the risk 
profiles of misuse at specific population levels to stem overdose deaths. Biopsychosocial 
characteristics include sociodemographic (e.g., age group, race/ethnicity, biological sex, 
sexual identity, family income, educational attainment, and employment), 
socioecological (e.g., criminality), and health factors (e.g., self-reported general health; 
mental health, suicidality; access to health services), as well as other substance 
dependence or abuse. Current epidemiological studies, however, have not focused on 
comprehensive risk profiles. For instance, while non-Hispanic Whites and Native 
Americans/Alaska Natives are a primary focus, affected groups are found to be at 
differential risk depending on biopsychosocial characteristics studies selected from year 




Baldwin, 2019). Therefore, I comprehensively examined biopsychosocial characteristics 
in four domains to determine risk factors to opioid misuse in a representative, 
noninstitutionalized U.S. adult sample.  
The four biopsychosocial domains I tested were sociodemographic factors, 
socioecological factors, health factors, and other substance dependence or abuse. I 
hypothesized that sociodemographic factors, while crucial to adjust for the 
comprehensive risk profile, would not be as critical a risk factor when compared to 
socioecological factors, health factors, or other substance dependence or abuse. The 
purpose of this study was to add to a critical gap in the literature to improve population-
level prevention strategies by identifying the most salient predictors of opioid misuse. 
Methods 
I used multivariable logistic regression to analyze data from the 2017 National 
Survey on Drug Use and Health (NSDUH), examining the relationship between 
biopsychosocial characteristics and opioid misuse (measured as opioid dependence or 
abuse). Characteristics were tested independently in unadjusted models to examine their 
effect on opioid misuse. Models were then built using a block entry method to test 
biopsychosocial characteristics as risk factors in four blocks: (1) sociodemographic 
factors; (2) socioecological factors; (3) health factors; and (4) other substance 





Risk and Protective Biopsychosocial Characteristics  
Sociodemographic variables and factors. Five age categories were used: (1) 18 
to 25 years of age; (2) 26 to 34 years of age; (3) 35 to 49 years of age; (4) 50 to 64 years 
of age; and (5) 65 years and older. The sex/gender binary of male and female was used. 
Race/ethnicity was divided into seven categories: (1) non-Hispanic White; (2) non-
Hispanic Black/African American; (3) non-Hispanic Native American/Alaska Native; 
(4) non-Hispanic Native Hawaiian/other Pacific Islander; (5) non-Hispanic Asian; (6) 
non-Hispanic more than one race; and (7) Hispanic. Sexual identity had three categories: 
(1) heterosexual; (2) gay/lesbian; and (3) bisexual. Place of residence was based on 2009 
Core-Based Statistical Areas (CBSAs) defined by the Office of Management and Budget 
(2009): (1) CBSA with 1 million or more persons; (2) CBSA with fewer than 1 million 
persons; and (3) segment not in a CBSA. Total family income was divided into four 
categories: (1) less than $20,000; (2) $20,000 to $49,999; (3) $50,000 to $74,999; and 
(4) $75,000 or more. Employment within the past week was divided into eight 
categories: (1) full-time job; (2) part-time job; (3) has job or volunteer work, and did not 
work in past week; (4) unemployed/laid-off, looking for work, or no job with other 
reason; (5) disabled; (6) retired; (7) keeping house full time; and (8) in school/training. 
Educational attainment was divided into four categories: (1) less than high school; (2) 
high school graduate; (3) some college/associate’s degree; and (4) college graduate.  
Socioecological factors. Criminality was assessed if the participant had been 




was defined as taken into custody and processed by the legal system, even if later 
released.  
Health factors. Participants were asked to rank their overall health in the 
following manner: (1) excellent; (2) very good; (3) good; (4) fair/poor. A severe 
psychological distress indicator within the past year was based on responses from past-
month Kessler-6 (K6) items and the worst month in the past-year K6 items. K6 items are 
from a screening instrument for nonspecific psychological distress developed by 
Furukawa, Kessler, Slade, and Andrews (2003) and Kessler et al. (2003). The K6 
measures how frequently participants experience psychological distress during the past 
30 days and during a month in the past year where they felt more depressed, anxious, or 
emotionally stressed than in the past month. Participants who had a score of 13 and 
above were considered to be in severe psychological distress. Suicidality was assessed if 
at any time in the past year a participant had seriously thought about trying to commit 
suicide. Private health insurance was also assessed. A participant possessed private 
health insurance if the participant had insurance that could be obtained (1) through work 
by paying premiums to an insurance company; (2) through the Health Insurance 
Marketplace; or (3) through a health maintenance organization (HMO), fee-for-service 
plans, or single-service plans.  
Other substance dependence or abuse factors. Nicotine dependence in the past 
month was assessed using Nicotine Dependence Syndrome Scale scores and the 
Fagerstrom Test of Nicotine Dependence scale. Alcohol dependence and abuse in the 




substances were also determined: marijuana, cocaine, hallucinogens, inhalants, 
methamphetamine, tranquilizers, stimulants (i.e., independent of methamphetamine), and 
sedatives (Center for Behavioral Health Statistics, 2018). 
Statistical Analysis 
All analyses accounted for the 2017 NSDUH complex survey design to best 
present a representative sample of noninstitutionalized U.S. adults. In other words, all 
models were weighted and accounted for clustering and stratification. SAS 9.4 (SAS 
Institute Inc.) was used for all analyses. The final model was assessed by model 
convergence and max-rescaled R2. Max-rescaled R2 was used because it is a useful 
method to compare competing models; the larger the value indicates the better model 
(Nagelkerke, 1991). All findings are reported in odds ratios (ORs) using a 95% 






Sample Characteristics  
The sample consisted of 42,554 individuals (weighted N = 247,160,541) over the 
age of 18. Male and female participants were represented about equally—48% male 
(weighted N = 119,287,343) and 52% female (weighted N = 127,873,198), respectively. 
The majority of the weighted sample was non-Hispanic White (63.8%), resided in a high 
population density CBSA (54.3%), identified as heterosexual (94.9%), had a family 
income of $75,000 or more (38.5%), were college graduates (32.3%), were employed 
(46.9%), had no history of arrest and booking (83.2%), were in very good health 
(36.6%), had no serious psychological distress (88.8%), displayed no suicidality 
(95.6%), and had private health insurance (66.7%). See Table 3.1 for a detailed 




Table 3.1. Descriptive biopsychosocial characteristics of the 2017 NSDUH 
representative sample (N = 42,554; weighted N = 247,160,541). 
 N Weighted N SE % 
Age Groups  
   
18-25 years old 13,840 34,306,312 574,946 13.88 
26-34 years old 8,786 39,559,271 591,850 16.01 
35-49 years old 11,214 60,963,591 795,401 24.67 
50-64 years old 4,997 62,458,057 962,107 25.27 
65 or older 3,717 49,873,311 1,116,852 20.18 
Sex/Gender     
Male 19,987 119,287,343 1,139,976 48.26 
Female 22,567 127,873,198 1,209,432 51.74 
Race/Ethnicity     
White 25,870 157,649,306 1,649,074 63.78 
Black/African American 5,230 29,460,536 930,571 11.92 
Native American/Alaska Native 640 1,326,686 110,870 0.54 
Native Hawaiian/Other Pacific Islander 195 957,395 152,767 0.39 
Asian 2,070 13,977,480 468,826 5.66 
Non-Hispanic more than one race 1,381 4,050,463 267,462 1.64 
Hispanic 7,168 39,738,675 1,079,486 16.08 
Area of Residence by Population Density     
Segment in a CBSA with 1 million or more 17,857 134,228,253 1,268,575 54.31 
Segment in a CBSA with less than 1 million 21,202 98,425,658 1,424,517 39.82 
Segment not in a CBSA 3,495 14,506,630 806,408 5.87 
Sexual Identity     
Heterosexual, i.e., straight 38,862 230,458,807 1,781,353 94.93 
Lesbian or gay 951 4,815,318 272,130 1.98 
Bisexual 1,989 7,480,558 258,000 3.08 
Family Income     
Less than $20,000 8,370 39,858,134 837,676 16.13 
$20,000-$49,999 13,321 72,790,284 1,118,333 29.45 
$50,000-$74,999 6,704 39,336,329 733,309 15.92 
$75,000 or more 14,159 95,175,794 1,474,951 38.51 
Level of Education     
Less than high school 5,395 30,286,502 808,944 12.25 
High school graduate 11,269 60,269,350 940,128 24.38 
Some college/associate’s degree 14,288 76,814,204 1,117,733 31.08 
College graduate 11,602 79,790,484 1,471,119 32.28 
Employment Status (past week)     
Worked at full-time job 20,726 115,001,494 1,228,846 46.95 
Worked at part-time job 5,654 27,526,144 518,702 11.24 
Has job or volunteer worker, did not work 2,348 11,519,610 403,639 4.70 
Unemployed/laid off/looking for work 5,349 24,757,893 476,522 10.11 
Disabled 1,546 11,486,025 369,423 4.69 
Keeping house full-time 1,938 9,115,864 277,250 3.72 
In school/training 1,477 4,517,261 185,088 1.84 
Retired 3,075 41,001,799 928,254 16.74 
Ever Arrested and Booked     
No 34,989 205,040,372 1,771,646 83.27 




Table 3.1. Continued.     
 N Weighted N SE % 
Overall Health Status     
Fair/poor 4,829 34,281,053 760,566 13.88 
Good 11,800 70,418,663 989,602 28.50 
Very good 16,151 90,430,046 1,091,958 36.60 
Excellent 9,761 51,936,820 968,872 21.02 
Serious Psychological Distress Indicator (past year)    
No 35,934 219,428,393 1,782,252 88.78 
Yes 6,620 27,732,148 521,899 11.22 
Suicidality (past year)     
No 39,652 234,837,595 1,841,729 95.61 
Yes 2,588 10,789,164 391,116 4.39 
Covered by Private Health Insurance     
No 15,331 81,958,362 1,165,322 33.31 




 Of the weighted sample, 2,018,922 individuals (n = 476) reported opioid misuse. 
Opioid misuse was characterized by three categories: (1) those using heroin only; (2) 
those using prescription pain relievers; and (3) those that used both heroin and 
prescription pain relievers. The majority of the weighted sample used only pain relievers 
(66.0%). Other substances that the sample had dependence on or abused were nicotine, 
alcohol, marijuana, cocaine, inhalants, methamphetamine, tranquilizers, stimulants, 
hallucinogens, and sedatives. See Table 3.2 for a complete report of the sample’s 




Table 3.2. Substance dependence and abuse descriptives among the 2017 NSDUH 
representative sample. 
 N Weighted N SE % 
Nicotine dependence (past month)     
No 37,295 220,176,618 1,753,729 89.08 
Yes 5,259 26,983,923 536,289 10.92 
Alcohol dependence or abuse (past year)     
No/Unknown 39,352 233,120,658 1,736,561 94.32 
Yes 3,202 14,039,883 368,169 5.68 
Marijuana dependence or abuse (past year)    
No/Unknown 41,528 243,761,480 1,771,558 98.62 
Yes 1,026 3,399,061 156,208 1.38 
Cocaine dependence or abuse (past year)    
No/Unknown 42,336 246,207,296 1,821,123 99.61 
Yes 218 953,245 83,112 0.39 
Inhalant dependence or abuse (past year)    
No 42,529 247,081,929 1,826,055 99.97 
Yes 25 78,612 23,659 0.03 
Methamphetamine dependence or abuse (past year)   
No 42,344 246,181,316 1,823,711 99.60 
Yes 210 979,226 83,033 0.40 
Tranquilizer dependence or abuse (past year)    
No 42,391 246,472,747 1,822,516 99.72 
Yes 163 687,794 76,503 0.28 
Stimulant dependence or abuse (past year)    
No 42,410 246,652,454 1,810,136 99.79 
Yes 144 508,087 56,146 0.21 
Hallucinogen dependence or abuse (past year)    
No 42,480 246,895,056 1,820,361 99.89 
Yes 74 265,485 39,301 0.11 
Sedative dependence or abuse (past year)    
No 42,520 246,956,278 1,815,154 99.92 
Yes 34 204,264 49,397 0.08 
Opioid dependence or abuse (past year)     
No 42,078 245,141,619 1,814,631 99.18 




Independent unadjusted models. All biopsychosocial characteristics were 
tested independently in unadjusted models to examine the relationship of each 
characteristic on opioid misuse. All characteristics tested independently at some level 





Table 3.3. The unadjusted relationships between independent biopsychosocial 
characteristics and opioid misuse (N = 42,554; weighted N = 247,160,541). 
  95% CI 
 OR Lower Upper 
Age     
18-25 years old 16.36 6.77 39.50 
26-34 years old 18.42 7.86 43.18 
35-49 years old 9.96 4.08 24.34 
50-64 years old 10.48 4.20 26.13 
65 years and older ref. - - 
Sex/Gender    
Male 1.65 1.23 2.23 
Female ref. - - 
Race/Ethnicity    
White 3.75 1.42 9.92 
Black/African American 2.52 0.82 7.72 
Native American/AK Native 7.93 2.50 25.22 
Native HI/Other Pacific Islander 2.97 0.31 28.14 
Non-Hispanic more than one race  3.80 1.27 11.40 
Hispanic 1.28 0.41 4.02 
Asian ref. - - 
Sexual Identity    
Lesbian or gay 1.32 0.62 2.78 
Bisexual 2.40 1.55 3.71 
Heterosexual, i.e., straight ref. - - 
Educational attainment    
Less than high school  2.69 1.54 4.71 
High school grad 1.93 1.24 3.00 
Some college/associate’s degree 2.25 1.42 3.56 
College graduate ref. - - 
Family Income    
Less than $20,000 2.99 1.88 4.76 
$20,000-$49,999 1.94 1.33 2.84 
$50,000-$74,999 1.95 1.16 3.29 
$75,000 or more ref. - - 
Population Density    
Segment in a CBSA with 1 million+ 1.17 0.76 1.81 
Segment in a CBSA with less than 1 million 1.65 1.05 2.58 
Segment not in a CBSA ref. - - 
Employment (past week)    
Disabled  8.64 3.62 20.63 
Has job/volunteer worker, did not work past week 1.54 0.64 3.69 
In school/training  2.51 0.85 7.38 
Retired 0.46 0.15 1.43 
Unemployed/laid-off, looking for work 7.78 3.67 16.50 
Worked at full-time job 2.61 1.19 5.72 
Worked at part-time job 2.27 0.90 5.74 
Keeping house full-time ref. - - 
Arrested and Booked for Breaking the Law   
No ref. - - 




Table 3.3. Continued.   
  95% CI 
 OR Lower Upper 
Overall Health Status    
Fair/Poor 8.32 5.09 13.59 
Good  5.29 3.28 8.52 
Very Good 3.25 2.08 5.08 
Excellent ref. - - 
Serious Psychological Distress in Past Year   
No ref. - - 
Yes 10.56 8.11 13.75 
Suicidality in Past Year    
No ref. - - 
Yes 8.94 6.50 12.31 
Private Health Insurance    
No 3.66 2.65 5.06 
Yes ref. - - 
Nicotine Dependence (past month)    
No ref. - - 
Yes 10.61 7.82 14.40 
Alcohol Dependence or Abuse (past year)   
No/Unknown ref. - - 
Yes 5.61 4.25 7.41 
Marijuana Dependence or Abuse (past year)   
No/Unknown ref. - - 
Yes 16.95 10.95 26.24 
Cocaine Dependence or Abuse (past year)   
No/Unknown ref. - - 
Yes 54.88 34.72 86.73 
Inhalant Dependence or Abuse (past year)   
No ref. - - 
Yes 133.03 36.47 485.30 
Methamphetamine Dependence or Abuse (past year)  
No ref. - - 
Yes 55.35 34.91 87.74 
Tranquilizer Dependence or Abuse (past year)   
No ref. - - 
Yes 132.24 86.83 201.40 
Stimulant Dependence or Abuse (past year)   
No ref. - - 
Yes 68.84 40.61 116.67 
Hallucinogen Dependence or Abuse (past year)   
No ref. - - 
Yes 41.60 21.67 79.85 
Sedative Dependence or Abuse (past year)   
No ref. - - 
Yes 77.83 30.93 195.86 





Adjusted multivariate logistic regression models. Model 1 found that 
sociodemographic factors such as age, sex/gender, race/ethnicity, sexual identity, 
educational attainment, family income, residence based on population density, and 
employment were positively predictive of opioid misuse. In Model 2, I added the 
socioecological factor of past criminality, which was predictive of opioid misuse, while 
controlling for sociodemographic factors. In Model 3, health factors such as overall 
reported health, serious psychological distress in past year, suicidality in the past year, 
and not having private health insurance were added (while controlling for 
sociodemographic and socioecological factors), and were predictive of opioid misuse. In 
Model 4, other substance dependences and abuses were added to the model, which was 
controlled for sociodemographic, socioecological, and health factors. The model fit 
using a max-rescaled R2 value of 0.36 revealed that Model 4 was superior, and as such 
was selected for interpretation (see Table 3.4 for complete model comparisons).  
Age groups were associated with opioid misuse; 26- to 34-year-olds were at 4.5 
odds (95% CI: 1.2-16.2) and 50- to 64-years-olds were at 3.6 odds (95% CI: 1.1-11.7) of 
opioid misuse compared to 65 and older individuals. Those participants residing in a 
CBSA with 1 million or more individuals or residing in a CBSA with less 1 million 
individuals were at about 2.1 odds (95% CI: 1.3-3.5 and 95% CI: 1.2-3.6, respectively) 
of opioid misuse compared to those not residing in CBSA. Types of employment were 
also predictive of opioid misuse; a participant working a full-time job was at 2.4 odds 
(95% CI: 1.1-5.5) and an unemployed participant was at 3.1 odds (95% CI: 1.4-6.7) of 




compared to no prior history of criminality, was a positive predictor of opioid misuse 
(AOR = 2.9, 95% CI: 2.1-3.9). Moreover, overall self-reported health was a positive 
predictor of opioid misuse when individuals reported fair/poor (AOR = 3.0, 95% CI: 1.7-
35.4), good (AOR = 2.9, 95% CI: 1.7-4.9), and very good health (AOR = 2.3, 95% CI: 
1.5-3.6) rather than excellent health. Participants with mental health indicators, such as 
serious psychological distress in the past year or suicidality in the past year, were at 3.8 
odds (95% CI: 2.4-6.0) and 1.7 odds (95% CI: 1.0-2.8) of opioid misuse when compared 
to those participants having no respective reports in the past year. Participants not having 
health insurance were associated with 2.1 increased odds (95% CI: 1.8-3.4) of opioid 
misuse compared to participants with health insurance. Participants exhibiting substance 
dependence or abuse, with the notable exception of alcohol, were positively associated 
with increased odds of opioid misuse compared to those with no substance dependence 
or abuse (nicotine: AOR = 3.0, 95% CI: 2.1-4.2; marijuana: AOR = 2.9, 95% CI: 1.4-
5.9; cocaine: AOR = 3.2, 95% CI: 1.6-6.5; inhalant: AOR = 13.8, 95% CI: 3.2-59.9; 
methamphetamine: AOR = 3.7, 95% CI: 1.7-8.2; tranquilizers: AOR = 13.8, 95% CI: 






Table 3.4. Adjusted multivariate logistic regression models testing the relationship of biopsychosocial factors on opioid 
misuse on the 2017 NSDUH sample. 
 Model 1 Model 2 Model 3 Model 4 
  95% CI  95% CI  95% CI  95% CI 
 AOR Lower Upper AOR Lower Upper AOR Lower Upper AOR Lower Upper 
Age                 
18-25 years old 11.45 3.61 36.26 11.10 3.45 35.73 5.86 1.85 18.53 3.52 1.00 12.41 
26-34 years old 16.90 5.28 54.15 11.49 3.50 37.78 6.29 1.91 20.67 4.52 1.26 16.20 
35-49 years old 9.31 2.84 30.60 6.06 1.82 20.22 3.65 1.10 12.16 3.12 0.88 11.10 
50-64 years old 7.78 2.53 23.98 5.67 1.83 17.62 4.44 1.43 13.81 3.57 1.09 11.67 
65 years and older ref. - - ref. - - ref. - - ref. - - 
Sex/Gender              
Male 1.49 1.11 2.00 1.02 0.77 1.36 1.33 1.00 1.76 1.25 0.90 1.73 
Female ref. - - ref. - - ref. - - ref. - - 
Race/Ethnicity             
White 3.27 1.21 8.84 2.29 0.85 6.14 2.00 0.68 5.82 1.34 0.47 3.79 
Black/African American 1.32 0.44 3.91 0.93 0.31 2.77 0.87 0.28 2.76 0.72 0.26 2.02 
Native American/Alaska Native 3.99 1.23 12.90 2.19 0.68 7.08 2.14 0.59 7.69 1.28 0.37 4.47 
Native Hawaiian/Pacific Islander 1.75 0.18 17.11 1.23 0.14 11.15 1.04 0.11 9.77 0.65 0.07 6.10 
Non-Hispanic more than one race  2.14 0.69 6.69 1.35 0.43 4.27 1.08 0.32 3.67 0.89 0.26 3.00 
Hispanic 0.59 0.19 1.87 0.50 0.15 1.64 0.49 0.14 1.70 0.45 0.13 1.55 
Non-Hispanic Asian ref. - - ref. - - ref. - - ref. - - 
Sexual Identity             
Lesbian or gay 1.07 0.49 2.30 1.00 0.45 2.20 0.75 0.33 1.70 0.54 0.20 1.50 
Bisexual 1.63 1.04 2.56 1.46 0.92 2.31 0.84 0.51 1.38 0.64 0.35 1.17 
Heterosexual, i.e., straight ref. - - ref. - - ref. - - ref. - - 
Educational Attainment             
Less than high school  2.69 1.54 4.71 2.01 1.15 3.54 1.57 0.90 2.75 1.08 0.55 2.14 
High school grad 1.93 1.24 3.00 1.48 0.94 2.34 1.27 0.82 1.97 1.12 0.67 1.89 
Some college/associate’s degree 2.25 1.42 3.56 1.77 1.09 2.89 1.46 0.91 2.33 1.22 0.68 2.20 
College graduate ref. - - ref. - - ref. - - ref. - - 
Family Income             
Less than $20,000 2.05 1.19 3.53 1.56 0.93 2.64 0.88 0.56 1.40 0.71 0.43 1.20 
$20,000-$49,999 1.74 1.12 2.71 1.48 0.96 2.28 0.94 0.63 1.40 0.91 0.58 1.41 
$50,000-$74,999 1.81 1.02 3.19 1.62 0.92 2.85 1.31 0.76 2.25 1.25 0.69 2.28 






Table 3.4. Continued. Model 1 Model 2 Model 3 Model 4 
  95% CI  95% CI  95% CI  95% CI 
 AOR Lower Upper AOR Lower Upper AOR Lower Upper AOR Lower Upper 
Population Density of Residence                
In a CBSA with 1 million+ 1.92 1.20 3.07 1.84 1.16 2.94 1.90 1.22 2.97 2.09 1.25 3.51 
In a CBSA with < 1 million 1.95 1.23 3.08 1.88 1.18 2.98 1.92 1.22 3.02 2.11 1.23 3.63 
Not in a CBSA ref. - - ref. - - ref. - - ref. - - 
Employment (past week)             
Worked at full-time job 2.45 1.14 5.27 2.36 1.08 5.15 2.80 1.23 6.38 2.42 1.07 5.46 
Worked at part-time job 2.23 0.89 5.59 2.27 0.90 5.70 2.05 0.78 5.40 1.94 0.74 5.06 
Has job/volunteer worker 1.60 0.65 3.90 1.53 0.61 3.81 1.26 0.45 3.51 0.62 0.14 2.81 
Unemployed/laid-off 6.72 3.23 13.95 6.44 3.10 13.41 5.00 2.28 10.98 3.10 1.43 6.71 
In school/training  1.65 0.56 4.87 2.00 0.67 5.97 2.20 0.72 6.71 2.72 0.93 7.93 
Retired 1.74 0.42 7.26 1.71 0.39 7.40 1.43 0.35 5.81 1.37 0.32 5.86 
Disabled  6.55 2.77 15.51 5.60 2.33 13.45 2.39 0.93 6.18 1.96 0.74 5.15 
Keeping house full-time ref. - - ref. - - ref. - - ref. - - 
Arrested and Booked     5.64 4.29 7.40 4.27 3.32 5.49 2.89 2.14 3.90 
Overall Health               
Fair/poor       4.19 2.44 7.19 3.00 1.65 5.44 
Good        3.85 2.33 6.37 2.88 1.71 4.86 
Very good       2.85 1.81 4.50 2.32 1.51 3.56 
Excellent       ref. - - ref. - - 
Serious Psychological Distress a         4.93 3.43 7.07 3.82 2.44 6.00 
Suicidality in Past Year a         2.12 1.42 3.16 1.67 1.01 2.75 
No Private Health Insurance a         2.48 1.82 3.39 2.12 1.46 3.09 
Nicotine Dependence a             3.01 2.14 4.23 
Alcohol Dependence or Abuse a             1.26 0.87 1.81 
Marijuana Dependence or Abuse a             2.88 1.39 5.94 
Cocaine Dependence or Abuse a             3.18 1.57 6.45 
Inhalant Dependence or Abuse a             13.76 3.16 59.94 
Methamphetamine Dependence or Abuse a            3.71 1.68 8.20 
Tranquilizer Dependence or Abuse a             13.75 5.90 32.07 
Stimulant Dependence or Abuse a             5.25 1.76 15.63 
Model Fit             
Max-rescaled R2  0.115   0.169   0.263   0.363  





A comprehensive approach to understand the role of biopsychosocial 
characteristics as risk factors influencing opioid misuse in the form of dependence or 
abuse was undertaken. I found that the domains of sociodemographic, sociocultural, and 
health factors, as well as other substance dependence or abuse, were significant 
biopsychosocial risk characteristics predicting opioid misuse. Sociodemographic factors 
of age group, population density of residence, and employment in past week were 
significant. The socioecological factor of criminality was also significant. All health 
factors, which are self-reported health status, serious psychological distress, suicidality, 
and private health insurance, were significant risk characteristics of opioid misuse. 
Nicotine, marijuana, cocaine, inhalant, methamphetamine, tranquilizer, and stimulant 
substance dependence or abuse were significant predictors of opioid misuse. 
Sociodemographic indicators such as age have generally been a definitive risk 
factor in opioid misuse, as has sex/gender and race/ethnicity at an epidemiological level 
when considering overdose death studies like Scholl et al. (2019) and Joshi et al. (2019). 
However, I found that sociodemographic factors in the comprehensive model were not 
the strongest predictors to opioid misuse. Similar to Scholl et al.’s findings on opioid 
overdose deaths, which reported that from 2016 to 2017 there was an increase in misuse 
among those over the age of 25, I found that the age groups of 26- to 34-year-olds and 
50- to 64-year-olds remained as predictors of opioid misuse. Scholl et al. found that the 
largest increase was among males aged 25 to 44 years old. An inverse relationship was 




the 15- to 24-year-old age group (Scholl et al., 2019), which may explain my findings 
concerning the 18- to 25-year-old age group. Thus, 18- to 25-year-olds may be at 
increased risk, but we must interpret with caution (AOR = 3.5, 95% CI: 1.0-12.4). In 
regard to the 50- to 64-year-old age group misusing opioids, recent studies have reported 
this relationship in certain scenarios. Chang (2018) found 50- to 64-year-olds to be at 
risk of opioid misuse when in chronic pain, and Choi, DiNitto, Marti, and Choi (2018) 
found this older adult group at risk when using emergency department services.  
Age, sex/gender, and race/ethnicity demonstrate a mixed relationship with opioid 
misuse and disorders. In the comprehensive model, neither sex/gender nor race/ethnicity 
was found to be predictive of opioid misuse, which may be indicative of prescription 
opioid-related deaths remaining stable across all racial/ethnic groups in most states 
(Scholl et al., 2019). However, other variables may be confounding the effects of 
race/ethnicity on opioid misuse. Jones (2017) took a comprehensive approach to 
examine the trend of decreasing nonmedical use of prescription opioids from the 2003 to 
2014 NSDUH. In that study, the sociodemographic indicators of race/ethnicity and 
family income were found to be predictive of opioid dependence or abuse, specifically 
among non-Hispanic Whites when compared to other race/ethnicities and income groups 
under $50,000 compared to those over the $75,000 family income bracket. Jones, 
however, did not include sexual identity, criminality, general health, or mental health 
indicators, such as psychological distress and suicidality. Winkelman Chang, and 
Binswanger (2018) found that those reporting any level of opioid use versus no opioid 




reporting chronic health condition, severe mental health issues, disability, or co-
occurring substance use.  
Examining opioid misuse using nationally representative data, Mojtabai, Amin‐
Esmaeili, Nejat, & Olfson (2019) found that prescribed-opioid misuse was associated 
with criminality, mental health distress, benzodiazepine misuse and other substance 
abuse or dependence. Similarly, Grigsby & Howard (2019) found that prescription 
opioid and polysubstance users had the greatest probability of past-year criminality and 
mental health distress. Moreover, Prince (2019) found that individuals with opioid 
misuse disorder who had a severe mental illness were at an increased risk of criminality 
and suicidality. The risk increased between those using only heroin, both heroin and 
prescription opioids, and all other substance use disorders, in that order. 
Other substance dependence or abuse has been associated with opioid misuse 
based on varying sociodemographic factors (John et al., 2019; Jones, 2017; Nicholson & 
Vincent, 2018; Snyder, Morse, & Bride, 2019; Tetrault et al., 2008). I specifically 
examined nicotine (John et al., 2019; Rajabi, Dehghani, Shojaei, Farjam, & Motevalian, 
2019), marijuana (John et al., 2019), cocaine (Snyder et al., 2019), inhalant (Tetrault et 
al., 2008), methamphetamine (Ellis, Kasper, & Cicero, 2018), tranquilizers (Jones, 
Mogali, & Comer, 2012; Maree, Marcum, Saghafi, Weiner, & Karp, 2016; Schepis, 
Simoni-Wastila, & McCabe, 2019), and stimulants (Kecojevic, Wong, Corliss, & 
Lankenau, 2015) and found a relationship of increased odds toward opioid misuse in the 
adjusted models. Although the present study revealed an increased association of opioid 




literature has been mixed. A more recent review found that marijuana use may have a 
decrease the probability of opioid misuse (Campbell, Hall, & Nielsen, 2018). In fact, in 
reviewing ecological and epidemiological studies, Campbell et al. (2018) found that 
medical cannabis laws/use decreases opioid overdose deaths in states that allow 
marijuana use compared to states that do not have medical marijuana laws. Furthermore, 
unlike the findings of other studies (e.g., Fernandez et al., 2019), alcohol dependence or 
abuse was not associated with opioid misuse in my adjusted model.  
Overall, prevention strategies and prevention programs must focus on both the 
combined use of legal and illicit substances and medically prescribed psychotherapeutic 
substances (e.g., benzodiazepines) to stave off the opioid epidemic. Our study took a 
comprehensive approach to understand how multiple biopsychosocial variables combine 
to predict opioid misuse. Individuals are influenced by collections of multiple factors, 
and any research should account for this variety of factors when considering causes, 
effects, and cures. Although comprehensive models can be cumbersome, they allow the 
researcher the ability to examine multiple risk factors to create profiles of misuse at a 
population level. 
Limitations 
To my knowledge, this is the first U.S. population-level study to 
comprehensively address risk profiles of opioid misuse using the latest data available. As 
with most surveys of this kind, there are limitations to the NSDUH. The most prominent 
limitation is the use of self-reported data. These data are subject to the individual 




established the validity of the NSDUH, the data are not longitudinal, but cross-sectional. 
The data are nationally representative; however, they do exclude a small population 
subset. The NSDUH targets noninstitutionalized U.S. citizens, so active-duty military 
members and institutionalized groups (e.g., prisoners, hospital patients, treatment center 
patients, and nursing home members) are excluded. Thus, if substance use differs 
between U.S. noninstitutionalized and institutionalized groups by more than 3%, data 
may be problematic for the total U.S. population (Center for Behavioral Health 
Statistics, 2018). Another issue that may have introduced bias is participant knowledge 
or lack thereof concerning opioids and other substances (Palamar, 2018). Finally, opioid 
misuse data does not fully account for synthetic opioids like fentanyl. 
Conclusion 
This study provides the most recent and comprehensive risk assessment of 
possible biopsychosocial characteristics indicative of opioid misuse. Findings provide 
the population-level risk factors to improve risk assessments and to tailor future 
interventions to stem and ameliorate the opioid epidemic. For instance, at-risk 
individuals were both full-time employed or unemployed with a history of criminality, 
serious psychological distress, suicidality, no private health insurance, and substance 
dependence or abuse. Individuals, however, are not variables representative of risk 
factors on an outcome to opioid misuse. At a population-level analysis, we must 
acknowledge that findings of a person-centered approach such as this work only 
represent findings based on a population average. More specialized approaches, such as 




findings serve a population-level risk profile using the most recent U.S. nationally-
representative data to inform epidemiological trends and possible large-scale 
interventions.  
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The statistics delineating the opioid epidemic in the United States are both 
staggering and sobering. Over 130 people die daily from opioid overdose (National 
Institute on Drug Abuse, 2019). Opioid misuse in the U.S. resulted in an estimated 1.68 
million years of life lost in 2016 (Gomes, Tadrous, Mamdani, Paterson, & Juurlink, 
2018). Every year, opioid-related deaths have increased and are projected to continue to 
increase in the years to come. Over 63,630 overdose deaths were reported in 2016, with 
66.4% (42,249) involving an opioid of some kind (Hedegaard, Warner, & Miniño, 
2017). In 2017, more than 67.8% (47,600) of the 70,237 overdose deaths reported in the 
U.S. involved opioids (Scholl, Seth, Kariisa, Wilson, & Baldwin, 2019). The true extent 
of overdose deaths may also be underestimated (Seth, Rudd, Noonan, & Haegerich, 
2018). Despite the staggering number of opioid overdose deaths attributed to misuse, 
prevention strategies and intervention programs have been seemingly ineffective in 
stemming the opioid epidemic.  
Conventional interventions, while effective in stemming overdose deaths, have 
had a minimal impact since deaths have only increased from year to year. Projections 
have also been foreboding; opioid overdose deaths are estimated to increase 61% by 




targeting the incidence of opioid prescriptions would decrease overdose deaths by 2025. 
It was found that the worst-case scenario would decrease overdose deaths by 3.0% and 
the best-case scenario by 5.3%. The best-case scenario was projected under the scenario 
of a 50% decrease in prescribing opioids based on historical trends. A similar study by 
Pitt, Humphreys, and Brandeau (2018) modeled how multiple interventions would affect 
the status quo trajectory of the opioid epidemic.  
  Pitt et al. (2018) found some interventions over a 5-year projection would have 
a positive impact on life years, quality-adjusted life years, and opioid related-overdose 
deaths. Such interventions included naloxone availability, needle exchange programs, 
opioid medication-assisted addiction treatment, as well as psychosocial treatment. Other 
interventions, such as reduced prescribing for pain patients and excess opioid medication 
management, would positively impact life years and quality-adjusted life years, but not 
overdose deaths. The 5-year projections found that in the case of these interventions, 
overdose deaths would actually increase and be heroin-related because patients would 
transition to heroin use. The most poignant finding from Pitt et al. was that the largest 
projected impact from an intervention was increasing naloxone availability. The 
projected overdose death decrease was 4%. However, much work is still needed to 
improve surveillance and response needed to effectively provide naloxone in the United 
States (Dodson, Enki Yoo, Martin-Gill, & Roth, 2018).  
  Chen et al. (2019) and Pitt et al.’s (2018) studies revealed that current universal 
interventions are not enough in addressing the multidimensional and dynamic aspects of 




levels, and others are related to opioid overdose deaths (Scholl et al., 2019). Before 
providing treatment, we must first understand opioid misuse and related disorders that 
lead to overdose. Patients prescribed opioids for chronic pain misuse them at rates 
estimated between 21 to 29% in the U.S. (National Institute on Drug Abuse, 2019; U.S. 
Department of Health and Human Services, 2019). Misuse can then lead to 12% of 
patients developing a misuse disorder (U.S. Department of Health and Human Services, 
2019).  
Multiple biopsychosocial factors—such as demographic characteristics 
(Nicholson & Vincent, 2018; Tetrault et al., 2008), socioecological indicators 
(Winkelman, Chang, & Binswanger, 2018), overall general and mental health status 
(Becker, Sullivan, Tetrault, Desai, & Fiellin, 2008; Braden, Edlund, & Sullivan, 2017), 
and co-substance dependence and abuse (Grigsby & Howard, 2019; Rajabi, Dehghani, 
Shojaei, Farjam, & Motevalian, 2019)—have been related to opioid misuse disorders 
(Havens et al., 2009; Schuler, Rice, Evans-Polce, & Collins, 2018). By exploring these 
factors, the most successful public health strategies identify the most salient factors to 
address unique, high-risk subgroups that can be hidden in the epidemiological data.  
To ameliorate the public health burden and intervene upon opioid-related deaths, 
we need targeted interventions designed from identifying risk profiles of opioid misuse. I 
identified risk subgroups using biopsychosocial characteristics as risk factors leading to 
opioid misuse in the form of heroin, prescription pain relievers, or heroin and 
prescription pain reliever use. This study is among the first to use a person-centered 




and examine opioid misuse subgroup risk profiles. While it is known that individual’s 
misusing opioids will use heroin, prescription pain relievers, or a combination of both, 
the respective risk profiles are unknown. The purpose of this study is to fill a critical gap 
in the literature by identifying opioid misuse risk subgroups to better inform prevention 
strategies and intervention programs.   
Methods 
Latent class analysis (LCA) is a person-centered approach that allows for 
observed variables to group on an unobserved or latent outcome. This approach provides 
a less biased model because algorithms, not the researcher, group variables into classes 
or risk subgroups based on the outcome. The 2017 National Survey on Drug Use and 
Health (NSDUH) provided a representative sample of noninstitutionalized U.S. adults 18 
years and older that self-reported opioid dependence or abuse. LCA was used on the 
2017 NSDUH to identify the number of risk subgroups using biopsychosocial 
characteristics as observed risk factors to opioid misuse—in other words, the distal 
outcome. Other substance dependence or abuse was also accounted for as covariates in 
the model. 
Risk Factors, Indicator Variables, and Latent Outcome 
Opioid misuse risk groups were identified using the following 14 observed 
variables from the 2017 NSDUH: (1) age group; (2) sex/gender; (3) race/ethnicity (i.e., 
non-Hispanic White, Black, and other racial/ethnic groups, which included Native 
American/Alaska Native, Native Hawaiian/other Pacific Islander, Asian, and Hispanic); 




bisexual); (5) residence (i.e., based on core-based statistical areas [CBSAs] detailed in 
the Office of Management and Budget, 2009); (6) family income; (7) educational 
attainment; (8) employment; (9) past criminality (i.e., arrested and booked in lifetime); 
(10) overall general health; (11) serious psychological distress in past year; (12) 
suicidality in past year; (13) private health insurance; and (14) type of opioid 
dependence and abuse (i.e., heroin, prescription pain reliever, or both heroin and 
prescription pain reliever). All aforementioned observed variables were used as risk 
indicators to model the latent categorical distal outcome of opioid misuse. 
Substance Dependence and Abuse Covariates 
Nicotine dependence in the past month was assessed using Nicotine Dependence 
Syndrome Scale scores, as well as the Fagerstrom Test of Nicotine Dependence scale. 
Self-reported alcohol and marijuana dependence and abuse in the last year was also 
ascertained. Moreover, dependence and abuse in the past year were ascertained for the 
following substances: cocaine, hallucinogens, inhalants, methamphetamines, 
tranquilizers, stimulants (independent of methamphetamine), and sedatives.  
Latent Class Analysis Model Assessment 
A model comparison approach was used to determine the number of classes. 
Multiple models were created (i.e., 2-, 3-, 4-, 5-class solutions, and so on) to then select 
the best model based on two criteria: (1) high entropy (i.e., the acceptable quality of 
classification); and (2) parsimony assessed via a sample-size-adjusted Bayesian 
information criterion (ssaBIC; Nylund, Asparouhov, & Muthén, 2007). Models were 




calculated to assess fit indices and compare with subsequent models. Covariates were 
assessed using multinomial logistic regression on the final model selected. All LCAs 
were conducted using Mplus 8.2 (Muthén & Muthén). 
 Results 
Sample Characteristics 
The sample selected for analysis from the 2017 NSDUH was restricted to 
noninstitutionalized U.S. adults 18 years and older who self-reported opioid dependence 
or abuse (N = 476; weighted N = 2,018,922). The weighted sample’s age was almost 
evenly distributed between 18- to 25-year-olds and 50- to 64-year-olds. The weighted 
sample was mostly male (60.6%), non-Hispanic White (77.9%), resided in a CBSA with 
less than 1 million people (48.4%), was heterosexual (90.5%), had a family income of 
$50,000 or more (39.8%), had some college or an associate’s degree (39.2%), worked 
full-time (42.4%), had been arrested and booked (61.8%), was in overall good health 
(37.1%), had serious psychological distress (56.2%), had no suicidality (71.9%), and was 






Table 4.1. Sample descriptive characteristics (N = 476; Weighted N = 2,018,922). 
 N Weighted N SE % 
Age Groups     
18-25 years old 184 434,589 40,663 21.53 
26-34 years old 135 563,428 54,187 27.91 
35-49 years old 112 472,721 47,539 23.41 
50 and older 45 548,185 90,514 27.15 
Sex     
Male 265 1,222,669 115,706 60.56 
Female 211 796,254 75,701 39.44 
Race/Ethnicity     
White 338 1,571,681 110,436 77.85 
Black/African American 39 197,841 42,519 9.80 
Hispanic 55 135,898 29,026 6.73 
Other 44 113,503 23,833 5.62 
Area of Residence by Population Density    
Segment in a CBSA with 1 million or more 174 953,553 89,220 47.23 
Segment in a CBSA with less than 1 million 271 977,657 85,843 48.42 
Segment not in a CBSA 31 87,712 19,306 4.34 
Sexual Identity     
Heterosexual, i.e., straight 415 1,787,231 124,244 90.54 
Lesbian or gay or bisexual 56 186,810 32,311 9.46 
Family Income     
Less than $20,000 146 554,213 58,753 27.45 
$20,000-$49,999 160 660,461 76,797 32.71 
$50,000 or more 170 804,248 89,361 39.84 
Level of Education     
Less than high school 85 365,647 69,763 18.11 
High school graduate 170 574,564 49,728 28.46 
Some college/associate’s degree 178 791,363 83,051 39.20 
College graduate 43 287,347 52,808 14.23 
Employment Status (past week)     
Not employed 244 978,466 76,555 49.15 
Employed 226 1,012,321 106,086 50.85 
Ever Arrested and Booked     
No 199 769,653 71,355 38.24 
Yes 274 1,242,914 117,828 61.76 
Overall Health Status     
Fair/poor 199 568,500 64,611 28.25 
Good 179 746,798 76,174 37.11 
Very good/excellent 177 696,856 81,016 34.63 
Serious Psychological Distress Indicator (past year)   
No 208 883,497 80,824 43.76 
Yes 268 1,135,425 101,215 56.24 
Suicidality (past year)     
No 342 1,443,794 112,109 71.86 
Yes 131 565,507 74,671 28.14 
Covered by Private Health Insurance    
No 173 714,748 94,283 35.62 





Opioid misuse was characterized by three categories: (1) those using heroin only; 
(2) those using prescription pain relievers; and (3) those who used both heroin and 
prescription pain relievers. The majority of the weighted sample used only pain relievers 
(66.0%). The weighted sample also reported 55.6% nicotine dependence in the past 
month, as well as 24.7% alcohol and 17.6% marijuana dependence or abuse in the past 
year. Other concurrent substance dependence or abuse in the past year (35.5) was also 
reported (i.e., inhalants, methamphetamine, tranquilizers, stimulants, hallucinogens, and 
sedatives). The substance that NSDUH participants reported having the highest 
dependence on was nicotine (55.6%). See Table 4.2 for the sample’s full substance 
dependence or abuse profile. 
 
Table 4.2. Substance dependence and abuse among 2017 NSDUH sample (N = 476; 
Weighted N = 2,018,922). 
 N Weighted N SE % 
Nicotine Dependence (past month)    
No 209 896,857 97,419 44.42 
Yes 267 1,122,066 104,780 55.58 
Alcohol Dependence or Abuse (past year)   
No/unknown 334 1,520,322 115,962 75.30 
Yes 142 498,601 55,085 24.70 
Marijuana Dependence or Abuse (past year)   
No/unknown 394 1,664,216 115,234 82.43 
Yes 82 354,706 66,896 17.57 
Other Substance Dependences or Abuse (past year)   
No/unknown 301 1,307,249 103,939 64.75 
Yes 60 711,673 75,572 35.25 
Opioid Dependence or Abuse (past year)  
Heroin only 103 433,756 60,786 21.48 
Pain reliever only 311 1,333,263 104,414 66.04 






Latent Class Analysis Model Selection 








Classification accuracy of the four-class model solution was high, with an 
entropy value of 0.864 (see Table 4.3). 
 
 
Table 4.3. LCA fit statistics for model comparisons.  
Models Sample Size Adjusted BIC Entropy 
One-class solution 11102.879 - 
Two-class solution 10822.043 0.743 
Three-class solution 10752.437 0.777 
Four-class solution a 10697.874 0.864 
Five-class solution 10642.134 0.859 
Six-class solution 10586.156 0.860 
Seven-class solution 10555.860 0.852 


























Latent Class Analysis  
Class 1, or single opioid users (25.7% of sample), primarily used prescription 
opioids or heroin (71.5% and 24.0% conditional probability, respectively). This class 
was not defined by a single age group, but had a high conditional probability of being in 
the 26-34 age group (31.1%). Single opioid users had a high likelihood of being male 
(87.5%), identifying as heterosexual (95.3%), residing in a CBSA with more than 
1 million individuals (60.6%), reporting a family income of more than $50,000 (72.2%), 
being employed (84.4%), having some college or associate’s degree (46.0%), and never 
being arrested and booked (66.9%). Single opioid users also had one of the most 
racially/ethnically diverse groups, as well as the highest likelihood of non-Hispanic 
Black/African Americans (12.6%) and Hispanics (11.6%) compared to any other classes. 
Health wise, single opioid users reported a higher likelihood of excellent or very good 
health (55.9%), no serious psychological distress in the past year (72.8%), no past year 
suicidality (85.9%), and having private health insurance (72.9%).  
Class 2, or prescription opioid or combination users (4.7% of sample), used 
either prescription opioids or a combination of heroin and prescription opioids (78.1% 
and 21.9% conditional probability, respectively). This class was exclusively in the 50 
and older age group, male, non-Hispanic White, heterosexual, resided in a CBSA with 
more than 1 million individuals, was in good overall health, and had no private health 
insurance. Prescription opioid or combination users had a high likelihood of having a 




having a college degree (55.9%), having been arrested and booked (66.1%), no serious 
psychological distress (66.0%), and past-year suicidality (56.6%).  
Class 3, or prescription opioid users (14.5% of sample), almost exclusively used 
prescription opioids (89.9% conditional probability). This group was not defined by a 
single age group, but the 50 and older group had a 41.4% higher likelihood of being in 
this group as compared to other age groups. Prescription opioid users were found to have 
the highest conditional probabilities of being female (93.8%), residing in a CBSA with 
less than 1 million individuals (56.8%), having private health insurance (81.7%), and 
having serious psychological distress within the past year (76.7%). Prescription opioid 
users also had a high likelihood of having been employed in the past week (76.3%) and 
reporting past-year suicidality (46.8%). Finally, Class 4, or mixed opioid users (55.2% of 
sample), used heroin, prescription opioids, or a combination of heroin and prescription 
opioids (27.4%, 56.5%, and 16.0% conditional probability, respectively). This class, 
similar to single opioid users, had a higher likelihood (31.4%) of being 26-34 years of 
age. Mixed opioid users were almost evenly split between males and females and had the 
highest conditional probability of being in a sexual minority (12.1%), having a family 
income of less than $20,000 (47.0%), having been arrested and booked (74.2%), being 
unemployed in the past week (68.8%), and being in fair/poor overall health (44.4%). 
Mixed opioid users also had a high probability of residing in a CBSA with less than 
1 million individuals (56.7%), reporting serious psychological distress in the past year 
(66.3%), exhibiting no suicidality in past year (72.5%), and having no private health 























(n = 122) 
4.7% 
(n = 22) 
14.5% 
(n = 69) 
55.2% 
(n = 263) 
Age Category     
18-25 years old  0.263 0.000 0.228 0.208 
26-34 years old   0.311 0.000 0.172 0.314 
35-49 years old   0.251 0.000 0.186 0.258 
50 and older 0.175 1.000 0.414 0.220 
Sex/Gender     
Male 0.875 1.000 0.062 0.585 
Female 0.125 0.000 0.938 0.415 
Race/Ethnicity     
White 0.707 1.000 0.863 0.772 
Black/African American 0.126 0.000 0.059 0.103 
Hispanic 0.116 0.000 0.042 0.057 
Other 0.052 0.000 0.037 0.068 
Sexual Identity     
Heterosexual 0.953 1.000 0.901 0.879 
Sexual minority 0.047 0.000 0.099 0.121 
Population Density      
Segment in CBSA 1 million + 0.606 1.000 0.430 0.378 
Segment in CBSA less than 1 million 0.346 0.000 0.568 0.567 
Segment not in CBSA 0.048 0.000 0.002 0.055 
Family Income     
Less than $20,000 0.001 0.007 0.084 0.470 
$20,000-$49,999 0.277 0.219 0.264 0.375 
$50,000 or over 0.722 0.774 0.652 0.155 
Employment Status, Past Week     
Unemployed 0.156 0.653 0.237 0.688 
Employed 0.844 0.347 0.763 0.312 
Education     
Less than high school 0.081 0.321 0.005 0.260 
High school graduate 0.298 0.000 0.112 0.345 
Some college/associate’s degree 0.460 0.120 0.456 0.367 
College graduate 0.161 0.559 0.427 0.028 
Ever Arrested and Booked for Breaking  
the Law 
No 0.331 0.339 1.000 0.258 
Yes 0.669 0.661 0.000 0.742 
Overall Health     
Fair/poor 0.075 0.000 0.106 0.444 
Good 0.366 1.000 0.327 0.333 
Excellent/very good 0.559 0.000 0.568 0.222 
Serious Psychological Distress Indicator in  
Past Year 
No 0.728 0.660 0.233 0.337 























(n = 122) 
4.7% 
(n = 22) 
14.5% 
(n = 69) 
55.2% 
(n = 263) 
 
Seriously Thought About Killing Self in Past Year 
No 0.859 0.434 0.532 0.725 
Yes 0.141 0.566 0.468 0.275 
Private Health Insurance     
No 0.271 1.000 0.183 0.898 
Yes 0.729 0.000 0.817 0.102 
Opioid Dependence or Abuse     
Heroin only 0.240 0.000 0.002 0.274 
Pain reliever only 0.715 0.781 0.899 0.565 
Heroin and pain reliever 0.045 0.219 0.098 0.160 
     
 
 The multinomial logistic regression (see Table 4.5) revealed that prescription 
opioid users (Class 3) were about 77% less likely (95% CI: .23-.82) to report nicotine 
dependence in the last month compared to single opioid users (Class 1). In contrast, 
mixed opioid users (Class 4) were 350% more likely (OR = 4.54, 95% CI: 2.18-9.46) to 
report nicotine dependence in the last month, as well as almost 200% more likely (OR = 
2.98, 95% CI: 1.17-7.60) to report a combination of substance dependence or abuse, than 
single opioid users (Class 1). 
Table 4.5. Multinomial logistic regression of substance dependence and abuse 




Prescription opioid and 
combination users 
Class 3 
Prescription opioid users 
Class 4 
Mixed opioid users 
  95% CI  95% CI  95% CI 
 OR Lower Upper OR Lower Upper OR Lower Upper 
Nicotine Dependence 2.87 0.28 28.99 0.23 0.07 0.82 4.54 2.18 9.46 
Alcohol Dependence 
or Abuse 0.49 0.03 7.77 0.91 0.30 2.70 0.75 0.28 2.03 
Marijuana 
Dependence or Abuse 4.81 0.32 73.00 0.91 0.17 4.91 1.04 0.30 3.60 
Other Substances 





This study revealed four risk subgroups of opioid misuse. I identified single 
opioid users, prescription or combination opioid users, prescription opioid users, and 
mixed opioid users. The single opioid user class had a high likelihood of either using 
only prescription pain relievers or heroin, in that order. This group was racially and 
ethnically diverse—although participants of color were limited in the sample—followed 
by the mixed opioid user class, both of which echoed the epidemiological findings of 
opioid overdose deaths reported in Scholl et al. (2019). Specifically, the two racial/ethnic 
groups with the largest overdose death increase were observed in Black/African 
Americans and Hispanics. The prescription opioid user class was comparatively less 
diverse and predominantly shifted toward non-Hispanic White. The prescription or 
combination opioid use class was the only exclusive non-Hispanic White risk subgroup. 
Unlike what the media has portrayed (Hansen & Netherland, 2016), the opioid epidemic 
involves many racial/ethnic groups. 
I considered the prescription or combination opioid user class to be the highest 
at-risk group because of the reported likelihood of a combination of heroin and 
prescription pain reliever use. The combination opioid misuse suggests that this class 
may have transitioned to heroin use from prescription pain relievers since there was no 
likelihood of heroin-only use. This class exclusively used prescription opioids that are 
known to be risk factor to heroin use (Becker et al., 2008; Carlson, Nahhas, Martins, & 
Daniulaityte, 2016; Cicero, Ellis, Surratt, & Kurtz, 2014; Jones, 2013; Muhuri, Gfroerer, 




individuals using heroin had almost four times increased odds of reporting nonmedical 
use of opioids, as well as almost triple the odds of being dependent on or abusing opioids 
compared to those who did not use heroin. Muhuri et al. (2013), using multiple waves of 
the NSDUH, found that approximately 80% of recent heroin users had initiated opioid 
use with nonmedically prescribed pain relievers. Similarly, Jones (2013), using U.S. 
epidemiological data, found that over 77% of combination heroin and nonmedical 
prescription opioid users reported opioid initiation with prescription pain relievers. 
A temporal effect may also exist with combination opioid use and initiation. 
Cicero et al. (2014) reported that from the 1960s to the 1990s there has been a near 
linear decrease in heroin being the opioid initiation. Based on the prescription or 
combination opioid use class being exclusively age 50 or older, if opioid initiation were 
to have occurred between the 1960s and 1970s, the retrospective probability of heroin 
use would have been more than 80% to 70%, respectively. Inversely, from the 1990s to 
the 2000s, there was a 50% to 75% probability of opioid misuse being a result of 
prescription pain relievers. In the 2010s, however, there was another shift where heroin 
initiation began to increase as prescription opioid initiation dropped (Cicero et al., 2014). 
Initiation cannot be ascertained or if a transition occurred; nevertheless, the high 
combination use of opioids within this class is indicative of specialized prevention 
strategies. Particularly as past-year prescription opioid misuse has been related to a 
lower perception of harm from heroin initiation and risk of regular use (Kapadia & Bao, 
2019). The prescription opioid user class may also be at high risk of transitioning to 




The mixed opioid user class had the second highest likelihood of combined 
heroin and prescription opioid use, as well as the highest likelihood of heroin-only use. 
This risk subgroup may be affected by temporality and initiation effects of heroin use, as 
previously discussed concerning the prescription or combination opioid class. However, 
combination heroin and prescription opioid use, as well as heroin-only use, have been 
associated with various geographic factors (i.e., rural versus urban), socioeconomic 
status, socioecological factors (e.g., criminality), sexual identity (i.e., sexual minority), 
overall health (i.e., poor/fair health), mental health issues (e.g., psychological distress, 
depression, or anxiety), suicidality, and substance-dependence/abuse (Becker et al., 
2008; Braden et al., 2017; Havens et al., 2009; Schuler et al., 2018; Winkelman et al., 
2018). 
Moreover, the mixed opioid use class had almost three times the odds of multiple 
substance dependence or abuse than did the single opioid user class. This fact is 
especially troublesome because mixed opioid users already have a risk of moving from 
the intended oral administration route of prescription pain relievers to non-oral routes of 
administration. Misuse may then take routes of ingestion via non-intended forms (e.g., 
chewing; mixing with water or other substances; rectal administration), inhalation (e.g., 
smoking, snorting, or vaping), or injection (Gasior, Bond, & Malamut, 2016; 
Kestenbaum et al., 2014; Kirsh, Peppin, & Coleman, 2012). When using alternative 
routes of administration, opioid tolerance can also result more readily, which will often 
necessitate a preferred dosing route to increase the potency of the particular substance in 




2012). Other bodily harms are associated with alternative routes of administration that 
can range from minor irritations to tissue necrosis. Intravenous routes of administration 
have also been associated with increased risk of HIV and HCV exposure (Havens, 
Walker, & Leukefeld, 2007; Surratt, Kurtz, & Cicero, 2011; Zibbell et al., 2018). The 
ultimate consequence of alternative routes of administration are unintentional death due 
to overdose (Gasior et al., 2016; Kirsh et al., 2012). 
Limitations  
The NSDUH is a nationally representative instrument for collecting estimates of 
drug use and mental health; however, there are limitations associated with using it. One 
limitation is the use of self-report data, which is subject to the individual bias, 
truthfulness, and recollection of the responder. To address this issue, the NSDUH 
employed the use of audio computer-assisted self-interview (ACASI) software instead of 
human interviewers. While studies have established the validity of the NSDUH, the 
ACASI design and other implementation procedures are designed to boost recall. 
Nevertheless, as is the nature with these survey types, a level of under- and over-
reporting exist (Palamar, 2018). For the purposes of recall in the 2017 cycle, prescription 
drug inquiries for specific and related medications allowed participants to report any 
use/misuse in the past 12 months to allow for the data collection of a given active 
ingredient. These self-reports do not guarantee accuracy in identifying the drugs taken, 
particularly when drugs are reported by brand name. Furthermore, the 2017 NSDUH did 
not include a section for synthetic opioids like fentanyl. Another limitation of the 




offers a momentary prevalence of substance use. Finally, although the data are nationally 
representative, they do exclude a small population subset. The NSDUH targets 
noninstitutionalized U.S. citizens, so active-duty military members and institutionalized 
groups (e.g., prisoners, hospital patients, treatment center patients, and nursing home 
members) are excluded. Therefore, if substance use differs between U.S. 
noninstitutionalized and institutionalized groups by more than approximately 3%, 
estimates provided by the NSDUH data may be inaccurate for the total U.S. population 
(Center for Behavioral Health Statistics, 2018). This inaccuracy has been suggested for 
the prevalence of heroin since it is a less commonly used drug (Center for Behavioral 
Health Statistics, 2018; Palamar, 2018). 
Public Health Implications 
Person-centered approaches such as LCA allow a less biased method to identify 
risk profiles. Latent class analysis uses a mixture analysis wherein algorithms group 
variables to reveal latent or unobserved patterns. Variable-centered approaches like 
logistic regressions may lead to unintentional bias because variables must be selected to 
assess the relationship to an outcome. The person-centered approach, as compared to 
variable-centered approach, provides a method where observed biopsychosocial 
characteristics reveal unobserved opioid misuse risk profiles. Consequently, from a 
single variable of opioid dependence or abuse, I was able to identify four risk subgroups. 
These four subgroups had varied sociodemographic, socioecological, and health 
indicators with varying probabilities of licit and illicit substance dependence and abuse. 




further examined to determine their levels of increasing or transitioning risk. Of 
importance is the fact that all four groups identified were dependent and/or abusing 
opioids and will need tailored interventions to intervene against the possible outcome of 
overdose death. Using LCA, we can examine the risk profiles of each risk subgroup or 
class to create the best and most salient selective interventions, thereby replacing those 
universal opioid prevention strategies that have been found lacking (Fraser & Plescia, 
2019). 
Human Participant Protection 
The Texas A&M University Institutional Review Board assessed the research 
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To my knowledge, no previous studies have used a systematic literature review 
to construct a comprehensive risk profile of opioid misuse in the United States. The 
findings from the systematic literature review elucidated the quality of findings 
concerning opioid misuse risk factors. Similarly, no previous study has used the latest 
wave of the 2017 National Survey on Drug Use and Health (NSDUH; i.e., a nationally 
representative dataset containing opioid misuse data) to construct a population-level risk 
profile and subgroup risk profiles of individuals misusing opioid. Moreover, to my 
knowledge, no known studies have previously identified at-risk subgroups of opioid 
misuse using a person-centered approach.  
Previous chapters have discussed the strengths and weaknesses of both variable-
centered and person-centered methodologies in addressing the growing public health 
crisis of the opioid epidemic using the latest NSDUH and examined the findings of both 
approaches. The goal of this comparative process was to identify population-level risk 
factors to opioid misuse and identify risk subgroups currently dependent on or abusing 
opioids. By using this process, prevention strategies and intervention programs can be 
designed to efficiently and efficaciously intervene upon opioid misuse, specifically in 
regard to heroin and/or prescription opioid use. To this end, this study’s contribution to 
the literature can further inform strategies and programs to substantially stem overdose 




Review of Findings 
Current opioid misuse interventions minimally affect U.S. overdose deaths. 
Every year since the first wave of the opioid epidemic, misuse and overdose deaths have 
increased—so much so that, some two decades after the onset, the U.S. Department of 
Health and Human Services (2019) finally acknowledged the opioid epidemic in 2017. 
However, even after more than two decades of research, projections of prevention 
strategies and intervention programs reveal that by 2025 misuse and overdose deaths 
will only continue to rise (Chen et al., 2019; Pitt, Humphreys, & Brandeau, 2018). Thus, 
in this dissertation, I first assessed the high-quality research available on opioid misuse 
risk factors. Next, using the latest nationally representative data set, I tested the risk 
factors that were identified using a variable-centered approach; that is, the relationship of 
risk factors for opioid misuse were assessed using a multivariable logistic regression. 
The next step was to assess the various risk subgroups for opioid misuse. Four subgroups 
were identified to inform the literature as to what subgroups were at highest risk and 
what biopsychosocial characteristics defined them. By using this process, researchers 
can tailor successful prevention strategies and intervention programs to specific 
symptoms. Each of the three studies contained herein were the first of their kind and will 
be published accordingly. The findings will ultimately inform the gaps in the literature 
and help provide some amelioration to the ever growing opioid epidemic and the 




The Methodological Differences of Variable-Centered and Person-Centered 
Approaches to Understand the U.S. Opioid Epidemic  
Critical to curbing the impact of the opioid epidemic is gaining an understanding 
of the etiology of nonmedical misuse—that is, the factors leading to dependence and 
abuse. Currently, a reductionist, linear perspective predominates the research landscape. 
Variable-centered and linear approaches within that perspective are critical to 
understanding the relationships between biopsychosocial risk factors and opioid misuse, 
and work under the assumption of population homogeneity, which can be presented as 
either a strength or a weakness; this attribution can be tenuous nevertheless. What can be 
attributed as a strength is that inferences can be drawn at a population level. In my case, 
however, relationships are likely not linear or additive, and may be indicative of some 
rudimentary or crude correlations; as the relationships and trends from linear approaches 
are based on averages, which may obscure contextual group or individual level 
differences. Subpopulations and subgroups tend to deviate from assumptions of 
population homogeneity, as in many cases they are outliers. As such, variable-centered 
approaches do not provide a reliable manner to study outlier groups. Person-centered 
approaches using mixture models like latent class analysis (LCA) allow for a method to 
deviate from population-level assumptions and generalize all individuals within the 
subpopulation being studied (Howard & Hoffman, 2017). 
Using data from the NSDUH, I reviewed the strengths and weaknesses of the 




weaknesses of the person-centered approach using LCA and explored how this approach 
can complement variable-centered approaches. 
Study Strengths, Limitations, and Future Directions 
I will first focus on my findings of race/ethnicity on opioid misuse to discuss 
differences between variable-centered and person-centered approaches. Using a variable-
centered approach, race/ethnicity at the population level was not a direct factor on opioid 
misuse; although it did have a stronger role in the LCA. Possible issues in the variable-
centered approach could be other variances from variables in the model were explaining 
the relationship, or perhaps possible unseen interaction effects. Albeit, person-centered 
approaches are not sensitive to averages as variable-centered approaches. I must contend 
with the issue of race/ethnicity as a categorical construct, like many other 
biopsychosocial characteristics (Lillie-Blanton & Laveist, 1996; Nazroo & Williams, 
2006). Thus, the issue with race/ethnicity is threefold. First, it is a construct by which 
marginalization is experienced and perpetrated into biological reality (Gravlee, 2009). 
Second, the construct is a non-intervenable factor, but a predictor of risk (Kriger, 1987; 
Nazroo & Williams, 2006; Williams, Lavizzo-Mourey, & Warren, 1994). Third, race is 
not ethnicity (Helms & Talleyrand, 1997; Nazroo & Williams, 2006), yet most 
constructs use them interchangeably. I cannot discern what the possible issues might be 
as analyses would require further stratification by racial categories and ethnicities. 
Moreover, race/ethnicity is a social construct that has become a disease etiology 
through biological embodiment (see Kuzawa & Sweet, 2009). As revealed through 




predictive component to health and dependence outcomes. In the unadjusted models of 
Chapter III, race/ethnicity was seen as a significant predictor to opioid dependence and 
abuse, specifically for the categories of non-Hispanic White and Native 
American/Alaska Native. In other similar studies that looked at different biopsychosocial 
characteristics, race/ethnicity was found to be predictive, but not in the same type of 
comprehensive model tested in this study. Using the final adjusted model from Chapter 
III, I found that race/ethnicity was not predictive of opioid misuse. This effect was 
probably because other factors within the model explained the variation on opioid 
misuse in a more meaningful manner. Furthermore, there may be a hidden interaction 
from socioecological, health, or other substance-use factors that can be explored in 
subsequent studies (e.g., sex/gender and sexual identity; family income and employment; 
employment and educational attainment; criminality and educational attainment). Other 
sociodemographic factors like the adult age groups, sex/gender, and sexual identity also 
were found to not be predictive in the model, whereas in other studies they were found to 
be significant. Again, in such studies the factors were not presented in comprehensive 
models, and in some they were stratified, which could be considered to be parsimonious 
models. The advantages and disadvantages that exist in using parsimonious models will 
not be discussed here. Nevertheless, in parsimonious models, the complexity of 
individuals is lost; moreover, no individual can choose to be represented by 
biopsychosocial characteristics at any given time.  
Using person-centered approaches like LCA enables the researcher to account for 




Hoffman, 2017). In direct contrast to findings from the variable-centered approach in 
Chapter III, while using a person-centered approach in Chapter IV, I found that 
race/ethnicity was a significant indicator to opioid misuse. For instance, in some models 
not selected for interpretation as well as the final selected model, non-Hispanic Whites 
were at the highest risk of combination opioid misuse compared to other risk subgroups 
or classes. Other subgroups more racially/ethnically diverse were also observed to have 
higher likelihoods of heroin use or mixed opioid use. 
Sex/gender differences are also a major point of contention in opioid misuse 
studies. In my variable-centered analysis, sex/gender was not a significant predictor, but 
in the LCA it was a major indicator. These contrasting results suggest a gendering in 
opioid misuse reports since there is evidence of gender differences in opioid misuse and 
initiation (Serdarevic, Striley, & Cottler, 2017; Tetrault et al., 2008), although the 
majority of the epidemiological data report that men have a higher likelihood of 
substance misuse in general (National Institute on Drug Abuse, 2019b). 
Overall, when comparing the variable-centered approach to the person-centered 
approach, dynamic differences exist. In the variable-centered approach, I used the 
multivariable logistic regression to find a relationship between variables, which revealed 
that an individual’s racial/ethnic affiliation or self-report is not significant in light of 
opioid misuse even though paradoxically the epidemiological data indicate that it is, 
especially when considering opioid overdose death (e.g., Scholl, Seth, Kariisa, Wilson, 
& Baldwin, 2019). Similarly, although race/ethnicity is a social construct that is not 




opioid misuse risk in certain types of parsimonious linear models. The adjusted model in 
Chapter III also presents an interesting paradox because variable-to-variable 
relationships are being assessed even as variations are being considered within a model. 
In other words, the relationships are interpreted individually but their variations are 
accounted for collectively. These models are subject to researcher bias as well because 
the variables within the models must be selected and accounted for by the researcher.  
On the other hand, using a person-centered approach such as LCA allows the 
constellation of variables to group using an algorithm (Muthén & Muthén, 2000; 
Nylund, Asparouhov, & Muthén, 2007) to help minimize the bias introduced by the 
researcher. The indicator variables provide a constellation of combinations that group 
into a possible outcome to help explain the likelihood of the type of opioid misuse. 
Latent class analysis helps captures the complex dynamic systems in which individuals’ 
misuse of opioids are embedded. If methods do not capture the dynamic systems, then 
the issues at hand cannot be dealt with. For instance, as is the case with opioid 
prescription reduction, if the incidence and prevalence of opioid prescribing is dealt 
with, then an individual’s misuse of prescription opioids may transition to either heroin 
only or a combination of heroin and prescription opioid use. Moreover, dynamic systems 
must also employ multiple lines of interventions to work in concert to help deal with the 
opioid epidemic and subsequent overdose deaths. Furthermore, dynamic systems are 
systems based on models of equilibria—as a system adapts, only the status quo will 




As such, we must identify the most intervenable and changeable factors within the 
dynamic system of opioid misuse. 
We must also recognize that there is an additional methodological approach that 
looks at individuals as dynamic systems while acknowledging that population 
homogeneity is a rigid construct (Howard & Hoffman, 2017). This person-specific, or 
idiosyncratic, approach is to make person-specific inferences that do not necessarily 
describe the larger population. Sometimes individuals are not reflections of the 
population in general, nor is the population in general a reflection of an individual. This 
approach recognizes that individuals are unique; in order to describe and understand an 
individual, an individualized model is needed. Such models can be achieved through 
methods like state-space modeling or dynamic factor analysis (Howard & Hoffman, 
2017). In future applications, using person-specific methods can help develop more 
effective and efficacious universal and selective interventions, as well as help develop 
indicated interventions. Indicated interventions for opioid misuse can be targeted to 
individuals at early stages of dependence in which salient prevention strategies and 
intervention programs can be applied in clinical and community settings (Fraser & 
Plescia, 2019). Clinical interventions might include a prescription drug monitoring 
program, identifying those seeking opioids inappropriately, psychosocial counseling, 
medication-assisted treatment (MAT), and recovery programs when possible. 
Community setting interventions can include needle exchange programs as well as 
referral services to clinical treatment, public health services, and recovery programs 




affects risk factors, such as identity, sexuality, educational attainment, and employment. 
The majority of the attempts look at how risk factors affect opioid misuse. By using 
person-specific approaches, we will be able to use more dynamic models and understand 
feedback loops among these factors rather than just exploring linear trends.  
Concluding Thoughts 
Currently, while there are multiple prevention strategies and prevention programs 
for opioid misuse, a need exists to go beyond the standard public health research track 
and include more social justice solutions in order to create meaningful change. One such 
solution might be to target companies responsible for the opioid epidemic and current 
crisis. The U.S. federal government has indicated a willingness to take such additional 
steps to resolve the opioid epidemic. For instance, the federal government for the first 
time indicted the Rochester Drug Cooperative (Hopkins, 2019), one of the largest U.S. 
drug distributors, which paid $20 million to settle civil and criminal claims against its 
executives for distributing opioids illegally. Stiffer penalties may need to be enforced 
because some the costs of the epidemic in 2013 alone were $78.5 billion (Florence, 
Zhou, Luo, & Xu, 2016). Companies such Purdue Pharma, which patented OxyContin, 
has made over $35 billion on opioids alone, was valued at $35 billion in 2017 (Stickler, 
2019), and has an annual revenue of about $3 billion a year (Morrell, 2015). Opioid 
companies, much like Big Tobacco, should be fined to pay for (a) misrepresenting the 
medication as non-habit forming, (b) damages, and (c) treatment. Big Tobacco has paid 
over $100 billion to settle claims during the past 20 years (Mann, 2018), so opioid 




Prevention strategies and intervention programs. Multiple interventions exist 
(e.g., prescription monitoring programs; acute/chronic pain management prevention 
programs; transitioning pain programs; prescription pain reliever rescheduling; 
substance reformulation; opioid disposal programs; needle exchanges and similar 
programs; MAT; psychosocial services and treatment; Pitt et al., 2018; Substance Abuse 
and Mental Health Services Administration, 2019a). Nevertheless, only four 
interventions are projected to have an impact on opioid overdose deaths, the ultimate 
consequence of abuse: psychosocial treatment, needle exchange programs, opioid 
medication-assisted addiction treatment, and naloxone availability (Pitt et al., 2018). 
MAT for opioid dependence has relied on methadone, buprenorphine, and 
naltrexone (Substance Abuse and Mental Health Services Administration, 2019a). All 
three MATs are somewhat controversial but do provide a level of relief from opioid 
dependence. Methadone and buprenorphine can be misused to provide a “high” as well. 
Furthermore, methadone is an opioid agonist that can only be provided in clinical 
settings, although clinical trials have tested the use of methadone in non-clinical settings. 
Buprenorphine is an opioid antagonist and partial agonist, which can be dispensed 
outside of clinical settings that can block the effects of other narcotic substances. Both 
buprenorphine and naltrexone can be dispensed outside of clinical settings from 
pharmacies (Substance Abuse and Mental Health Services Administration, 2019a). 
Purdue Pharma, however, holds the patent for buprenorphine (Ivanova, 2018), which 
may become conflict of interest in the near future. Only naltrexone, of the three MATs, 




substances as well (Substance Abuse and Mental Health Services Administration, 
2019a). Naltrexone, however, should not be used in combination with other substances, 
especially opioids. This medication does reduce opioid tolerance, so relapse can lead to 
overdose and death (Substance Abuse and Mental Health Services Administration, 
2019a). 
Most recently, the use of naloxone as MAT for opioid overdose has emerged into 
the limelight. Naloxone is an opioid antagonist that helps reverse and stop the effects of 
opioid overdose. Naloxone is used to prevent opioid misuse and is often given in 
combination with buprenorphine. This combination is often used to prevent the diversion 
effect and prevent misuse (National Institute on Drug Abuse, 2019a; Substance Abuse 
and Mental Health Services Administration, 2019b). Thus, naloxone has been found to 
be an effective MAT for the opioid epidemic (Dodson, Enki Yoo, Martin-Gill, & Roth, 
2018) that can curb some of the associated overdose deaths (Pitt et al., 2018). 
Nevertheless, current and projected interventions face many challenges, and if current 
usage trajectories continue apace, they will have a minimal overall impact. Conversely, 
the use of both universal and selective interventions can have a meaningful impact on 
the epidemic (Fraser & Plescia, 2019), but only if targeted prevention strategies are 
accounted for using the appropriate methodological approaches and methods. 
By applying the findings contained in this study, we can identify population-level 
risk factors for opioid misuse and improve on possible surveillance and intervention 
strategies. Furthermore, though current opioid misuse interventions are severely limited, 




prevention strategies and intervention programs. My person-centered analysis also 
allowed me to find at-risk subgroups that might be more vulnerable to particular opioid 
substances. By identifying these risk subgroups, we can better tailor interventional 
measures and strategies to stem the impact of the opioid epidemic and reduce overdose 
deaths. Future studies, as such, should stratify their analyses by race/ethnicity and 
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SAS 9.4 SYNTAX AND COMMAND PROCEDURES FOR VARIABLE-CENTERED 
APPROACH IN CHAPTER III 
 
LIBNAME NSDUH 'C:\Users\...\NSDUH\2017\'; 
FILENAME NSDUH17 'C:\Users\...\NSDUH_2017-data-sas.stc'; 
PROC CIMPORT INFILE=NSDUH17 LIBRARY=WORK; *IMPORT STC FILE; 
RUN; 
DATA NSDUH.diss; *SET DATA PERM; 
 SET PUF2017_100918; 
RUN; 
 
DATA NSDUH.dissr; *SAS DATA STEP FOR MISS; 
SET NSDUH.diss; 
*USER-DEFINED MISSING VALUES RECODE TO SAS SYSMIS; 
 IF (ACTD2001  >= 85 ) THEN ACTD2001  = .; 
 IF (ACTD7590  >= 85 ) THEN ACTD7590  = .; 
 IF (ACTD9001  >= 85 ) THEN ACTD9001  = .; 
 IF (ACTDEVER  >= 85 ) THEN ACTDEVER  = .; 
 IF (ACTDPRIV  >= 85 ) THEN ACTDPRIV  = .; 
 IF (ACTDVIET  >= 85 ) THEN ACTDVIET  = .; 
 IF (ADCOUNS  >= 94 ) THEN ADCOUNS  = .; 
 IF (ADDPDISC  >= 85 ) THEN ADDPDISC  = .; 
 IF (ADDPLSIN  >= 85 ) THEN ADDPLSIN  = .; 
 IF (ADDPPROB  >= 94 ) THEN ADDPPROB  = .; 
 IF (ADDPR2WK  >= 85 ) THEN ADDPR2WK  = .; 
 IF (ADDPREV  >= 85 ) THEN ADDPREV  = .; 
 IF (ADDSCEV  >= 94 ) THEN ADDSCEV  = .; 
 IF (ADDSLSIN  >= 94 ) THEN ADDSLSIN  = .; 
 IF (ADFAMDOC  >= 94 ) THEN ADFAMDOC  = .; 
 IF (ADHERBAL  >= 94 ) THEN ADHERBAL  = .; 
 IF (ADLOSEV  >= 94 ) THEN ADLOSEV  = .; 
 IF (ADLSI2WK  >= 97 ) THEN ADLSI2WK  = .; 
 IF (ADNURSE  >= 94 ) THEN ADNURSE  = .; 
 IF (ADOTHDOC  >= 94 ) THEN ADOTHDOC  = .; 
 IF (ADOTHHLP  >= 94 ) THEN ADOTHHLP  = .; 
 IF (ADOTHMHP  >= 94 ) THEN ADOTHMHP  = .; 
 IF (ADPB2WK  >= 85 ) THEN ADPB2WK  = .; 
 IF (ADPBAGE  >= 985 ) THEN ADPBAGE  = .; 
 IF (ADPBDLYA  >= 94 ) THEN ADPBDLYA  = .; 
 IF (ADPBINTF  >= 94 ) THEN ADPBINTF  = .; 
 IF (ADPBNUM  >= 9994 ) THEN ADPBNUM  = .; 
 IF (ADPBRMBR  >= 94 ) THEN ADPBRMBR  = .; 
 IF (ADPSDAYS  >= 994 ) THEN ADPSDAYS  = .; 
 IF (ADPSHMGT  >= 94 ) THEN ADPSHMGT  = .; 
 IF (ADPSRELS  >= 94 ) THEN ADPSRELS  = .; 
 IF (ADPSSOC  >= 94 ) THEN ADPSSOC  = .; 




 IF (ADPSYCH  >= 94 ) THEN ADPSYCH  = .; 
 IF (ADPSYMD  >= 94 ) THEN ADPSYMD  = .; 
 IF (ADRELIG  >= 94 ) THEN ADRELIG  = .; 
 IF (ADRX12MO  >= 85 ) THEN ADRX12MO  = .; 
 IF (ADRXHLP  >= 94 ) THEN ADRXHLP  = .; 
 IF (ADRXNOW  >= 97 ) THEN ADRXNOW  = .; 
 IF (ADSEEDOC  >= 85 ) THEN ADSEEDOC  = .; 
 IF (ADSMMDEA  >= 94 ) THEN ADSMMDEA  = .; 
 IF (ADSOCWRK  >= 94 ) THEN ADSOCWRK  = .; 
 IF (ADTMTHLP  >= 94 ) THEN ADTMTHLP  = .; 
 IF (ADTMTNOW  >= 94 ) THEN ADTMTNOW  = .; 
 IF (ADWRAGE  >= 985 ) THEN ADWRAGE  = .; 
 IF (ADWRCHR  >= 94 ) THEN ADWRCHR  = .; 
 IF (ADWRCONC  >= 94 ) THEN ADWRCONC  = .; 
 IF (ADWRDBTR  >= 94 ) THEN ADWRDBTR  = .; 
 IF (ADWRDCSN  >= 94 ) THEN ADWRDCSN  = .; 
 IF (ADWRDEPR  >= 94 ) THEN ADWRDEPR  = .; 
 IF (ADWRDIET  >= 94 ) THEN ADWRDIET  = .; 
 IF (ADWRDISC  >= 94 ) THEN ADWRDISC  = .; 
 IF (ADWRDLOT  >= 94 ) THEN ADWRDLOT  = .; 
 IF (ADWRDST  >= 94 ) THEN ADWRDST  = .; 
 IF (ADWRELES  >= 94 ) THEN ADWRELES  = .; 
 IF (ADWREMOR  >= 94 ) THEN ADWREMOR  = .; 
 IF (ADWRENRG  >= 94 ) THEN ADWRENRG  = .; 
 IF (ADWRGAIN  >= 94 ) THEN ADWRGAIN  = .; 
 IF (ADWRGNL2  >= 994 ) THEN ADWRGNL2  = .; 
 IF (ADWRGROW  >= 94 ) THEN ADWRGROW  = .; 
 IF (ADWRHRS  >= 85 ) THEN ADWRHRS  = .; 
 IF (ADWRIMP  >= 94 ) THEN ADWRIMP  = .; 
 IF (ADWRJINO  >= 94 ) THEN ADWRJINO  = .; 
 IF (ADWRJITT  >= 94 ) THEN ADWRJITT  = .; 
 IF (ADWRLOSE  >= 94 ) THEN ADWRLOSE  = .; 
 IF (ADWRLSIN  >= 94 ) THEN ADWRLSIN  = .; 
 IF (ADWRLSL2  >= 994 ) THEN ADWRLSL2  = .; 
 IF (ADWRNOGD  >= 94 ) THEN ADWRNOGD  = .; 
 IF (ADWRPLSR  >= 94 ) THEN ADWRPLSR  = .; 
 IF (ADWRPREG  >= 98 ) THEN ADWRPREG  = .; 
 IF (ADWRPROB  >= 94 ) THEN ADWRPROB  = .; 
 IF (ADWRSATP  >= 97 ) THEN ADWRSATP  = .; 
 IF (ADWRSLEP  >= 94 ) THEN ADWRSLEP  = .; 
 IF (ADWRSLNO  >= 94 ) THEN ADWRSLNO  = .; 
 IF (ADWRSLOW  >= 94 ) THEN ADWRSLOW  = .; 
 IF (ADWRSMOR  >= 94 ) THEN ADWRSMOR  = .; 
 IF (ADWRSPLN  >= 94 ) THEN ADWRSPLN  = .; 
 IF (ADWRSTHK  >= 94 ) THEN ADWRSTHK  = .; 
 IF (ADWRTHOT  >= 94 ) THEN ADWRTHOT  = .; 
 IF (ADWRWRTH  >= 94 ) THEN ADWRWRTH  = .; 
 IF (AD_MDEA1  >= 94 ) THEN AD_MDEA1  = .; 
 IF (AD_MDEA2  >= 94 ) THEN AD_MDEA2  = .; 
 IF (AD_MDEA3  >= 94 ) THEN AD_MDEA3  = .; 
 IF (AD_MDEA4  >= 94 ) THEN AD_MDEA4  = .; 
 IF (AD_MDEA5  >= 94 ) THEN AD_MDEA5  = .; 




 IF (AD_MDEA7  >= 94 ) THEN AD_MDEA7  = .; 
 IF (AD_MDEA8  >= 94 ) THEN AD_MDEA8  = .; 
 IF (AD_MDEA9  >= 94 ) THEN AD_MDEA9  = .; 
 IF (AIRDUSTER  >= 85 ) THEN AIRDUSTER  = .; 
 IF (AL30EST  >= 91 ) THEN AL30EST  = .; 
 IF (ALBSTWAY  >= 85 ) THEN ALBSTWAY  = .; 
 IF (ALCAGLST  >= 985 ) THEN ALCAGLST  = .; 
 IF (ALCBNG30D  >= 85 ) THEN ALCBNG30D  = .; 
 IF (ALCCUT1X  >= 83 ) THEN ALCCUT1X  = .; 
 IF (ALCCUTDN  >= 83 ) THEN ALCCUTDN  = .; 
 IF (ALCCUTEV  >= 83 ) THEN ALCCUTEV  = .; 
 IF (ALCDAYS  >= 85 ) THEN ALCDAYS  = .; 
 IF (ALCEMCTD  >= 83 ) THEN ALCEMCTD  = .; 
 IF (ALCEMOPB  >= 83 ) THEN ALCEMOPB  = .; 
 IF (ALCEVER  >= 85 ) THEN ALCEVER  = .; 
 IF (ALCFMCTD  >= 83 ) THEN ALCFMCTD  = .; 
 IF (ALCFMFPB  >= 83 ) THEN ALCFMFPB  = .; 
 IF (ALCGTOVR  >= 83 ) THEN ALCGTOVR  = .; 
 IF (ALCKPLMT  >= 83 ) THEN ALCKPLMT  = .; 
 IF (ALCLAWTR  >= 83 ) THEN ALCLAWTR  = .; 
 IF (ALCLIMIT  >= 83 ) THEN ALCLIMIT  = .; 
 IF (ALCLOTTM  >= 83 ) THEN ALCLOTTM  = .; 
 IF (ALCLSACT  >= 83 ) THEN ALCLSACT  = .; 
 IF (ALCLSEFX  >= 83 ) THEN ALCLSEFX  = .; 
 IF (ALCMFU  >= 85 ) THEN ALCMFU  = .; 
 IF (ALCMLU  >= 85 ) THEN ALCMLU  = .; 
 IF (ALCNDMOR  >= 83 ) THEN ALCNDMOR  = .; 
 IF (ALCPDANG  >= 83 ) THEN ALCPDANG  = .; 
 IF (ALCPHCTD  >= 83 ) THEN ALCPHCTD  = .; 
 IF (ALCPHLPB  >= 83 ) THEN ALCPHLPB  = .; 
 IF (ALCREC  >= 85 ) THEN ALCREC  = .; 
 IF (ALCSERPB  >= 83 ) THEN ALCSERPB  = .; 
 IF (ALCTRY  >= 985 ) THEN ALCTRY  = .; 
 IF (ALCUS30D  >= 985 ) THEN ALCUS30D  = .; 
 IF (ALCWD2SX  >= 83 ) THEN ALCWD2SX  = .; 
 IF (ALCWDSMT  >= 83 ) THEN ALCWDSMT  = .; 
 IF (ALCYFU  >= 9985 ) THEN ALCYFU  = .; 
 IF (ALCYLU  >= 9985 ) THEN ALCYLU  = .; 
 IF (ALCYRBFR  >= 85 ) THEN ALCYRBFR  = .; 
 IF (ALCYRTOT  >= 985 ) THEN ALCYRTOT  = .; 
 IF (ALDAYPMO  >= 85 ) THEN ALDAYPMO  = .; 
 IF (ALDAYPWK  >= 85 ) THEN ALDAYPWK  = .; 
 IF (ALDAYPYR  >= 985 ) THEN ALDAYPYR  = .; 
 IF (ALDYSFG  >= 98 ) THEN ALDYSFG  = .; 
 IF (ALFQFLG  >= 98 ) THEN ALFQFLG  = .; 
 IF (ALTOTFG  >= 98 ) THEN ALTOTFG  = .; 
 IF (AMYLNIT  >= 85 ) THEN AMYLNIT  = .; 
 IF (ANYHLTI2  >= 94 ) THEN ANYHLTI2  = .; 
 IF (ANYNDLREC  >= 91 ) THEN ANYNDLREC  = .; 
 IF (APPDRGMON  >= 85 ) THEN APPDRGMON  = .; 
 IF (ASTHMAAGE  >= 985 ) THEN ASTHMAAGE  = .; 
 IF (ASTHMAEVR  >= 85 ) THEN ASTHMAEVR  = .; 




 IF (AUALACUP  >= 85 ) THEN AUALACUP  = .; 
 IF (AUALCHIR  >= 94 ) THEN AUALCHIR  = .; 
 IF (AUALHERB  >= 94 ) THEN AUALHERB  = .; 
 IF (AUALHLIN  >= 94 ) THEN AUALHLIN  = .; 
 IF (AUALINET  >= 94 ) THEN AUALINET  = .; 
 IF (AUALMASG  >= 85 ) THEN AUALMASG  = .; 
 IF (AUALOTH  >= 94 ) THEN AUALOTH  = .; 
 IF (AUALOTS2  >= 985 ) THEN AUALOTS2  = .; 
 IF (AUALRELG  >= 85 ) THEN AUALRELG  = .; 
 IF (AUALSGRP  >= 94 ) THEN AUALSGRP  = .; 
 IF (AUALTYR  >= 85 ) THEN AUALTYR  = .; 
 IF (AUINAHSP  >= 94 ) THEN AUINAHSP  = .; 
 IF (AUINMEDU  >= 94 ) THEN AUINMEDU  = .; 
 IF (AUINPGEN  >= 94 ) THEN AUINPGEN  = .; 
 IF (AUINPSYH  >= 85 ) THEN AUINPSYH  = .; 
 IF (AUINPYR  >= 85 ) THEN AUINPYR  = .; 
 IF (AUINRESD  >= 94 ) THEN AUINRESD  = .; 
 IF (AUINSFAC  >= 94 ) THEN AUINSFAC  = .; 
 IF (AUMOTVYR  >= 85 ) THEN AUMOTVYR  = .; 
 IF (AUNMAHS2  >= 994 ) THEN AUNMAHS2  = .; 
 IF (AUNMCLN2  >= 985 ) THEN AUNMCLN2  = .; 
 IF (AUNMDOC2  >= 985 ) THEN AUNMDOC2  = .; 
 IF (AUNMDTM2  >= 985 ) THEN AUNMDTM2  = .; 
 IF (AUNMMED2  >= 994 ) THEN AUNMMED2  = .; 
 IF (AUNMMEN2  >= 985 ) THEN AUNMMEN2  = .; 
 IF (AUNMOTO2  >= 994 ) THEN AUNMOTO2  = .; 
 IF (AUNMPGE2  >= 994 ) THEN AUNMPGE2  = .; 
 IF (AUNMPSY2  >= 985 ) THEN AUNMPSY2  = .; 
 IF (AUNMRES2  >= 994 ) THEN AUNMRES2  = .; 
 IF (AUNMSFA2  >= 994 ) THEN AUNMSFA2  = .; 
 IF (AUNMTHE2  >= 985 ) THEN AUNMTHE2  = .; 
 IF (AUOPCLNC  >= 85 ) THEN AUOPCLNC  = .; 
 IF (AUOPDOC  >= 85 ) THEN AUOPDOC  = .; 
 IF (AUOPDTMT  >= 85 ) THEN AUOPDTMT  = .; 
 IF (AUOPMENT  >= 85 ) THEN AUOPMENT  = .; 
 IF (AUOPOTOP  >= 94 ) THEN AUOPOTOP  = .; 
 IF (AUOPTHER  >= 85 ) THEN AUOPTHER  = .; 
 IF (AUOPTYR  >= 85 ) THEN AUOPTYR  = .; 
 IF (AUOPYRS2  >= 85 ) THEN AUOPYRS2  = .; 
 IF (AUPINEMP  >= 94 ) THEN AUPINEMP  = .; 
 IF (AUPINFM2  >= 85 ) THEN AUPINFM2  = .; 
 IF (AUPINFRE  >= 85 ) THEN AUPINFRE  = .; 
 IF (AUPINMCD  >= 94 ) THEN AUPINMCD  = .; 
 IF (AUPINMCR  >= 94 ) THEN AUPINMCR  = .; 
 IF (AUPINMIL  >= 94 ) THEN AUPINMIL  = .; 
 IF (AUPINOFM  >= 94 ) THEN AUPINOFM  = .; 
 IF (AUPINPHI  >= 94 ) THEN AUPINPHI  = .; 
 IF (AUPINPRV  >= 94 ) THEN AUPINPRV  = .; 
 IF (AUPINPUB  >= 94 ) THEN AUPINPUB  = .; 
 IF (AUPINREH  >= 94 ) THEN AUPINREH  = .; 
 IF (AUPINSLF  >= 85 ) THEN AUPINSLF  = .; 
 IF (AUPOPAMT  >= 85 ) THEN AUPOPAMT  = .; 




 IF (AUPOPFRE  >= 85 ) THEN AUPOPFRE  = .; 
 IF (AUPOPMCD  >= 94 ) THEN AUPOPMCD  = .; 
 IF (AUPOPMCR  >= 94 ) THEN AUPOPMCR  = .; 
 IF (AUPOPMIL  >= 94 ) THEN AUPOPMIL  = .; 
 IF (AUPOPMOS  >= 97 ) THEN AUPOPMOS  = .; 
 IF (AUPOPOFM  >= 94 ) THEN AUPOPOFM  = .; 
 IF (AUPOPPHI  >= 94 ) THEN AUPOPPHI  = .; 
 IF (AUPOPPRV  >= 85 ) THEN AUPOPPRV  = .; 
 IF (AUPOPPUB  >= 94 ) THEN AUPOPPUB  = .; 
 IF (AUPOPREH  >= 94 ) THEN AUPOPREH  = .; 
 IF (AUPOPSLF  >= 85 ) THEN AUPOPSLF  = .; 
 IF (AURXYR  >= 85 ) THEN AURXYR  = .; 
 IF (AUUNBUSY  >= 94 ) THEN AUUNBUSY  = .; 
 IF (AUUNCFID  >= 94 ) THEN AUUNCFID  = .; 
 IF (AUUNCMIT  >= 94 ) THEN AUUNCMIT  = .; 
 IF (AUUNCOST  >= 85 ) THEN AUUNCOST  = .; 
 IF (AUUNENUF  >= 94 ) THEN AUUNENUF  = .; 
 IF (AUUNFOUT  >= 94 ) THEN AUUNFOUT  = .; 
 IF (AUUNHNDL  >= 94 ) THEN AUUNHNDL  = .; 
 IF (AUUNJOB  >= 94 ) THEN AUUNJOB  = .; 
 IF (AUUNMTYR  >= 85 ) THEN AUUNMTYR  = .; 
 IF (AUUNNBR  >= 94 ) THEN AUUNNBR  = .; 
 IF (AUUNNCOV  >= 94 ) THEN AUUNNCOV  = .; 
 IF (AUUNNHLP  >= 94 ) THEN AUUNNHLP  = .; 
 IF (AUUNNOND  >= 94 ) THEN AUUNNOND  = .; 
 IF (AUUNNTSP  >= 94 ) THEN AUUNNTSP  = .; 
 IF (AUUNRIM2  >= 85 ) THEN AUUNRIM2  = .; 
 IF (AUUNSOR  >= 94 ) THEN AUUNSOR  = .; 
 IF (AUUNWHER  >= 94 ) THEN AUUNWHER  = .; 
 IF (BKARSON  >= 85 ) THEN BKARSON  = .; 
 IF (BKBURGL  >= 85 ) THEN BKBURGL  = .; 
 IF (BKDRUG  >= 85 ) THEN BKDRUG  = .; 
 IF (BKDRUNK  >= 85 ) THEN BKDRUNK  = .; 
 IF (BKDRVINF  >= 85 ) THEN BKDRVINF  = .; 
 IF (BKFRAUD  >= 85 ) THEN BKFRAUD  = .; 
 IF (BKLARCNY  >= 85 ) THEN BKLARCNY  = .; 
 IF (BKMVTHFT  >= 85 ) THEN BKMVTHFT  = .; 
 IF (BKOTH  >= 85 ) THEN BKOTH  = .; 
 IF (BKOTHOF2  >= 85 ) THEN BKOTHOF2  = .; 
 IF (BKPOSTOB  >= 85 ) THEN BKPOSTOB  = .; 
 IF (BKROB  >= 85 ) THEN BKROB  = .; 
 IF (BKSEXNR  >= 85 ) THEN BKSEXNR  = .; 
 IF (BKSMASLT  >= 85 ) THEN BKSMASLT  = .; 
 IF (BKSRVIOL  >= 85 ) THEN BKSRVIOL  = .; 
 IF (BLNT30C1  >= 98 ) THEN BLNT30C1  = .; 
 IF (BLNT30C2  >= 98 ) THEN BLNT30C2  = .; 
 IF (BLNT30DY  >= 85 ) THEN BLNT30DY  = .; 
 IF (BLNTAGE  >= 981 ) THEN BLNTAGE  = .; 
 IF (BLNTEVER  >= 85 ) THEN BLNTEVER  = .; 
 IF (BLNTMFU  >= 81 ) THEN BLNTMFU  = .; 
 IF (BLNTNOMJ  >= 91 ) THEN BLNTNOMJ  = .; 
 IF (BLNTREC  >= 81 ) THEN BLNTREC  = .; 




 IF (BLRECFL2  >= 98 ) THEN BLRECFL2  = .; 
 IF (BOOKED  >= 85 ) THEN BOOKED  = .; 
 IF (CABINGAGE  >= 985 ) THEN CABINGAGE  = .; 
 IF (CABINGEVR  >= 85 ) THEN CABINGEVR  = .; 
 IF (CABINGFLG  >= 85 ) THEN CABINGFLG  = .; 
 IF (CABINGMFU  >= 85 ) THEN CABINGMFU  = .; 
 IF (CABINGYFU  >= 9985 ) THEN CABINGYFU  = .; 
 IF (CABLADDER  >= 85 ) THEN CABLADDER  = .; 
 IF (CABLOLEULYM  >= 85 ) THEN CABLOLEULYM  = .; 
 IF (CABPLACE  >= 91 ) THEN CABPLACE  = .; 
 IF (CABREAST  >= 85 ) THEN CABREAST  = .; 
 IF (CABUNDAG  >= 91 ) THEN CABUNDAG  = .; 
 IF (CABUYFRE  >= 85 ) THEN CABUYFRE  = .; 
 IF (CABUYWHO  >= 91 ) THEN CABUYWHO  = .; 
 IF (CACERVIX  >= 85 ) THEN CACERVIX  = .; 
 IF (CACOLNRECT  >= 85 ) THEN CACOLNRECT  = .; 
 IF (CADRBAR  >= 89 ) THEN CADRBAR  = .; 
 IF (CADRCAR  >= 91 ) THEN CADRCAR  = .; 
 IF (CADREVNT  >= 91 ) THEN CADREVNT  = .; 
 IF (CADRHOME  >= 85 ) THEN CADRHOME  = .; 
 IF (CADRKCOCN  >= 91 ) THEN CADRKCOCN  = .; 
 IF (CADRKDRUG  >= 85 ) THEN CADRKDRUG  = .; 
 IF (CADRKHALL  >= 91 ) THEN CADRKHALL  = .; 
 IF (CADRKHERN  >= 91 ) THEN CADRKHERN  = .; 
 IF (CADRKINHL  >= 91 ) THEN CADRKINHL  = .; 
 IF (CADRKMARJ  >= 91 ) THEN CADRKMARJ  = .; 
 IF (CADRKMETH  >= 91 ) THEN CADRKMETH  = .; 
 IF (CADRLAST  >= 985 ) THEN CADRLAST  = .; 
 IF (CADROTH  >= 91 ) THEN CADROTH  = .; 
 IF (CADROTHM  >= 91 ) THEN CADROTHM  = .; 
 IF (CADROTS2  >= 85 ) THEN CADROTS2  = .; 
 IF (CADRPEOP  >= 85 ) THEN CADRPEOP  = .; 
 IF (CADRPUBL  >= 91 ) THEN CADRPUBL  = .; 
 IF (CADRSCHL  >= 91 ) THEN CADRSCHL  = .; 
 IF (CAESOPSTOM  >= 85 ) THEN CAESOPSTOM  = .; 
 IF (CAFRESP2  >= 85 ) THEN CAFRESP2  = .; 
 IF (CAFREWHO  >= 85 ) THEN CAFREWHO  = .; 
 IF (CAGALLIVPAN  >= 85 ) THEN CAGALLIVPAN  = .; 
 IF (CAGVMONY  >= 91 ) THEN CAGVMONY  = .; 
 IF (CAGVWHO  >= 91 ) THEN CAGVWHO  = .; 
 IF (CAIDCHIP  >= 85 ) THEN CAIDCHIP  = .; 
 IF (CAKIDNEY  >= 85 ) THEN CAKIDNEY  = .; 
 IF (CALARYLUNG  >= 85 ) THEN CALARYLUNG  = .; 
 IF (CAMELANOM  >= 85 ) THEN CAMELANOM  = .; 
 IF (CAMOUTTHRO  >= 85 ) THEN CAMOUTTHRO  = .; 
 IF (CANCEREVR  >= 85 ) THEN CANCEREVR  = .; 
 IF (CANCERYR  >= 85 ) THEN CANCERYR  = .; 
 IF (CAOTHER2  >= 85 ) THEN CAOTHER2  = .; 
 IF (CAOVARY  >= 85 ) THEN CAOVARY  = .; 
 IF (CAPROSTEST  >= 85 ) THEN CAPROSTEST  = .; 
 IF (CASKINDK  >= 85 ) THEN CASKINDK  = .; 
 IF (CASKINOTH  >= 85 ) THEN CASKINOTH  = .; 




 IF (CAUTERUS  >= 85 ) THEN CAUTERUS  = .; 
 IF (CC30EST  >= 91 ) THEN CC30EST  = .; 
 IF (CCBSTWAY  >= 85 ) THEN CCBSTWAY  = .; 
 IF (CCDAYPMO  >= 89 ) THEN CCDAYPMO  = .; 
 IF (CCDAYPWK  >= 85 ) THEN CCDAYPWK  = .; 
 IF (CCDAYPYR  >= 985 ) THEN CCDAYPYR  = .; 
 IF (CCFQFLG  >= 98 ) THEN CCFQFLG  = .; 
 IF (CCTOTFG  >= 98 ) THEN CCTOTFG  = .; 
 IF (CELLNOTCL  >= 85 ) THEN CELLNOTCL  = .; 
 IF (CELLWRKNG  >= 85 ) THEN CELLWRKNG  = .; 
 IF (CG30EST  >= 91 ) THEN CG30EST  = .; 
 IF (CGR30BR2  >= 9991 ) THEN CGR30BR2  = .; 
 IF (CGR30USE  >= 91 ) THEN CGR30USE  = .; 
 IF (CGRAGLST  >= 985 ) THEN CGRAGLST  = .; 
 IF (CHAMPUS  >= 85 ) THEN CHAMPUS  = .; 
 IF (CHMNDLREC  >= 91 ) THEN CHMNDLREC  = .; 
 IF (CI30EST  >= 91 ) THEN CI30EST  = .; 
 IF (CIG100LF  >= 91 ) THEN CIG100LF  = .; 
 IF (CIG30AV  >= 85 ) THEN CIG30AV  = .; 
 IF (CIG30BR2  >= 9985 ) THEN CIG30BR2  = .; 
 IF (CIG30MEN  >= 85 ) THEN CIG30MEN  = .; 
 IF (CIG30MLN  >= 85 ) THEN CIG30MLN  = .; 
 IF (CIG30RO2  >= 85 ) THEN CIG30RO2  = .; 
 IF (CIG30TPE  >= 85 ) THEN CIG30TPE  = .; 
 IF (CIG30USE  >= 85 ) THEN CIG30USE  = .; 
 IF (CIGAGE  >= 985 ) THEN CIGAGE  = .; 
 IF (CIGAGLST  >= 985 ) THEN CIGAGLST  = .; 
 IF (CIGAREVR  >= 94 ) THEN CIGAREVR  = .; 
 IF (CIGARMFU  >= 85 ) THEN CIGARMFU  = .; 
 IF (CIGARMLU  >= 85 ) THEN CIGARMLU  = .; 
 IF (CIGARREC  >= 91 ) THEN CIGARREC  = .; 
 IF (CIGARTRY  >= 985 ) THEN CIGARTRY  = .; 
 IF (CIGARYFU  >= 9985 ) THEN CIGARYFU  = .; 
 IF (CIGARYLU  >= 9985 ) THEN CIGARYLU  = .; 
 IF (CIGAVOID  >= 85 ) THEN CIGAVOID  = .; 
 IF (CIGCRAGP  >= 85 ) THEN CIGCRAGP  = .; 
 IF (CIGCRAVE  >= 85 ) THEN CIGCRAVE  = .; 
 IF (CIGDLLST  >= 985 ) THEN CIGDLLST  = .; 
 IF (CIGDLMFU  >= 85 ) THEN CIGDLMFU  = .; 
 IF (CIGDLMLU  >= 85 ) THEN CIGDLMLU  = .; 
 IF (CIGDLYFU  >= 9985 ) THEN CIGDLYFU  = .; 
 IF (CIGDLYLU  >= 9985 ) THEN CIGDLYLU  = .; 
 IF (CIGDLYMO  >= 91 ) THEN CIGDLYMO  = .; 
 IF (CIGFNLKE  >= 85 ) THEN CIGFNLKE  = .; 
 IF (CIGFNSMK  >= 85 ) THEN CIGFNSMK  = .; 
 IF (CIGINCRS  >= 85 ) THEN CIGINCRS  = .; 
 IF (CIGINCTL  >= 85 ) THEN CIGINCTL  = .; 
 IF (CIGINFLU  >= 85 ) THEN CIGINFLU  = .; 
 IF (CIGIRTBL  >= 85 ) THEN CIGIRTBL  = .; 
 IF (CIGLOTMR  >= 85 ) THEN CIGLOTMR  = .; 
 IF (CIGMFU  >= 85 ) THEN CIGMFU  = .; 
 IF (CIGMLU  >= 85 ) THEN CIGMLU  = .; 




 IF (CIGNOINF  >= 85 ) THEN CIGNOINF  = .; 
 IF (CIGOFRSM  >= 94 ) THEN CIGOFRSM  = .; 
 IF (CIGPLANE  >= 85 ) THEN CIGPLANE  = .; 
 IF (CIGREC  >= 91 ) THEN CIGREC  = .; 
 IF (CIGREGDY  >= 85 ) THEN CIGREGDY  = .; 
 IF (CIGREGNM  >= 85 ) THEN CIGREGNM  = .; 
 IF (CIGREGWK  >= 85 ) THEN CIGREGWK  = .; 
 IF (CIGRNOUT  >= 85 ) THEN CIGRNOUT  = .; 
 IF (CIGSATIS  >= 85 ) THEN CIGSATIS  = .; 
 IF (CIGSVLHR  >= 85 ) THEN CIGSVLHR  = .; 
 IF (CIGTRY  >= 985 ) THEN CIGTRY  = .; 
 IF (CIGWAKE  >= 85 ) THEN CIGWAKE  = .; 
 IF (CIGWILYR  >= 85 ) THEN CIGWILYR  = .; 
 IF (CIGYFU  >= 9985 ) THEN CIGYFU  = .; 
 IF (CIGYLU  >= 9985 ) THEN CIGYLU  = .; 
 IF (CIGYRBFR  >= 85 ) THEN CIGYRBFR  = .; 
 IF (CIRROSAGE  >= 985 ) THEN CIRROSAGE  = .; 
 IF (CIRROSEVR  >= 85 ) THEN CIRROSEVR  = .; 
 IF (CLEFLU  >= 85 ) THEN CLEFLU  = .; 
 IF (COCAGE  >= 985 ) THEN COCAGE  = .; 
 IF (COCAGLST  >= 985 ) THEN COCAGLST  = .; 
 IF (COCCUT1X  >= 85 ) THEN COCCUT1X  = .; 
 IF (COCCUTDN  >= 85 ) THEN COCCUTDN  = .; 
 IF (COCCUTEV  >= 91 ) THEN COCCUTEV  = .; 
 IF (COCEMCTD  >= 91 ) THEN COCEMCTD  = .; 
 IF (COCEMOPB  >= 85 ) THEN COCEMOPB  = .; 
 IF (COCEVER  >= 85 ) THEN COCEVER  = .; 
 IF (COCFLBLU  >= 91 ) THEN COCFLBLU  = .; 
 IF (COCFMCTD  >= 91 ) THEN COCFMCTD  = .; 
 IF (COCFMFPB  >= 85 ) THEN COCFMFPB  = .; 
 IF (COCGTOVR  >= 85 ) THEN COCGTOVR  = .; 
 IF (COCKPLMT  >= 91 ) THEN COCKPLMT  = .; 
 IF (COCLAWTR  >= 85 ) THEN COCLAWTR  = .; 
 IF (COCLIMIT  >= 85 ) THEN COCLIMIT  = .; 
 IF (COCLOTTM  >= 85 ) THEN COCLOTTM  = .; 
 IF (COCLSACT  >= 85 ) THEN COCLSACT  = .; 
 IF (COCLSEFX  >= 85 ) THEN COCLSEFX  = .; 
 IF (COCMFU  >= 85 ) THEN COCMFU  = .; 
 IF (COCMLU  >= 85 ) THEN COCMLU  = .; 
 IF (COCNDMOR  >= 85 ) THEN COCNDMOR  = .; 
 IF (COCNEEDL  >= 85 ) THEN COCNEEDL  = .; 
 IF (COCPDANG  >= 85 ) THEN COCPDANG  = .; 
 IF (COCPHCTD  >= 91 ) THEN COCPHCTD  = .; 
 IF (COCPHLPB  >= 85 ) THEN COCPHLPB  = .; 
 IF (COCREC  >= 85 ) THEN COCREC  = .; 
 IF (COCSERPB  >= 85 ) THEN COCSERPB  = .; 
 IF (COCUS30A  >= 85 ) THEN COCUS30A  = .; 
 IF (COCWD2SX  >= 91 ) THEN COCWD2SX  = .; 
 IF (COCWDSMT  >= 91 ) THEN COCWDSMT  = .; 
 IF (COCYFU  >= 9985 ) THEN COCYFU  = .; 
 IF (COCYLU  >= 9985 ) THEN COCYLU  = .; 
 IF (COCYRBFR  >= 85 ) THEN COCYRBFR  = .; 




 IF (COLDMEDS  >= 94 ) THEN COLDMEDS  = .; 
 IF (COLDREC  >= 85 ) THEN COLDREC  = .; 
 IF (COMBATPY  >= 85 ) THEN COMBATPY  = .; 
 IF (CONDLREC  >= 91 ) THEN CONDLREC  = .; 
 IF (COPDAGE  >= 985 ) THEN COPDAGE  = .; 
 IF (COPDEVER  >= 85 ) THEN COPDEVER  = .; 
 IF (CR30EST  >= 91 ) THEN CR30EST  = .; 
 IF (CRAKREC  >= 85 ) THEN CRAKREC  = .; 
 IF (CRBSTWAY  >= 85 ) THEN CRBSTWAY  = .; 
 IF (CRDAYPMO  >= 85 ) THEN CRDAYPMO  = .; 
 IF (CRDAYPWK  >= 85 ) THEN CRDAYPWK  = .; 
 IF (CRDAYPYR  >= 991 ) THEN CRDAYPYR  = .; 
 IF (CRFQFLG  >= 98 ) THEN CRFQFLG  = .; 
 IF (CRKAGE  >= 985 ) THEN CRKAGE  = .; 
 IF (CRKAGLST  >= 985 ) THEN CRKAGLST  = .; 
 IF (CRKEVER  >= 85 ) THEN CRKEVER  = .; 
 IF (CRKMFU  >= 85 ) THEN CRKMFU  = .; 
 IF (CRKMLU  >= 85 ) THEN CRKMLU  = .; 
 IF (CRKUS30A  >= 85 ) THEN CRKUS30A  = .; 
 IF (CRKYFU  >= 9985 ) THEN CRKYFU  = .; 
 IF (CRKYLU  >= 9985 ) THEN CRKYLU  = .; 
 IF (CRKYRTOT  >= 985 ) THEN CRKYRTOT  = .; 
 IF (CRTOTFG  >= 98 ) THEN CRTOTFG  = .; 
 IF (DAMTFXREC  >= 91 ) THEN DAMTFXREC  = .; 
 IF (DIABETEAG  >= 985 ) THEN DIABETEAG  = .; 
 IF (DIABETEVR  >= 85 ) THEN DIABETEVR  = .; 
 IF (DIFFDRESS  >= 85 ) THEN DIFFDRESS  = .; 
 IF (DIFFERAND  >= 85 ) THEN DIFFERAND  = .; 
 IF (DIFFHEAR  >= 85 ) THEN DIFFHEAR  = .; 
 IF (DIFFSEE  >= 85 ) THEN DIFFSEE  = .; 
 IF (DIFFTHINK  >= 85 ) THEN DIFFTHINK  = .; 
 IF (DIFFWALK  >= 85 ) THEN DIFFWALK  = .; 
 IF (DIFGETCOC  >= 85 ) THEN DIFGETCOC  = .; 
 IF (DIFGETCRK  >= 85 ) THEN DIFGETCRK  = .; 
 IF (DIFGETHER  >= 85 ) THEN DIFGETHER  = .; 
 IF (DIFGETLSD  >= 85 ) THEN DIFGETLSD  = .; 
 IF (DIFGETMRJ  >= 85 ) THEN DIFGETMRJ  = .; 
 IF (DMTAMTFXY  >= 91 ) THEN DMTAMTFXY  = .; 
 IF (DRVINALCO  >= 85 ) THEN DRVINALCO  = .; 
 IF (DRVINALON  >= 85 ) THEN DRVINALON  = .; 
 IF (DRVINCOCN  >= 85 ) THEN DRVINCOCN  = .; 
 IF (DRVINHALL  >= 91 ) THEN DRVINHALL  = .; 
 IF (DRVINHERN  >= 91 ) THEN DRVINHERN  = .; 
 IF (DRVININHL  >= 85 ) THEN DRVININHL  = .; 
 IF (DRVINMARJ  >= 85 ) THEN DRVINMARJ  = .; 
 IF (DRVINMETH  >= 91 ) THEN DRVINMETH  = .; 
 IF (DSTCHR12  >= 85 ) THEN DSTCHR12  = .; 
 IF (DSTCHR30  >= 85 ) THEN DSTCHR30  = .; 
 IF (DSTEFF12  >= 85 ) THEN DSTEFF12  = .; 
 IF (DSTEFF30  >= 85 ) THEN DSTEFF30  = .; 
 IF (DSTHOP12  >= 85 ) THEN DSTHOP12  = .; 
 IF (DSTHOP30  >= 85 ) THEN DSTHOP30  = .; 




 IF (DSTNGD30  >= 85 ) THEN DSTNGD30  = .; 
 IF (DSTNRV12  >= 85 ) THEN DSTNRV12  = .; 
 IF (DSTNRV30  >= 85 ) THEN DSTNRV30  = .; 
 IF (DSTRST12  >= 85 ) THEN DSTRST12  = .; 
 IF (DSTRST30  >= 85 ) THEN DSTRST30  = .; 
 IF (DSTWORST  >= 85 ) THEN DSTWORST  = .; 
 IF (ECSTMOAGE  >= 985 ) THEN ECSTMOAGE  = .; 
 IF (ECSTMOAGL  >= 985 ) THEN ECSTMOAGL  = .; 
 IF (ECSTMOLLY  >= 91 ) THEN ECSTMOLLY  = .; 
 IF (ECSTMOMFU  >= 85 ) THEN ECSTMOMFU  = .; 
 IF (ECSTMOMLU  >= 85 ) THEN ECSTMOMLU  = .; 
 IF (ECSTMOREC  >= 91 ) THEN ECSTMOREC  = .; 
 IF (ECSTMOYFU  >= 9985 ) THEN ECSTMOYFU  = .; 
 IF (ECSTMOYLU  >= 9985 ) THEN ECSTMOYLU  = .; 
 IF (EDFAM18  >= 98 ) THEN EDFAM18  = .; 
 IF (EDUFULPAR  >= 85 ) THEN EDUFULPAR  = .; 
 IF (EDUSCHGRD2  >= 98 ) THEN EDUSCHGRD2  = .; 
 IF (EDUSCHLGO  >= 85 ) THEN EDUSCHLGO  = .; 
 IF (EDUSCKCOM  >= 94 ) THEN EDUSCKCOM  = .; 
 IF (EDUSCKEST  >= 94 ) THEN EDUSCKEST  = .; 
 IF (EDUSCKMON  >= 85 ) THEN EDUSCKMON  = .; 
 IF (EDUSKPCOM  >= 85 ) THEN EDUSKPCOM  = .; 
 IF (EDUSKPEST  >= 85 ) THEN EDUSKPEST  = .; 
 IF (EDUSKPMON  >= 85 ) THEN EDUSKPMON  = .; 
 IF (ETHER  >= 85 ) THEN ETHER  = .; 
 IF (FELTMARKR  >= 85 ) THEN FELTMARKR  = .; 
 IF (GAS  >= 85 ) THEN GAS  = .; 
 IF (GHB  >= 94 ) THEN GHB  = .; 
 IF (GHBREC  >= 91 ) THEN GHBREC  = .; 
 IF (GLUE  >= 85 ) THEN GLUE  = .; 
 IF (GNNDCLEN  >= 85 ) THEN GNNDCLEN  = .; 
 IF (GNNDGET2  >= 85 ) THEN GNNDGET2  = .; 
 IF (GNNDLSH1  >= 85 ) THEN GNNDLSH1  = .; 
 IF (GNNDLSH2  >= 85 ) THEN GNNDLSH2  = .; 
 IF (GNNDREUS  >= 85 ) THEN GNNDREUS  = .; 
 IF (GRPHLTIN  >= 85 ) THEN GRPHLTIN  = .; 
 IF (HALFQFLG  >= 98 ) THEN HALFQFLG  = .; 
 IF (HALLAGLST  >= 985 ) THEN HALLAGLST  = .; 
 IF (HALLDYPMO  >= 85 ) THEN HALLDYPMO  = .; 
 IF (HALLDYPWK  >= 85 ) THEN HALLDYPWK  = .; 
 IF (HALLDYSYR  >= 985 ) THEN HALLDYSYR  = .; 
 IF (HALLEASWY  >= 85 ) THEN HALLEASWY  = .; 
 IF (HALLMOLST  >= 85 ) THEN HALLMOLST  = .; 
 IF (HALLUC30E  >= 91 ) THEN HALLUC30E  = .; 
 IF (HALLUC30N  >= 83 ) THEN HALLUC30N  = .; 
 IF (HALLUCAGE  >= 985 ) THEN HALLUCAGE  = .; 
 IF (HALLUCEVR  >= 91 ) THEN HALLUCEVR  = .; 
 IF (HALLUCMFU  >= 85 ) THEN HALLUCMFU  = .; 
 IF (HALLUCOT1  >= 9985 ) THEN HALLUCOT1  = .; 
 IF (HALLUCOT2  >= 9985 ) THEN HALLUCOT2  = .; 
 IF (HALLUCOT3  >= 9985 ) THEN HALLUCOT3  = .; 
 IF (HALLUCOT4  >= 9991 ) THEN HALLUCOT4  = .; 




 IF (HALLUCOTH  >= 91 ) THEN HALLUCOTH  = .; 
 IF (HALLUCREC  >= 91 ) THEN HALLUCREC  = .; 
 IF (HALLUCYFQ  >= 985 ) THEN HALLUCYFQ  = .; 
 IF (HALLUCYFU  >= 9985 ) THEN HALLUCYFU  = .; 
 IF (HALLYRLST  >= 9985 ) THEN HALLYRLST  = .; 
 IF (HALTOTFG  >= 98 ) THEN HALTOTFG  = .; 
 IF (HALUCUTDN  >= 91 ) THEN HALUCUTDN  = .; 
 IF (HALUCUTEV  >= 91 ) THEN HALUCUTEV  = .; 
 IF (HALUEMCTD  >= 91 ) THEN HALUEMCTD  = .; 
 IF (HALUEMOPB  >= 91 ) THEN HALUEMOPB  = .; 
 IF (HALUFMCTD  >= 91 ) THEN HALUFMCTD  = .; 
 IF (HALUFMFPB  >= 91 ) THEN HALUFMFPB  = .; 
 IF (HALUGTOVR  >= 91 ) THEN HALUGTOVR  = .; 
 IF (HALUKPLMT  >= 91 ) THEN HALUKPLMT  = .; 
 IF (HALULAWTR  >= 91 ) THEN HALULAWTR  = .; 
 IF (HALULIMIT  >= 91 ) THEN HALULIMIT  = .; 
 IF (HALULOTTM  >= 91 ) THEN HALULOTTM  = .; 
 IF (HALULSACT  >= 91 ) THEN HALULSACT  = .; 
 IF (HALULSEFX  >= 91 ) THEN HALULSEFX  = .; 
 IF (HALUNDMOR  >= 91 ) THEN HALUNDMOR  = .; 
 IF (HALUPDANG  >= 91 ) THEN HALUPDANG  = .; 
 IF (HALUPHCTD  >= 91 ) THEN HALUPHCTD  = .; 
 IF (HALUPHLPB  >= 91 ) THEN HALUPHLPB  = .; 
 IF (HALUSERPB  >= 91 ) THEN HALUSERPB  = .; 
 IF (HEALTH  >= 94 ) THEN HEALTH  = .; 
 IF (HEOTNDL  >= 91 ) THEN HEOTNDL  = .; 
 IF (HEOTOTH  >= 91 ) THEN HEOTOTH  = .; 
 IF (HEOTSMK  >= 91 ) THEN HEOTSMK  = .; 
 IF (HEOTSNF  >= 91 ) THEN HEOTSNF  = .; 
 IF (HEOTSP  >= 85 ) THEN HEOTSP  = .; 
 IF (HEPBCAGE  >= 985 ) THEN HEPBCAGE  = .; 
 IF (HEPBCEVER  >= 85 ) THEN HEPBCEVER  = .; 
 IF (HER30USE  >= 85 ) THEN HER30USE  = .; 
 IF (HERAGE  >= 985 ) THEN HERAGE  = .; 
 IF (HERAGLST  >= 985 ) THEN HERAGLST  = .; 
 IF (HERCUT1X  >= 91 ) THEN HERCUT1X  = .; 
 IF (HERCUTDN  >= 91 ) THEN HERCUTDN  = .; 
 IF (HERCUTEV  >= 91 ) THEN HERCUTEV  = .; 
 IF (HEREMCTD  >= 91 ) THEN HEREMCTD  = .; 
 IF (HEREMOPB  >= 91 ) THEN HEREMOPB  = .; 
 IF (HEREVER  >= 94 ) THEN HEREVER  = .; 
 IF (HERFMCTD  >= 91 ) THEN HERFMCTD  = .; 
 IF (HERFMFPB  >= 91 ) THEN HERFMFPB  = .; 
 IF (HERGTOVR  >= 91 ) THEN HERGTOVR  = .; 
 IF (HERKPLMT  >= 91 ) THEN HERKPLMT  = .; 
 IF (HERLAWTR  >= 91 ) THEN HERLAWTR  = .; 
 IF (HERLIMIT  >= 91 ) THEN HERLIMIT  = .; 
 IF (HERLOTTM  >= 91 ) THEN HERLOTTM  = .; 
 IF (HERLSACT  >= 91 ) THEN HERLSACT  = .; 
 IF (HERLSEFX  >= 91 ) THEN HERLSEFX  = .; 
 IF (HERMFU  >= 85 ) THEN HERMFU  = .; 
 IF (HERMLU  >= 85 ) THEN HERMLU  = .; 




 IF (HERNEEDL  >= 91 ) THEN HERNEEDL  = .; 
 IF (HERPDANG  >= 91 ) THEN HERPDANG  = .; 
 IF (HERPHCTD  >= 91 ) THEN HERPHCTD  = .; 
 IF (HERPHLPB  >= 91 ) THEN HERPHLPB  = .; 
 IF (HERREC  >= 91 ) THEN HERREC  = .; 
 IF (HERSERPB  >= 91 ) THEN HERSERPB  = .; 
 IF (HERSMOKE  >= 91 ) THEN HERSMOKE  = .; 
 IF (HERSNIFF  >= 91 ) THEN HERSNIFF  = .; 
 IF (HERWD3SX  >= 91 ) THEN HERWD3SX  = .; 
 IF (HERWDSMT  >= 91 ) THEN HERWDSMT  = .; 
 IF (HERYFU  >= 9985 ) THEN HERYFU  = .; 
 IF (HERYLU  >= 9985 ) THEN HERYLU  = .; 
 IF (HERYRTOT  >= 985 ) THEN HERYRTOT  = .; 
 IF (HIGHBPAGE  >= 985 ) THEN HIGHBPAGE  = .; 
 IF (HIGHBPEVR  >= 85 ) THEN HIGHBPEVR  = .; 
 IF (HIGHBPMED  >= 85 ) THEN HIGHBPMED  = .; 
 IF (HIVAIDSAG  >= 985 ) THEN HIVAIDSAG  = .; 
 IF (HIVAIDSEV  >= 85 ) THEN HIVAIDSEV  = .; 
 IF (HLCALL99  >= 98 ) THEN HLCALL99  = .; 
 IF (HLCALLFG  >= 98 ) THEN HLCALLFG  = .; 
 IF (HLCLAST  >= 94 ) THEN HLCLAST  = .; 
 IF (HLCNOTMO  >= 85 ) THEN HLCNOTMO  = .; 
 IF (HLCNOTYR  >= 85 ) THEN HLCNOTYR  = .; 
 IF (HLLOSRSN  >= 85 ) THEN HLLOSRSN  = .; 
 IF (HLNVCOST  >= 94 ) THEN HLNVCOST  = .; 
 IF (HLNVNEED  >= 94 ) THEN HLNVNEED  = .; 
 IF (HLNVOFFR  >= 94 ) THEN HLNVOFFR  = .; 
 IF (HLNVREF  >= 94 ) THEN HLNVREF  = .; 
 IF (HLNVSOR  >= 94 ) THEN HLNVSOR  = .; 
 IF (HLTINALC  >= 85 ) THEN HLTINALC  = .; 
 IF (HLTINDRG  >= 85 ) THEN HLTINDRG  = .; 
 IF (HLTINMNT  >= 85 ) THEN HLTINMNT  = .; 
 IF (HLTINNOS  >= 94 ) THEN HLTINNOS  = .; 
 IF (HPALCAMT  >= 85 ) THEN HPALCAMT  = .; 
 IF (HPALCCUT  >= 91 ) THEN HPALCCUT  = .; 
 IF (HPALCFRQ  >= 85 ) THEN HPALCFRQ  = .; 
 IF (HPALCNOT  >= 85 ) THEN HPALCNOT  = .; 
 IF (HPALCPRB  >= 91 ) THEN HPALCPRB  = .; 
 IF (HPALCTX  >= 91 ) THEN HPALCTX  = .; 
 IF (HPDRGTALK  >= 85 ) THEN HPDRGTALK  = .; 
 IF (HPQTTOB  >= 85 ) THEN HPQTTOB  = .; 
 IF (HPUSEALC  >= 85 ) THEN HPUSEALC  = .; 
 IF (HPUSEDRG  >= 85 ) THEN HPUSEDRG  = .; 
 IF (HPUSETOB  >= 85 ) THEN HPUSETOB  = .; 
 IF (HR30EST  >= 91 ) THEN HR30EST  = .; 
 IF (HRBSTWAY  >= 85 ) THEN HRBSTWAY  = .; 
 IF (HRDAYPMO  >= 85 ) THEN HRDAYPMO  = .; 
 IF (HRDAYPWK  >= 85 ) THEN HRDAYPWK  = .; 
 IF (HRDAYPYR  >= 985 ) THEN HRDAYPYR  = .; 
 IF (HRFQFLG  >= 98 ) THEN HRFQFLG  = .; 
 IF (HRNDLREC  >= 91 ) THEN HRNDLREC  = .; 
 IF (HRSMKREC  >= 91 ) THEN HRSMKREC  = .; 




 IF (HRTCONDAG  >= 985 ) THEN HRTCONDAG  = .; 
 IF (HRTCONDEV  >= 85 ) THEN HRTCONDEV  = .; 
 IF (HRTCONDYR  >= 85 ) THEN HRTCONDYR  = .; 
 IF (HRTOTFG  >= 98 ) THEN HRTOTFG  = .; 
 IF (HTANSWER  >= 85 ) THEN HTANSWER  = .; 
 IF (HTINCHE2  >= 985 ) THEN HTINCHE2  = .; 
 IF (IICGAVD  >= 98 ) THEN IICGAVD  = .; 
 IF (IICGCRGP  >= 98 ) THEN IICGCRGP  = .; 
 IF (IICGCRV  >= 98 ) THEN IICGCRV  = .; 
 IF (IICGINCR  >= 98 ) THEN IICGINCR  = .; 
 IF (IICGINFL  >= 98 ) THEN IICGINFL  = .; 
 IF (IICGIRTB  >= 98 ) THEN IICGIRTB  = .; 
 IF (IICGLMR  >= 98 ) THEN IICGLMR  = .; 
 IF (IICGNCG  >= 98 ) THEN IICGNCG  = .; 
 IF (IICGNCTL  >= 98 ) THEN IICGNCTL  = .; 
 IF (IICGNINF  >= 98 ) THEN IICGNINF  = .; 
 IF (IICGPLN  >= 98 ) THEN IICGPLN  = .; 
 IF (IICGRGDY  >= 98 ) THEN IICGRGDY  = .; 
 IF (IICGRGNM  >= 98 ) THEN IICGRGNM  = .; 
 IF (IICGRGWK  >= 98 ) THEN IICGRGWK  = .; 
 IF (IICGROUT  >= 98 ) THEN IICGROUT  = .; 
 IF (IICGSAT  >= 98 ) THEN IICGSAT  = .; 
 IF (IICGSLHR  >= 98 ) THEN IICGSLHR  = .; 
 IF (IMPCONCN  >= 85 ) THEN IMPCONCN  = .; 
 IF (IMPDYFRQ  >= 85 ) THEN IMPDYFRQ  = .; 
 IF (IMPGOUT  >= 85 ) THEN IMPGOUT  = .; 
 IF (IMPGOUTM  >= 94 ) THEN IMPGOUTM  = .; 
 IF (IMPHHLD  >= 85 ) THEN IMPHHLD  = .; 
 IF (IMPHHLDM  >= 97 ) THEN IMPHHLDM  = .; 
 IF (IMPPEOP  >= 85 ) THEN IMPPEOP  = .; 
 IF (IMPPEOPM  >= 94 ) THEN IMPPEOPM  = .; 
 IF (IMPREMEM  >= 85 ) THEN IMPREMEM  = .; 
 IF (IMPRESP  >= 85 ) THEN IMPRESP  = .; 
 IF (IMPRESPM  >= 94 ) THEN IMPRESPM  = .; 
 IF (IMPSOC  >= 85 ) THEN IMPSOC  = .; 
 IF (IMPSOCM  >= 94 ) THEN IMPSOCM  = .; 
 IF (IMPWEEKS  >= 85 ) THEN IMPWEEKS  = .; 
 IF (IMPWORK  >= 85 ) THEN IMPWORK  = .; 
 IF (IMPYDAYS  >= 985 ) THEN IMPYDAYS  = .; 
 IF (INHAL30ES  >= 91 ) THEN INHAL30ES  = .; 
 IF (INHAL30N  >= 85 ) THEN INHAL30N  = .; 
 IF (INHALAGE  >= 985 ) THEN INHALAGE  = .; 
 IF (INHALEVER  >= 91 ) THEN INHALEVER  = .; 
 IF (INHALMFU  >= 85 ) THEN INHALMFU  = .; 
 IF (INHALOT1  >= 9985 ) THEN INHALOT1  = .; 
 IF (INHALOT2  >= 9985 ) THEN INHALOT2  = .; 
 IF (INHALOT3  >= 9985 ) THEN INHALOT3  = .; 
 IF (INHALOT4  >= 9991 ) THEN INHALOT4  = .; 
 IF (INHALOT5  >= 9991 ) THEN INHALOT5  = .; 
 IF (INHALOTH  >= 85 ) THEN INHALOTH  = .; 
 IF (INHALREC  >= 85 ) THEN INHALREC  = .; 
 IF (INHALYFQ  >= 985 ) THEN INHALYFQ  = .; 




 IF (INHDYPMO  >= 85 ) THEN INHDYPMO  = .; 
 IF (INHDYPWK  >= 85 ) THEN INHDYPWK  = .; 
 IF (INHDYSYR  >= 985 ) THEN INHDYSYR  = .; 
 IF (INHEASWY  >= 85 ) THEN INHEASWY  = .; 
 IF (INHFQFLG  >= 98 ) THEN INHFQFLG  = .; 
 IF (INHLAGLST  >= 985 ) THEN INHLAGLST  = .; 
 IF (INHLCUTDN  >= 85 ) THEN INHLCUTDN  = .; 
 IF (INHLCUTEV  >= 91 ) THEN INHLCUTEV  = .; 
 IF (INHLEMCTD  >= 91 ) THEN INHLEMCTD  = .; 
 IF (INHLEMOPB  >= 85 ) THEN INHLEMOPB  = .; 
 IF (INHLFMCTD  >= 91 ) THEN INHLFMCTD  = .; 
 IF (INHLFMFPB  >= 85 ) THEN INHLFMFPB  = .; 
 IF (INHLGTOVR  >= 85 ) THEN INHLGTOVR  = .; 
 IF (INHLKPLMT  >= 91 ) THEN INHLKPLMT  = .; 
 IF (INHLLAWTR  >= 85 ) THEN INHLLAWTR  = .; 
 IF (INHLLIMIT  >= 85 ) THEN INHLLIMIT  = .; 
 IF (INHLLOTTM  >= 85 ) THEN INHLLOTTM  = .; 
 IF (INHLLSACT  >= 85 ) THEN INHLLSACT  = .; 
 IF (INHLLSEFX  >= 85 ) THEN INHLLSEFX  = .; 
 IF (INHLMOLST  >= 85 ) THEN INHLMOLST  = .; 
 IF (INHLNDMOR  >= 85 ) THEN INHLNDMOR  = .; 
 IF (INHLPDANG  >= 85 ) THEN INHLPDANG  = .; 
 IF (INHLPHCTD  >= 91 ) THEN INHLPHCTD  = .; 
 IF (INHLPHLPB  >= 85 ) THEN INHLPHLPB  = .; 
 IF (INHLSERPB  >= 85 ) THEN INHLSERPB  = .; 
 IF (INHLYRLST  >= 9985 ) THEN INHLYRLST  = .; 
 IF (INHOSPYR  >= 85 ) THEN INHOSPYR  = .; 
 IF (INHTOTFG  >= 98 ) THEN INHTOTFG  = .; 
 IF (IRABUPOSHAL  >= 91 ) THEN IRABUPOSHAL  = .; 
 IF (IRABUPOSINH  >= 91 ) THEN IRABUPOSINH  = .; 
 IF (IRABUPOSMTH  >= 91 ) THEN IRABUPOSMTH  = .; 
 IF (IRABUPOSPNR  >= 91 ) THEN IRABUPOSPNR  = .; 
 IF (IRABUPOSSED  >= 91 ) THEN IRABUPOSSED  = .; 
 IF (IRABUPOSSTM  >= 91 ) THEN IRABUPOSSTM  = .; 
 IF (IRABUPOSTRQ  >= 91 ) THEN IRABUPOSTRQ  = .; 
 IF (IRALCAGE  >= 991 ) THEN IRALCAGE  = .; 
 IF (IRALCBNG30D  >= 91 ) THEN IRALCBNG30D  = .; 
 IF (IRALCFM  >= 91 ) THEN IRALCFM  = .; 
 IF (IRALCFY  >= 991 ) THEN IRALCFY  = .; 
 IF (IRALCYFU  >= 9999 ) THEN IRALCYFU  = .; 
 IF (IRCD2YFU  >= 9993 ) THEN IRCD2YFU  = .; 
 IF (IRCDUAGE  >= 991 ) THEN IRCDUAGE  = .; 
 IF (IRCGRAGE  >= 991 ) THEN IRCGRAGE  = .; 
 IF (IRCGRFM  >= 91 ) THEN IRCGRFM  = .; 
 IF (IRCGRYFU  >= 9999 ) THEN IRCGRYFU  = .; 
 IF (IRCIGAGE  >= 991 ) THEN IRCIGAGE  = .; 
 IF (IRCIGFM  >= 91 ) THEN IRCIGFM  = .; 
 IF (IRCIGYFU  >= 9999 ) THEN IRCIGYFU  = .; 
 IF (IRCOCAGE  >= 991 ) THEN IRCOCAGE  = .; 
 IF (IRCOCFM  >= 91 ) THEN IRCOCFM  = .; 
 IF (IRCOCFY  >= 991 ) THEN IRCOCFY  = .; 
 IF (IRCOCYFU  >= 9999 ) THEN IRCOCYFU  = .; 




 IF (IRCRKFM  >= 91 ) THEN IRCRKFM  = .; 
 IF (IRCRKFY  >= 991 ) THEN IRCRKFY  = .; 
 IF (IRCRKYFU  >= 9999 ) THEN IRCRKYFU  = .; 
 IF (IRDEPENDHAL  >= 91 ) THEN IRDEPENDHAL  = .; 
 IF (IRDEPENDINH  >= 91 ) THEN IRDEPENDINH  = .; 
 IF (IRDEPENDMTH  >= 91 ) THEN IRDEPENDMTH  = .; 
 IF (IRDEPENDPNR  >= 91 ) THEN IRDEPENDPNR  = .; 
 IF (IRDEPENDSED  >= 91 ) THEN IRDEPENDSED  = .; 
 IF (IRDEPENDSTM  >= 91 ) THEN IRDEPENDSTM  = .; 
 IF (IRDEPENDTRQ  >= 91 ) THEN IRDEPENDTRQ  = .; 
 IF (IRECSTMOAGE  >= 991 ) THEN IRECSTMOAGE  = .; 
 IF (IRECSTMOYFU  >= 9999 ) THEN IRECSTMOYFU  = .; 
 IF (IRHALLUC30N  >= 91 ) THEN IRHALLUC30N  = .; 
 IF (IRHALLUCAGE  >= 991 ) THEN IRHALLUCAGE  = .; 
 IF (IRHALLUCYFQ  >= 991 ) THEN IRHALLUCYFQ  = .; 
 IF (IRHALLUCYFU  >= 9999 ) THEN IRHALLUCYFU  = .; 
 IF (IRHERAGE  >= 991 ) THEN IRHERAGE  = .; 
 IF (IRHERFM  >= 91 ) THEN IRHERFM  = .; 
 IF (IRHERFY  >= 991 ) THEN IRHERFY  = .; 
 IF (IRHERYFU  >= 9999 ) THEN IRHERYFU  = .; 
 IF (IRINHAL30N  >= 91 ) THEN IRINHAL30N  = .; 
 IF (IRINHALAGE  >= 991 ) THEN IRINHALAGE  = .; 
 IF (IRINHALYFQ  >= 991 ) THEN IRINHALYFQ  = .; 
 IF (IRINHALYFU  >= 9999 ) THEN IRINHALYFU  = .; 
 IF (IRLSDAGE  >= 991 ) THEN IRLSDAGE  = .; 
 IF (IRLSDYFU  >= 9999 ) THEN IRLSDYFU  = .; 
 IF (IRMARIT  >= 99 ) THEN IRMARIT  = .; 
 IF (IRMETHAM30N  >= 91 ) THEN IRMETHAM30N  = .; 
 IF (IRMETHAMAGE  >= 991 ) THEN IRMETHAMAGE  = .; 
 IF (IRMETHAMYFQ  >= 991 ) THEN IRMETHAMYFQ  = .; 
 IF (IRMETHAMYFU  >= 9999 ) THEN IRMETHAMYFU  = .; 
 IF (IRMJAGE  >= 991 ) THEN IRMJAGE  = .; 
 IF (IRMJFM  >= 91 ) THEN IRMJFM  = .; 
 IF (IRMJFY  >= 991 ) THEN IRMJFY  = .; 
 IF (IRMJYFU  >= 9999 ) THEN IRMJYFU  = .; 
 IF (IROTHHLT  >= 99 ) THEN IROTHHLT  = .; 
 IF (IRPCPAGE  >= 991 ) THEN IRPCPAGE  = .; 
 IF (IRPCPYFU  >= 9999 ) THEN IRPCPYFU  = .; 
 IF (IRPNRNM30FQ  >= 91 ) THEN IRPNRNM30FQ  = .; 
 IF (IRPNRNMAGE  >= 993 ) THEN IRPNRNMAGE  = .; 
 IF (IRPNRNMINIT  >= 91 ) THEN IRPNRNMINIT  = .; 
 IF (IRPNRNMYFU  >= 9993 ) THEN IRPNRNMYFU  = .; 
 IF (IRSEDNM30FQ  >= 91 ) THEN IRSEDNM30FQ  = .; 
 IF (IRSEDNMAGE  >= 993 ) THEN IRSEDNMAGE  = .; 
 IF (IRSEDNMINIT  >= 91 ) THEN IRSEDNMINIT  = .; 
 IF (IRSEDNMYFU  >= 9993 ) THEN IRSEDNMYFU  = .; 
 IF (IRSMKLSS30N  >= 91 ) THEN IRSMKLSS30N  = .; 
 IF (IRSMKLSSTRY  >= 991 ) THEN IRSMKLSSTRY  = .; 
 IF (IRSMKLSSYFU  >= 9999 ) THEN IRSMKLSSYFU  = .; 
 IF (IRSTMNM30FQ  >= 91 ) THEN IRSTMNM30FQ  = .; 
 IF (IRSTMNMAGE  >= 993 ) THEN IRSTMNMAGE  = .; 
 IF (IRSTMNMINIT  >= 91 ) THEN IRSTMNMINIT  = .; 




 IF (IRTRQNM30FQ  >= 91 ) THEN IRTRQNM30FQ  = .; 
 IF (IRTRQNMAGE  >= 993 ) THEN IRTRQNMAGE  = .; 
 IF (IRTRQNMINIT  >= 91 ) THEN IRTRQNMINIT  = .; 
 IF (IRTRQNMYFU  >= 9993 ) THEN IRTRQNMYFU  = .; 
 IF (IRWELMOS  >= 99 ) THEN IRWELMOS  = .; 
 IF (IRWRKSTAT  >= 99 ) THEN IRWRKSTAT  = .; 
 IF (IRWRKSTAT18  >= 99 ) THEN IRWRKSTAT18  = .; 
 IF (KETMINESK  >= 91 ) THEN KETMINESK  = .; 
 IF (KETMINREC  >= 91 ) THEN KETMINREC  = .; 
 IF (KIDNYDSAG  >= 985 ) THEN KIDNYDSAG  = .; 
 IF (KIDNYDSEV  >= 85 ) THEN KIDNYDSEV  = .; 
 IF (LGAS  >= 85 ) THEN LGAS  = .; 
 IF (LSD  >= 91 ) THEN LSD  = .; 
 IF (LSDAGE  >= 985 ) THEN LSDAGE  = .; 
 IF (LSDAGLST  >= 985 ) THEN LSDAGLST  = .; 
 IF (LSDMFU  >= 85 ) THEN LSDMFU  = .; 
 IF (LSDMLU  >= 85 ) THEN LSDMLU  = .; 
 IF (LSDREC  >= 91 ) THEN LSDREC  = .; 
 IF (LSDYFU  >= 9985 ) THEN LSDYFU  = .; 
 IF (LSDYLU  >= 9985 ) THEN LSDYLU  = .; 
 IF (MEDICARE  >= 85 ) THEN MEDICARE  = .; 
 IF (MEDMJALL  >= 85 ) THEN MEDMJALL  = .; 
 IF (MEDMJYR  >= 85 ) THEN MEDMJYR  = .; 
 IF (MEFQFLG  >= 98 ) THEN MEFQFLG  = .; 
 IF (MESC  >= 91 ) THEN MESC  = .; 
 IF (METHAGLST  >= 985 ) THEN METHAGLST  = .; 
 IF (METHAM30E  >= 91 ) THEN METHAM30E  = .; 
 IF (METHAM30N  >= 85 ) THEN METHAM30N  = .; 
 IF (METHAMAGE  >= 985 ) THEN METHAMAGE  = .; 
 IF (METHAMEVR  >= 94 ) THEN METHAMEVR  = .; 
 IF (METHAMMFU  >= 85 ) THEN METHAMMFU  = .; 
 IF (METHAMREC  >= 91 ) THEN METHAMREC  = .; 
 IF (METHAMYFQ  >= 985 ) THEN METHAMYFQ  = .; 
 IF (METHAMYFU  >= 9985 ) THEN METHAMYFU  = .; 
 IF (METHCUT1X  >= 91 ) THEN METHCUT1X  = .; 
 IF (METHCUTDN  >= 91 ) THEN METHCUTDN  = .; 
 IF (METHCUTEV  >= 91 ) THEN METHCUTEV  = .; 
 IF (METHDYPMO  >= 85 ) THEN METHDYPMO  = .; 
 IF (METHDYPWK  >= 85 ) THEN METHDYPWK  = .; 
 IF (METHDYSYR  >= 985 ) THEN METHDYSYR  = .; 
 IF (METHEASWY  >= 85 ) THEN METHEASWY  = .; 
 IF (METHEMCTD  >= 91 ) THEN METHEMCTD  = .; 
 IF (METHEMOPB  >= 91 ) THEN METHEMOPB  = .; 
 IF (METHFLBLU  >= 91 ) THEN METHFLBLU  = .; 
 IF (METHFMCTD  >= 91 ) THEN METHFMCTD  = .; 
 IF (METHFMFPB  >= 91 ) THEN METHFMFPB  = .; 
 IF (METHGTOVR  >= 91 ) THEN METHGTOVR  = .; 
 IF (METHKPLMT  >= 91 ) THEN METHKPLMT  = .; 
 IF (METHLAWTR  >= 91 ) THEN METHLAWTR  = .; 
 IF (METHLIMIT  >= 91 ) THEN METHLIMIT  = .; 
 IF (METHLOTTM  >= 91 ) THEN METHLOTTM  = .; 
 IF (METHLSACT  >= 91 ) THEN METHLSACT  = .; 




 IF (METHMOLST  >= 85 ) THEN METHMOLST  = .; 
 IF (METHNDLRC  >= 91 ) THEN METHNDLRC  = .; 
 IF (METHNDMOR  >= 91 ) THEN METHNDMOR  = .; 
 IF (METHNEEDL  >= 91 ) THEN METHNEEDL  = .; 
 IF (METHPDANG  >= 91 ) THEN METHPDANG  = .; 
 IF (METHPHCTD  >= 91 ) THEN METHPHCTD  = .; 
 IF (METHPHLPB  >= 91 ) THEN METHPHLPB  = .; 
 IF (METHSERPB  >= 91 ) THEN METHSERPB  = .; 
 IF (METHWD2SX  >= 91 ) THEN METHWD2SX  = .; 
 IF (METHWDSMT  >= 91 ) THEN METHWDSMT  = .; 
 IF (METHYRLST  >= 9985 ) THEN METHYRLST  = .; 
 IF (METOTFG  >= 98 ) THEN METOTFG  = .; 
 IF (MILSTAT  >= 85 ) THEN MILSTAT  = .; 
 IF (MILTCHLDR  >= 85 ) THEN MILTCHLDR  = .; 
 IF (MILTFAMLY  >= 85 ) THEN MILTFAMLY  = .; 
 IF (MILTPARNT  >= 85 ) THEN MILTPARNT  = .; 
 IF (MILTSIBLN  >= 85 ) THEN MILTSIBLN  = .; 
 IF (MILTSPPAR  >= 85 ) THEN MILTSPPAR  = .; 
 IF (MJAGE  >= 985 ) THEN MJAGE  = .; 
 IF (MJDAY30A  >= 85 ) THEN MJDAY30A  = .; 
 IF (MJEVER  >= 94 ) THEN MJEVER  = .; 
 IF (MJFQFLG  >= 98 ) THEN MJFQFLG  = .; 
 IF (MJMFU  >= 85 ) THEN MJMFU  = .; 
 IF (MJREC  >= 91 ) THEN MJREC  = .; 
 IF (MJYFU  >= 9985 ) THEN MJYFU  = .; 
 IF (MJYRTOT  >= 985 ) THEN MJYRTOT  = .; 
 IF (MOVSINPYR2  >= 985 ) THEN MOVSINPYR2  = .; 
 IF (MR30EST  >= 91 ) THEN MR30EST  = .; 
 IF (MRBSTWAY  >= 85 ) THEN MRBSTWAY  = .; 
 IF (MRDAYPMO  >= 85 ) THEN MRDAYPMO  = .; 
 IF (MRDAYPWK  >= 85 ) THEN MRDAYPWK  = .; 
 IF (MRDAYPYR  >= 985 ) THEN MRDAYPYR  = .; 
 IF (MRJAGLST  >= 985 ) THEN MRJAGLST  = .; 
 IF (MRJCUTDN  >= 83 ) THEN MRJCUTDN  = .; 
 IF (MRJCUTEV  >= 83 ) THEN MRJCUTEV  = .; 
 IF (MRJEMCTD  >= 83 ) THEN MRJEMCTD  = .; 
 IF (MRJEMOPB  >= 83 ) THEN MRJEMOPB  = .; 
 IF (MRJFMCTD  >= 83 ) THEN MRJFMCTD  = .; 
 IF (MRJFMFPB  >= 83 ) THEN MRJFMFPB  = .; 
 IF (MRJGTOVR  >= 83 ) THEN MRJGTOVR  = .; 
 IF (MRJKPLMT  >= 83 ) THEN MRJKPLMT  = .; 
 IF (MRJLAWTR  >= 83 ) THEN MRJLAWTR  = .; 
 IF (MRJLIMIT  >= 83 ) THEN MRJLIMIT  = .; 
 IF (MRJLOTTM  >= 83 ) THEN MRJLOTTM  = .; 
 IF (MRJLSACT  >= 83 ) THEN MRJLSACT  = .; 
 IF (MRJLSEFX  >= 83 ) THEN MRJLSEFX  = .; 
 IF (MRJMLU  >= 85 ) THEN MRJMLU  = .; 
 IF (MRJNDMOR  >= 83 ) THEN MRJNDMOR  = .; 
 IF (MRJPDANG  >= 83 ) THEN MRJPDANG  = .; 
 IF (MRJPHCTD  >= 83 ) THEN MRJPHCTD  = .; 
 IF (MRJPHLPB  >= 83 ) THEN MRJPHLPB  = .; 
 IF (MRJSERPB  >= 83 ) THEN MRJSERPB  = .; 




 IF (MRJYRBFR  >= 85 ) THEN MRJYRBFR  = .; 
 IF (MRTOTFG  >= 98 ) THEN MRTOTFG  = .; 
 IF (MXMJPNLT  >= 85 ) THEN MXMJPNLT  = .; 
 IF (NDMORTALC  >= 91 ) THEN NDMORTALC  = .; 
 IF (NDMORTCOC  >= 91 ) THEN NDMORTCOC  = .; 
 IF (NDMORTHAL  >= 91 ) THEN NDMORTHAL  = .; 
 IF (NDMORTHER  >= 91 ) THEN NDMORTHER  = .; 
 IF (NDMORTINH  >= 91 ) THEN NDMORTINH  = .; 
 IF (NDMORTMRJ  >= 91 ) THEN NDMORTMRJ  = .; 
 IF (NDMORTMTH  >= 91 ) THEN NDMORTMTH  = .; 
 IF (NDMORTOTH  >= 91 ) THEN NDMORTOTH  = .; 
 IF (NDMORTPNR  >= 91 ) THEN NDMORTPNR  = .; 
 IF (NDMORTSED  >= 91 ) THEN NDMORTSED  = .; 
 IF (NDMORTSTM  >= 91 ) THEN NDMORTSTM  = .; 
 IF (NDMORTTRQ  >= 91 ) THEN NDMORTTRQ  = .; 
 IF (NDMORTXYR  >= 85 ) THEN NDMORTXYR  = .; 
 IF (NDMRDKWHR  >= 91 ) THEN NDMRDKWHR  = .; 
 IF (NDMREFFRT  >= 91 ) THEN NDMREFFRT  = .; 
 IF (NDMRFNDOU  >= 91 ) THEN NDMRFNDOU  = .; 
 IF (NDMRHANDL  >= 91 ) THEN NDMRHANDL  = .; 
 IF (NDMRJOBNG  >= 91 ) THEN NDMRJOBNG  = .; 
 IF (NDMRMIMPT  >= 91 ) THEN NDMRMIMPT  = .; 
 IF (NDMRNBRNG  >= 91 ) THEN NDMRNBRNG  = .; 
 IF (NDMRNOCOV  >= 91 ) THEN NDMRNOCOV  = .; 
 IF (NDMRNOHLP  >= 91 ) THEN NDMRNOHLP  = .; 
 IF (NDMRNONED  >= 91 ) THEN NDMRNONED  = .; 
 IF (NDMRNOTPY  >= 91 ) THEN NDMRNOTPY  = .; 
 IF (NDMRNSTOP  >= 91 ) THEN NDMRNSTOP  = .; 
 IF (NDMRNTIME  >= 91 ) THEN NDMRNTIME  = .; 
 IF (NDMROTRSN  >= 91 ) THEN NDMROTRSN  = .; 
 IF (NDMRPFULL  >= 91 ) THEN NDMRPFULL  = .; 
 IF (NDMRTSPHR  >= 91 ) THEN NDMRTSPHR  = .; 
 IF (NDMRWANTD  >= 91 ) THEN NDMRWANTD  = .; 
 IF (NDTXDKWHR  >= 91 ) THEN NDTXDKWHR  = .; 
 IF (NDTXEFFRT  >= 91 ) THEN NDTXEFFRT  = .; 
 IF (NDTXFNDOU  >= 91 ) THEN NDTXFNDOU  = .; 
 IF (NDTXHANDL  >= 91 ) THEN NDTXHANDL  = .; 
 IF (NDTXJOBNG  >= 91 ) THEN NDTXJOBNG  = .; 
 IF (NDTXMIMPT  >= 85 ) THEN NDTXMIMPT  = .; 
 IF (NDTXNBRNG  >= 91 ) THEN NDTXNBRNG  = .; 
 IF (NDTXNOCOV  >= 91 ) THEN NDTXNOCOV  = .; 
 IF (NDTXNOHLP  >= 91 ) THEN NDTXNOHLP  = .; 
 IF (NDTXNONED  >= 91 ) THEN NDTXNONED  = .; 
 IF (NDTXNOTPY  >= 91 ) THEN NDTXNOTPY  = .; 
 IF (NDTXNSTOP  >= 91 ) THEN NDTXNSTOP  = .; 
 IF (NDTXNTIME  >= 91 ) THEN NDTXNTIME  = .; 
 IF (NDTXOTRSN  >= 91 ) THEN NDTXOTRSN  = .; 
 IF (NDTXPFULL  >= 91 ) THEN NDTXPFULL  = .; 
 IF (NDTXTSPHR  >= 91 ) THEN NDTXTSPHR  = .; 
 IF (NDTXWANTD  >= 91 ) THEN NDTXWANTD  = .; 
 IF (NDTXYOTH1  >= 9985 ) THEN NDTXYOTH1  = .; 
 IF (NDTXYOTH2  >= 9985 ) THEN NDTXYOTH2  = .; 




 IF (NDTXYOTH4  >= 9991 ) THEN NDTXYOTH4  = .; 
 IF (NDTXYOTH5  >= 9991 ) THEN NDTXYOTH5  = .; 
 IF (NDTXYRADG  >= 85 ) THEN NDTXYRADG  = .; 
 IF (NDTXYRALC  >= 91 ) THEN NDTXYRALC  = .; 
 IF (NDTXYRCOC  >= 91 ) THEN NDTXYRCOC  = .; 
 IF (NDTXYRHAL  >= 91 ) THEN NDTXYRHAL  = .; 
 IF (NDTXYRHER  >= 91 ) THEN NDTXYRHER  = .; 
 IF (NDTXYRINH  >= 91 ) THEN NDTXYRINH  = .; 
 IF (NDTXYRMRJ  >= 91 ) THEN NDTXYRMRJ  = .; 
 IF (NDTXYRMTH  >= 91 ) THEN NDTXYRMTH  = .; 
 IF (NDTXYROTH  >= 91 ) THEN NDTXYROTH  = .; 
 IF (NDTXYRPNR  >= 91 ) THEN NDTXYRPNR  = .; 
 IF (NDTXYRSED  >= 91 ) THEN NDTXYRSED  = .; 
 IF (NDTXYRSTM  >= 91 ) THEN NDTXYRSTM  = .; 
 IF (NDTXYRTRQ  >= 91 ) THEN NDTXYRTRQ  = .; 
 IF (NITOXID  >= 85 ) THEN NITOXID  = .; 
 IF (NMERTMT2  >= 985 ) THEN NMERTMT2  = .; 
 IF (NMNGTHS2  >= 985 ) THEN NMNGTHS2  = .; 
 IF (NMVSOEST  >= 94 ) THEN NMVSOEST  = .; 
 IF (NMVSOPT2  >= 985 ) THEN NMVSOPT2  = .; 
 IF (NOBOOKY2  >= 985 ) THEN NOBOOKY2  = .; 
 IF (NOMARR2  >= 94 ) THEN NOMARR2  = .; 
 IF (NONABOVEV  >= 85 ) THEN NONABOVEV  = .; 
 IF (OTCFLAG  >= 98 ) THEN OTCFLAG  = .; 
 IF (OTDGNDLA  >= 9985 ) THEN OTDGNDLA  = .; 
 IF (OTDGNDLB  >= 9985 ) THEN OTDGNDLB  = .; 
 IF (OTDGNDLC  >= 9985 ) THEN OTDGNDLC  = .; 
 IF (OTDGNDLD  >= 9985 ) THEN OTDGNDLD  = .; 
 IF (OTDGNDLE  >= 9985 ) THEN OTDGNDLE  = .; 
 IF (OTDGNDLRC  >= 91 ) THEN OTDGNDLRC  = .; 
 IF (OTDGNEDL  >= 94 ) THEN OTDGNEDL  = .; 
 IF (OTHAEROS  >= 85 ) THEN OTHAEROS  = .; 
 IF (OXCNANYYR  >= 81 ) THEN OXCNANYYR  = .; 
 IF (OXCNNMAGE  >= 981 ) THEN OXCNNMAGE  = .; 
 IF (OXCNNMMFU  >= 81 ) THEN OXCNNMMFU  = .; 
 IF (OXCNNMYFU  >= 9981 ) THEN OXCNNMYFU  = .; 
 IF (OXCNNMYR  >= 81 ) THEN OXCNNMYR  = .; 
 IF (PAROLREL  >= 85 ) THEN PAROLREL  = .; 
 IF (PCP  >= 91 ) THEN PCP  = .; 
 IF (PCPAGE  >= 985 ) THEN PCPAGE  = .; 
 IF (PCPAGLST  >= 985 ) THEN PCPAGLST  = .; 
 IF (PCPMFU  >= 85 ) THEN PCPMFU  = .; 
 IF (PCPMLU  >= 85 ) THEN PCPMLU  = .; 
 IF (PCPREC  >= 91 ) THEN PCPREC  = .; 
 IF (PCPYFU  >= 9985 ) THEN PCPYFU  = .; 
 IF (PCPYLU  >= 9985 ) THEN PCPYLU  = .; 
 IF (PEYOTE  >= 91 ) THEN PEYOTE  = .; 
 IF (PIPE30DY  >= 91 ) THEN PIPE30DY  = .; 
 IF (PIPEVER  >= 94 ) THEN PIPEVER  = .; 
 IF (PNRANYLIF  >= 94 ) THEN PNRANYLIF  = .; 
 IF (PNRANYREC  >= 83 ) THEN PNRANYREC  = .; 
 IF (PNRLCUT1X  >= 83 ) THEN PNRLCUT1X  = .; 




 IF (PNRLCUTEV  >= 83 ) THEN PNRLCUTEV  = .; 
 IF (PNRLEMCTD  >= 83 ) THEN PNRLEMCTD  = .; 
 IF (PNRLEMOPB  >= 83 ) THEN PNRLEMOPB  = .; 
 IF (PNRLFMCTD  >= 83 ) THEN PNRLFMCTD  = .; 
 IF (PNRLFMFPB  >= 83 ) THEN PNRLFMFPB  = .; 
 IF (PNRLGTOVR  >= 83 ) THEN PNRLGTOVR  = .; 
 IF (PNRLKPLMT  >= 83 ) THEN PNRLKPLMT  = .; 
 IF (PNRLLAWTR  >= 83 ) THEN PNRLLAWTR  = .; 
 IF (PNRLLIMIT  >= 83 ) THEN PNRLLIMIT  = .; 
 IF (PNRLLOTTM  >= 83 ) THEN PNRLLOTTM  = .; 
 IF (PNRLLSACT  >= 83 ) THEN PNRLLSACT  = .; 
 IF (PNRLLSEFX  >= 83 ) THEN PNRLLSEFX  = .; 
 IF (PNRLNDMOR  >= 83 ) THEN PNRLNDMOR  = .; 
 IF (PNRLPDANG  >= 83 ) THEN PNRLPDANG  = .; 
 IF (PNRLPHCTD  >= 83 ) THEN PNRLPHCTD  = .; 
 IF (PNRLPHLPB  >= 83 ) THEN PNRLPHLPB  = .; 
 IF (PNRLSERPB  >= 83 ) THEN PNRLSERPB  = .; 
 IF (PNRLWD3SX  >= 83 ) THEN PNRLWD3SX  = .; 
 IF (PNRLWDSMT  >= 83 ) THEN PNRLWDSMT  = .; 
 IF (PNRNM30AL  >= 83 ) THEN PNRNM30AL  = .; 
 IF (PNRNM30D  >= 83 ) THEN PNRNM30D  = .; 
 IF (PNRNM30ES  >= 83 ) THEN PNRNM30ES  = .; 
 IF (PNRNM30FQ  >= 83 ) THEN PNRNM30FQ  = .; 
 IF (PNRNMAGE  >= 983 ) THEN PNRNMAGE  = .; 
 IF (PNRNMINIT  >= 83 ) THEN PNRNMINIT  = .; 
 IF (PNRNMLAS1  >= 83 ) THEN PNRNMLAS1  = .; 
 IF (PNRNMLIF  >= 85 ) THEN PNRNMLIF  = .; 
 IF (PNRNMMFU  >= 83 ) THEN PNRNMMFU  = .; 
 IF (PNRNMREC  >= 83 ) THEN PNRNMREC  = .; 
 IF (PNRNMYFU  >= 9983 ) THEN PNRNMYFU  = .; 
 IF (PNRNORXFG  >= 98 ) THEN PNRNORXFG  = .; 
 IF (PNRRSDGFX  >= 83 ) THEN PNRRSDGFX  = .; 
 IF (PNRRSEMOT  >= 83 ) THEN PNRRSEMOT  = .; 
 IF (PNRRSEXPT  >= 83 ) THEN PNRRSEXPT  = .; 
 IF (PNRRSHIGH  >= 83 ) THEN PNRRSHIGH  = .; 
 IF (PNRRSHOOK  >= 83 ) THEN PNRRSHOOK  = .; 
 IF (PNRRSMAIN  >= 83 ) THEN PNRRSMAIN  = .; 
 IF (PNRRSOTRS2  >= 983 ) THEN PNRRSOTRS2  = .; 
 IF (PNRRSPAIN  >= 83 ) THEN PNRRSPAIN  = .; 
 IF (PNRRSRELX  >= 83 ) THEN PNRRSRELX  = .; 
 IF (PNRRSSLEP  >= 83 ) THEN PNRRSSLEP  = .; 
 IF (PNRRSSOR  >= 83 ) THEN PNRRSSOR  = .; 
 IF (PNRWYGAMT  >= 83 ) THEN PNRWYGAMT  = .; 
 IF (PNRWYLNGR  >= 83 ) THEN PNRWYLNGR  = .; 
 IF (PNRWYNORX  >= 83 ) THEN PNRWYNORX  = .; 
 IF (PNRWYOFTN  >= 83 ) THEN PNRWYOFTN  = .; 
 IF (PNRWYOTWY  >= 83 ) THEN PNRWYOTWY  = .; 
 IF (PREGNANT  >= 85 ) THEN PREGNANT  = .; 
 IF (PROBATON  >= 85 ) THEN PROBATON  = .; 
 IF (PRVHLTIN  >= 85 ) THEN PRVHLTIN  = .; 
 IF (PRXRETRY  >= 94 ) THEN PRXRETRY  = .; 
 IF (PRXYDATA  >= 94 ) THEN PRXYDATA  = .; 




 IF (RKFQDBLT  >= 85 ) THEN RKFQDBLT  = .; 
 IF (RKFQPBLT  >= 85 ) THEN RKFQPBLT  = .; 
 IF (RSKBNGDLY  >= 85 ) THEN RSKBNGDLY  = .; 
 IF (RSKBNGWK  >= 85 ) THEN RSKBNGWK  = .; 
 IF (RSKCIGPKD  >= 85 ) THEN RSKCIGPKD  = .; 
 IF (RSKCOCMON  >= 85 ) THEN RSKCOCMON  = .; 
 IF (RSKCOCWK  >= 85 ) THEN RSKCOCWK  = .; 
 IF (RSKHERTRY  >= 85 ) THEN RSKHERTRY  = .; 
 IF (RSKHERWK  >= 85 ) THEN RSKHERWK  = .; 
 IF (RSKLSDTRY  >= 85 ) THEN RSKLSDTRY  = .; 
 IF (RSKLSDWK  >= 85 ) THEN RSKLSDWK  = .; 
 IF (RSKMRJMON  >= 85 ) THEN RSKMRJMON  = .; 
 IF (RSKMRJWK  >= 85 ) THEN RSKMRJWK  = .; 
 IF (RSKYFQDGR  >= 85 ) THEN RSKYFQDGR  = .; 
 IF (RSKYFQTES  >= 85 ) THEN RSKYFQTES  = .; 
 IF (RSNMRJMO  >= 98 ) THEN RSNMRJMO  = .; 
 IF (RSNOMRJ  >= 98 ) THEN RSNOMRJ  = .; 
 IF (SALVIADIV  >= 91 ) THEN SALVIADIV  = .; 
 IF (SALVIAREC  >= 91 ) THEN SALVIAREC  = .; 
 IF (SEDANYLIF  >= 94 ) THEN SEDANYLIF  = .; 
 IF (SEDANYREC  >= 83 ) THEN SEDANYREC  = .; 
 IF (SEDNM30AL  >= 83 ) THEN SEDNM30AL  = .; 
 IF (SEDNM30D  >= 83 ) THEN SEDNM30D  = .; 
 IF (SEDNM30ES  >= 91 ) THEN SEDNM30ES  = .; 
 IF (SEDNM30FQ  >= 83 ) THEN SEDNM30FQ  = .; 
 IF (SEDNMAGE  >= 983 ) THEN SEDNMAGE  = .; 
 IF (SEDNMINIT  >= 83 ) THEN SEDNMINIT  = .; 
 IF (SEDNMLAST  >= 83 ) THEN SEDNMLAST  = .; 
 IF (SEDNMLIF  >= 85 ) THEN SEDNMLIF  = .; 
 IF (SEDNMMFU  >= 83 ) THEN SEDNMMFU  = .; 
 IF (SEDNMREC  >= 83 ) THEN SEDNMREC  = .; 
 IF (SEDNMYFU  >= 9983 ) THEN SEDNMYFU  = .; 
 IF (SEDNORXFG  >= 98 ) THEN SEDNORXFG  = .; 
 IF (SEDRSDGFX  >= 83 ) THEN SEDRSDGFX  = .; 
 IF (SEDRSEMOT  >= 83 ) THEN SEDRSEMOT  = .; 
 IF (SEDRSEXPT  >= 85 ) THEN SEDRSEXPT  = .; 
 IF (SEDRSHIGH  >= 83 ) THEN SEDRSHIGH  = .; 
 IF (SEDRSHOOK  >= 83 ) THEN SEDRSHOOK  = .; 
 IF (SEDRSMAIN  >= 83 ) THEN SEDRSMAIN  = .; 
 IF (SEDRSOTRS2  >= 983 ) THEN SEDRSOTRS2  = .; 
 IF (SEDRSRELX  >= 83 ) THEN SEDRSRELX  = .; 
 IF (SEDRSSLEP  >= 83 ) THEN SEDRSSLEP  = .; 
 IF (SEDRSSOR  >= 83 ) THEN SEDRSSOR  = .; 
 IF (SEDVCUT1X  >= 83 ) THEN SEDVCUT1X  = .; 
 IF (SEDVCUTDN  >= 83 ) THEN SEDVCUTDN  = .; 
 IF (SEDVCUTEV  >= 83 ) THEN SEDVCUTEV  = .; 
 IF (SEDVEMCTD  >= 83 ) THEN SEDVEMCTD  = .; 
 IF (SEDVEMOPB  >= 83 ) THEN SEDVEMOPB  = .; 
 IF (SEDVFMCTD  >= 83 ) THEN SEDVFMCTD  = .; 
 IF (SEDVFMFPB  >= 83 ) THEN SEDVFMFPB  = .; 
 IF (SEDVGTOVR  >= 83 ) THEN SEDVGTOVR  = .; 
 IF (SEDVKPLMT  >= 83 ) THEN SEDVKPLMT  = .; 




 IF (SEDVLIMIT  >= 83 ) THEN SEDVLIMIT  = .; 
 IF (SEDVLOTTM  >= 83 ) THEN SEDVLOTTM  = .; 
 IF (SEDVLSACT  >= 83 ) THEN SEDVLSACT  = .; 
 IF (SEDVLSEFX  >= 83 ) THEN SEDVLSEFX  = .; 
 IF (SEDVNDMOR  >= 83 ) THEN SEDVNDMOR  = .; 
 IF (SEDVPDANG  >= 83 ) THEN SEDVPDANG  = .; 
 IF (SEDVPHCTD  >= 83 ) THEN SEDVPHCTD  = .; 
 IF (SEDVPHLPB  >= 83 ) THEN SEDVPHLPB  = .; 
 IF (SEDVSERPB  >= 83 ) THEN SEDVSERPB  = .; 
 IF (SEDVWD1SX  >= 83 ) THEN SEDVWD1SX  = .; 
 IF (SEDVWDSMT  >= 83 ) THEN SEDVWDSMT  = .; 
 IF (SEDWYGAMT  >= 83 ) THEN SEDWYGAMT  = .; 
 IF (SEDWYLNGR  >= 83 ) THEN SEDWYLNGR  = .; 
 IF (SEDWYNORX  >= 83 ) THEN SEDWYNORX  = .; 
 IF (SEDWYOFTN  >= 83 ) THEN SEDWYOFTN  = .; 
 IF (SEDWYOTWY  >= 83 ) THEN SEDWYOTWY  = .; 
 IF (SERVICE  >= 85 ) THEN SERVICE  = .; 
 IF (SEXATRACT  >= 85 ) THEN SEXATRACT  = .; 
 IF (SEXIDENT  >= 85 ) THEN SEXIDENT  = .; 
 IF (SMKAGLAST  >= 985 ) THEN SMKAGLAST  = .; 
 IF (SMKLSS30E  >= 91 ) THEN SMKLSS30E  = .; 
 IF (SMKLSS30N  >= 91 ) THEN SMKLSS30N  = .; 
 IF (SMKLSSEVR  >= 85 ) THEN SMKLSSEVR  = .; 
 IF (SMKLSSMFU  >= 85 ) THEN SMKLSSMFU  = .; 
 IF (SMKLSSREC  >= 85 ) THEN SMKLSSREC  = .; 
 IF (SMKLSSTRY  >= 985 ) THEN SMKLSSTRY  = .; 
 IF (SMKLSSYFU  >= 9985 ) THEN SMKLSSYFU  = .; 
 IF (SMKMOLAST  >= 85 ) THEN SMKMOLAST  = .; 
 IF (SMKYRLAST  >= 9985 ) THEN SMKYRLAST  = .; 
 IF (SNFAMJEV  >= 85 ) THEN SNFAMJEV  = .; 
 IF (SNRLDCSN  >= 85 ) THEN SNRLDCSN  = .; 
 IF (SNRLFRND  >= 85 ) THEN SNRLFRND  = .; 
 IF (SNRLGIMP  >= 85 ) THEN SNRLGIMP  = .; 
 IF (SNRLGSVC  >= 85 ) THEN SNRLGSVC  = .; 
 IF (SNYATTAK  >= 85 ) THEN SNYATTAK  = .; 
 IF (SNYSELL  >= 85 ) THEN SNYSELL  = .; 
 IF (SNYSTOLE  >= 85 ) THEN SNYSTOLE  = .; 
 IF (SOLVENT  >= 85 ) THEN SOLVENT  = .; 
 IF (SPEAKENGL  >= 85 ) THEN SPEAKENGL  = .; 
 IF (SPPAINT  >= 85 ) THEN SPPAINT  = .; 
 IF (STDANYYR  >= 85 ) THEN STDANYYR  = .; 
 IF (STIMCUT1X  >= 83 ) THEN STIMCUT1X  = .; 
 IF (STIMCUTDN  >= 83 ) THEN STIMCUTDN  = .; 
 IF (STIMCUTEV  >= 83 ) THEN STIMCUTEV  = .; 
 IF (STIMEMCTD  >= 83 ) THEN STIMEMCTD  = .; 
 IF (STIMEMOPB  >= 83 ) THEN STIMEMOPB  = .; 
 IF (STIMFLBLU  >= 83 ) THEN STIMFLBLU  = .; 
 IF (STIMFMCTD  >= 83 ) THEN STIMFMCTD  = .; 
 IF (STIMFMFPB  >= 83 ) THEN STIMFMFPB  = .; 
 IF (STIMGTOVR  >= 83 ) THEN STIMGTOVR  = .; 
 IF (STIMKPLMT  >= 83 ) THEN STIMKPLMT  = .; 
 IF (STIMLAWTR  >= 83 ) THEN STIMLAWTR  = .; 




 IF (STIMLOTTM  >= 83 ) THEN STIMLOTTM  = .; 
 IF (STIMLSACT  >= 83 ) THEN STIMLSACT  = .; 
 IF (STIMLSEFX  >= 83 ) THEN STIMLSEFX  = .; 
 IF (STIMNDMOR  >= 83 ) THEN STIMNDMOR  = .; 
 IF (STIMPDANG  >= 83 ) THEN STIMPDANG  = .; 
 IF (STIMPHCTD  >= 83 ) THEN STIMPHCTD  = .; 
 IF (STIMPHLPB  >= 83 ) THEN STIMPHLPB  = .; 
 IF (STIMSERPB  >= 83 ) THEN STIMSERPB  = .; 
 IF (STIMWD2SX  >= 83 ) THEN STIMWD2SX  = .; 
 IF (STIMWDSMT  >= 83 ) THEN STIMWDSMT  = .; 
 IF (STMANYLIF  >= 94 ) THEN STMANYLIF  = .; 
 IF (STMANYREC  >= 83 ) THEN STMANYREC  = .; 
 IF (STMNDLREC  >= 85 ) THEN STMNDLREC  = .; 
 IF (STMNDLYR  >= 83 ) THEN STMNDLYR  = .; 
 IF (STMNM30AL  >= 83 ) THEN STMNM30AL  = .; 
 IF (STMNM30D  >= 83 ) THEN STMNM30D  = .; 
 IF (STMNM30ES  >= 91 ) THEN STMNM30ES  = .; 
 IF (STMNM30FQ  >= 83 ) THEN STMNM30FQ  = .; 
 IF (STMNMAGE  >= 983 ) THEN STMNMAGE  = .; 
 IF (STMNMINIT  >= 83 ) THEN STMNMINIT  = .; 
 IF (STMNMLAS1  >= 83 ) THEN STMNMLAS1  = .; 
 IF (STMNMLIF  >= 85 ) THEN STMNMLIF  = .; 
 IF (STMNMMFU  >= 83 ) THEN STMNMMFU  = .; 
 IF (STMNMREC  >= 83 ) THEN STMNMREC  = .; 
 IF (STMNMYFU  >= 9983 ) THEN STMNMYFU  = .; 
 IF (STMNORXFG  >= 98 ) THEN STMNORXFG  = .; 
 IF (STMRSALRT  >= 83 ) THEN STMRSALRT  = .; 
 IF (STMRSCONC  >= 83 ) THEN STMRSCONC  = .; 
 IF (STMRSDGFX  >= 91 ) THEN STMRSDGFX  = .; 
 IF (STMRSEXPT  >= 91 ) THEN STMRSEXPT  = .; 
 IF (STMRSHIGH  >= 91 ) THEN STMRSHIGH  = .; 
 IF (STMRSHOOK  >= 91 ) THEN STMRSHOOK  = .; 
 IF (STMRSMAIN  >= 83 ) THEN STMRSMAIN  = .; 
 IF (STMRSOTRS2  >= 983 ) THEN STMRSOTRS2  = .; 
 IF (STMRSSOR  >= 83 ) THEN STMRSSOR  = .; 
 IF (STMRSSTDY  >= 91 ) THEN STMRSSTDY  = .; 
 IF (STMRSWGHT  >= 83 ) THEN STMRSWGHT  = .; 
 IF (STMWYGAMT  >= 83 ) THEN STMWYGAMT  = .; 
 IF (STMWYLNGR  >= 91 ) THEN STMWYLNGR  = .; 
 IF (STMWYNORX  >= 83 ) THEN STMWYNORX  = .; 
 IF (STMWYOFTN  >= 91 ) THEN STMWYOFTN  = .; 
 IF (STMWYOTWY  >= 83 ) THEN STMWYOTWY  = .; 
 IF (SUICPLAN  >= 85 ) THEN SUICPLAN  = .; 
 IF (SUICTHNK  >= 85 ) THEN SUICTHNK  = .; 
 IF (SUICTRY  >= 85 ) THEN SUICTRY  = .; 
 IF (TOOLONG  >= 98 ) THEN TOOLONG  = .; 
 IF (TROUBUND  >= 98 ) THEN TROUBUND  = .; 
 IF (TRQANYLIF  >= 94 ) THEN TRQANYLIF  = .; 
 IF (TRQANYREC  >= 83 ) THEN TRQANYREC  = .; 
 IF (TRQLCUTDN  >= 83 ) THEN TRQLCUTDN  = .; 
 IF (TRQLCUTEV  >= 83 ) THEN TRQLCUTEV  = .; 
 IF (TRQLEMCTD  >= 83 ) THEN TRQLEMCTD  = .; 




 IF (TRQLFMCTD  >= 83 ) THEN TRQLFMCTD  = .; 
 IF (TRQLFMFPB  >= 83 ) THEN TRQLFMFPB  = .; 
 IF (TRQLGTOVR  >= 83 ) THEN TRQLGTOVR  = .; 
 IF (TRQLKPLMT  >= 83 ) THEN TRQLKPLMT  = .; 
 IF (TRQLLAWTR  >= 83 ) THEN TRQLLAWTR  = .; 
 IF (TRQLLIMIT  >= 83 ) THEN TRQLLIMIT  = .; 
 IF (TRQLLOTTM  >= 83 ) THEN TRQLLOTTM  = .; 
 IF (TRQLLSACT  >= 83 ) THEN TRQLLSACT  = .; 
 IF (TRQLLSEFT  >= 83 ) THEN TRQLLSEFT  = .; 
 IF (TRQLNDMOR  >= 83 ) THEN TRQLNDMOR  = .; 
 IF (TRQLPDANG  >= 83 ) THEN TRQLPDANG  = .; 
 IF (TRQLPHCTD  >= 83 ) THEN TRQLPHCTD  = .; 
 IF (TRQLPHLPB  >= 83 ) THEN TRQLPHLPB  = .; 
 IF (TRQLSERPB  >= 83 ) THEN TRQLSERPB  = .; 
 IF (TRQNM30AL  >= 83 ) THEN TRQNM30AL  = .; 
 IF (TRQNM30D  >= 83 ) THEN TRQNM30D  = .; 
 IF (TRQNM30ES  >= 91 ) THEN TRQNM30ES  = .; 
 IF (TRQNM30FQ  >= 83 ) THEN TRQNM30FQ  = .; 
 IF (TRQNMAGE  >= 983 ) THEN TRQNMAGE  = .; 
 IF (TRQNMINIT  >= 83 ) THEN TRQNMINIT  = .; 
 IF (TRQNMLAS1  >= 83 ) THEN TRQNMLAS1  = .; 
 IF (TRQNMLIF  >= 85 ) THEN TRQNMLIF  = .; 
 IF (TRQNMMFU  >= 83 ) THEN TRQNMMFU  = .; 
 IF (TRQNMREC  >= 83 ) THEN TRQNMREC  = .; 
 IF (TRQNMYFU  >= 9983 ) THEN TRQNMYFU  = .; 
 IF (TRQNORXFG  >= 98 ) THEN TRQNORXFG  = .; 
 IF (TRQRSDGFX  >= 91 ) THEN TRQRSDGFX  = .; 
 IF (TRQRSEMOT  >= 85 ) THEN TRQRSEMOT  = .; 
 IF (TRQRSEXPT  >= 85 ) THEN TRQRSEXPT  = .; 
 IF (TRQRSHIGH  >= 85 ) THEN TRQRSHIGH  = .; 
 IF (TRQRSHOOK  >= 91 ) THEN TRQRSHOOK  = .; 
 IF (TRQRSMAIN  >= 85 ) THEN TRQRSMAIN  = .; 
 IF (TRQRSOTRS2  >= 985 ) THEN TRQRSOTRS2  = .; 
 IF (TRQRSRELX  >= 83 ) THEN TRQRSRELX  = .; 
 IF (TRQRSSLEP  >= 85 ) THEN TRQRSSLEP  = .; 
 IF (TRQRSSOR  >= 85 ) THEN TRQRSSOR  = .; 
 IF (TRQWYGAMT  >= 85 ) THEN TRQWYGAMT  = .; 
 IF (TRQWYLNGR  >= 85 ) THEN TRQWYLNGR  = .; 
 IF (TRQWYNORX  >= 83 ) THEN TRQWYNORX  = .; 
 IF (TRQWYOFTN  >= 85 ) THEN TRQWYOFTN  = .; 
 IF (TRQWYOTWY  >= 85 ) THEN TRQWYOTWY  = .; 
 IF (TXALCDAGE  >= 991 ) THEN TXALCDAGE  = .; 
 IF (TXALCDRGU  >= 91 ) THEN TXALCDRGU  = .; 
 IF (TXALCONAG  >= 991 ) THEN TXALCONAG  = .; 
 IF (TXALCONLY  >= 85 ) THEN TXALCONLY  = .; 
 IF (TXCURRENT  >= 85 ) THEN TXCURRENT  = .; 
 IF (TXDRGAAGE  >= 991 ) THEN TXDRGAAGE  = .; 
 IF (TXDRGALCU  >= 91 ) THEN TXDRGALCU  = .; 
 IF (TXDRGONAG  >= 991 ) THEN TXDRGONAG  = .; 
 IF (TXDRGONLY  >= 91 ) THEN TXDRGONLY  = .; 
 IF (TXENRLOCT  >= 85 ) THEN TXENRLOCT  = .; 
 IF (TXEVRRCVD  >= 85 ) THEN TXEVRRCVD  = .; 




 IF (TXFGALAGE  >= 91 ) THEN TXFGALAGE  = .; 
 IF (TXFGDGAGE  >= 91 ) THEN TXFGDGAGE  = .; 
 IF (TXLTYALCO  >= 85 ) THEN TXLTYALCO  = .; 
 IF (TXLTYCOCN  >= 85 ) THEN TXLTYCOCN  = .; 
 IF (TXLTYDAYS2  >= 99985 ) THEN TXLTYDAYS2  = .; 
 IF (TXLTYHALL  >= 85 ) THEN TXLTYHALL  = .; 
 IF (TXLTYHERN  >= 85 ) THEN TXLTYHERN  = .; 
 IF (TXLTYINHL  >= 91 ) THEN TXLTYINHL  = .; 
 IF (TXLTYMAIN2  >= 85 ) THEN TXLTYMAIN2  = .; 
 IF (TXLTYMETH  >= 85 ) THEN TXLTYMETH  = .; 
 IF (TXLTYMNPL2  >= 985 ) THEN TXLTYMNPL2  = .; 
 IF (TXLTYMRJH  >= 85 ) THEN TXLTYMRJH  = .; 
 IF (TXLTYOCOM2  >= 85 ) THEN TXLTYOCOM2  = .; 
 IF (TXLTYOTHR  >= 85 ) THEN TXLTYOTHR  = .; 
 IF (TXLTYPNRL  >= 85 ) THEN TXLTYPNRL  = .; 
 IF (TXLTYSEDV  >= 85 ) THEN TXLTYSEDV  = .; 
 IF (TXLTYSTIM  >= 85 ) THEN TXLTYSTIM  = .; 
 IF (TXLTYTRQL  >= 85 ) THEN TXLTYTRQL  = .; 
 IF (TXPAYBOSS  >= 85 ) THEN TXPAYBOSS  = .; 
 IF (TXPAYCOUR  >= 85 ) THEN TXPAYCOUR  = .; 
 IF (TXPAYFAML  >= 85 ) THEN TXPAYFAML  = .; 
 IF (TXPAYFREE  >= 85 ) THEN TXPAYFREE  = .; 
 IF (TXPAYHINS  >= 85 ) THEN TXPAYHINS  = .; 
 IF (TXPAYMCAD  >= 85 ) THEN TXPAYMCAD  = .; 
 IF (TXPAYMCRE  >= 85 ) THEN TXPAYMCRE  = .; 
 IF (TXPAYMILT  >= 85 ) THEN TXPAYMILT  = .; 
 IF (TXPAYOTHR  >= 85 ) THEN TXPAYOTHR  = .; 
 IF (TXPAYOTSP2  >= 85 ) THEN TXPAYOTSP2  = .; 
 IF (TXPAYPUBL  >= 85 ) THEN TXPAYPUBL  = .; 
 IF (TXPAYSVNG  >= 85 ) THEN TXPAYSVNG  = .; 
 IF (TXRCVDREC  >= 85 ) THEN TXRCVDREC  = .; 
 IF (TXSHGALDB  >= 91 ) THEN TXSHGALDB  = .; 
 IF (TXSHGFLAG  >= 91 ) THEN TXSHGFLAG  = .; 
 IF (TXSHGWENT  >= 85 ) THEN TXSHGWENT  = .; 
 IF (TXYALDAAG  >= 991 ) THEN TXYALDAAG  = .; 
 IF (TXYALDDAG  >= 985 ) THEN TXYALDDAG  = .; 
 IF (TXYALODAG  >= 991 ) THEN TXYALODAG  = .; 
 IF (TXYALODRG  >= 85 ) THEN TXYALODRG  = .; 
 IF (TXYALONAG  >= 985 ) THEN TXYALONAG  = .; 
 IF (TXYDROAAG  >= 991 ) THEN TXYDROAAG  = .; 
 IF (TXYDROALC  >= 85 ) THEN TXYDROALC  = .; 
 IF (TXYDRONAG  >= 985 ) THEN TXYDRONAG  = .; 
 IF (TXYRALDGB  >= 85 ) THEN TXYRALDGB  = .; 
 IF (TXYRDRPAD  >= 91 ) THEN TXYRDRPAD  = .; 
 IF (TXYRDRPRV  >= 85 ) THEN TXYRDRPRV  = .; 
 IF (TXYREMRAD  >= 91 ) THEN TXYREMRAD  = .; 
 IF (TXYREMRGN  >= 85 ) THEN TXYREMRGN  = .; 
 IF (TXYRERDRG  >= 85 ) THEN TXYRERDRG  = .; 
 IF (TXYRERNUM2  >= 991 ) THEN TXYRERNUM2  = .; 
 IF (TXYRHOSAD  >= 91 ) THEN TXYRHOSAD  = .; 
 IF (TXYRHOSOV  >= 85 ) THEN TXYRHOSOV  = .; 
 IF (TXYRMHCAD  >= 91 ) THEN TXYRMHCAD  = .; 




 IF (TXYRONDTX  >= 85 ) THEN TXYRONDTX  = .; 
 IF (TXYROTHAD  >= 91 ) THEN TXYROTHAD  = .; 
 IF (TXYROTHER  >= 85 ) THEN TXYROTHER  = .; 
 IF (TXYROTHSP2  >= 985 ) THEN TXYROTHSP2  = .; 
 IF (TXYROUTAD  >= 91 ) THEN TXYROUTAD  = .; 
 IF (TXYROUTPT  >= 85 ) THEN TXYROUTPT  = .; 
 IF (TXYRPRIAD  >= 91 ) THEN TXYRPRIAD  = .; 
 IF (TXYRPRISN  >= 85 ) THEN TXYRPRISN  = .; 
 IF (TXYRRECVD  >= 85 ) THEN TXYRRECVD  = .; 
 IF (TXYRRESAD  >= 91 ) THEN TXYRRESAD  = .; 
 IF (TXYRRESOV  >= 85 ) THEN TXYRRESOV  = .; 
 IF (TXYRSLFAD  >= 91 ) THEN TXYRSLFAD  = .; 
 IF (TXYRSLFHP  >= 85 ) THEN TXYRSLFHP  = .; 
 IF (WRK35WKUS  >= 85 ) THEN WRK35WKUS  = .; 
 IF (WRKDHRSWK2  >= 985 ) THEN WRKDHRSWK2  = .; 
 IF (WRKDPSTWK  >= 85 ) THEN WRKDPSTWK  = .; 
 IF (WRKDPSTYR  >= 85 ) THEN WRKDPSTYR  = .; 
 IF (WRKDRGALB  >= 85 ) THEN WRKDRGALB  = .; 
 IF (WRKDRGEDU  >= 85 ) THEN WRKDRGEDU  = .; 
 IF (WRKDRGHLP  >= 85 ) THEN WRKDRGHLP  = .; 
 IF (WRKDRGPOL  >= 85 ) THEN WRKDRGPOL  = .; 
 IF (WRKEFFORT  >= 94 ) THEN WRKEFFORT  = .; 
 IF (WRKHADJOB  >= 85 ) THEN WRKHADJOB  = .; 
 IF (WRKLASTYR2  >= 9985 ) THEN WRKLASTYR2  = .; 
 IF (WRKNJBPYR  >= 85 ) THEN WRKNJBPYR  = .; 
 IF (WRKNJBWKS  >= 85 ) THEN WRKNJBWKS  = .; 
 IF (WRKNUMJOB2  >= 85 ) THEN WRKNUMJOB2  = .; 
 IF (WRKOKPREH  >= 85 ) THEN WRKOKPREH  = .; 
 IF (WRKOKRAND  >= 85 ) THEN WRKOKRAND  = .; 
 IF (WRKRSNJOB  >= 985 ) THEN WRKRSNJOB  = .; 
 IF (WRKRSNNOT  >= 994 ) THEN WRKRSNNOT  = .; 
 IF (WRKSELFEM  >= 85 ) THEN WRKSELFEM  = .; 
 IF (WRKSICKMO  >= 85 ) THEN WRKSICKMO  = .; 
 IF (WRKSKIPMO  >= 85 ) THEN WRKSKIPMO  = .; 
 IF (WRKSTATWK2  >= 98 ) THEN WRKSTATWK2  = .; 
 IF (WRKTST1ST  >= 85 ) THEN WRKTST1ST  = .; 
 IF (WRKTSTALC  >= 85 ) THEN WRKTSTALC  = .; 
 IF (WRKTSTDRG  >= 85 ) THEN WRKTSTDRG  = .; 
 IF (WRKTSTHIR  >= 85 ) THEN WRKTSTHIR  = .; 
 IF (WRKTSTRDM  >= 85 ) THEN WRKTSTRDM  = .; 
 IF (WTANSWER  >= 85 ) THEN WTANSWER  = .; 
 IF (WTPOUND2  >= 9985 ) THEN WTPOUND2  = .; 
 IF (YEATNDYR  >= 85 ) THEN YEATNDYR  = .; 
 IF (YECOMACT  >= 85 ) THEN YECOMACT  = .; 
 IF (YEDECLAS  >= 85 ) THEN YEDECLAS  = .; 
 IF (YEDERGLR  >= 85 ) THEN YEDERGLR  = .; 
 IF (YEDESPCL  >= 85 ) THEN YEDESPCL  = .; 
 IF (YEDGPRGP  >= 85 ) THEN YEDGPRGP  = .; 
 IF (YEFAIACT  >= 85 ) THEN YEFAIACT  = .; 
 IF (YEFALDLY  >= 85 ) THEN YEFALDLY  = .; 
 IF (YEFMJEVR  >= 85 ) THEN YEFMJEVR  = .; 
 IF (YEFMJMO  >= 85 ) THEN YEFMJMO  = .; 




 IF (YEGALDLY  >= 85 ) THEN YEGALDLY  = .; 
 IF (YEGMJEVR  >= 85 ) THEN YEGMJEVR  = .; 
 IF (YEGMJMO  >= 85 ) THEN YEGMJMO  = .; 
 IF (YEGPKCIG  >= 85 ) THEN YEGPKCIG  = .; 
 IF (YEHMSLYR  >= 85 ) THEN YEHMSLYR  = .; 
 IF (YELSTGRD  >= 85 ) THEN YELSTGRD  = .; 
 IF (YEOTHACT  >= 85 ) THEN YEOTHACT  = .; 
 IF (YEPALDLY  >= 85 ) THEN YEPALDLY  = .; 
 IF (YEPCHKHW  >= 85 ) THEN YEPCHKHW  = .; 
 IF (YEPCHORE  >= 85 ) THEN YEPCHORE  = .; 
 IF (YEPGDJOB  >= 85 ) THEN YEPGDJOB  = .; 
 IF (YEPHLPHW  >= 85 ) THEN YEPHLPHW  = .; 
 IF (YEPLMTSN  >= 85 ) THEN YEPLMTSN  = .; 
 IF (YEPLMTTV  >= 85 ) THEN YEPLMTTV  = .; 
 IF (YEPMJEVR  >= 85 ) THEN YEPMJEVR  = .; 
 IF (YEPMJMO  >= 85 ) THEN YEPMJMO  = .; 
 IF (YEPPKCIG  >= 85 ) THEN YEPPKCIG  = .; 
 IF (YEPPROUD  >= 85 ) THEN YEPPROUD  = .; 
 IF (YEPRBSLV  >= 85 ) THEN YEPRBSLV  = .; 
 IF (YEPRGSTD  >= 85 ) THEN YEPRGSTD  = .; 
 IF (YEPRTDNG  >= 85 ) THEN YEPRTDNG  = .; 
 IF (YEPVNTYR  >= 85 ) THEN YEPVNTYR  = .; 
 IF (YERLDCSN  >= 85 ) THEN YERLDCSN  = .; 
 IF (YERLFRND  >= 85 ) THEN YERLFRND  = .; 
 IF (YERLGIMP  >= 85 ) THEN YERLGIMP  = .; 
 IF (YERLGSVC  >= 85 ) THEN YERLGSVC  = .; 
 IF (YESCHACT  >= 85 ) THEN YESCHACT  = .; 
 IF (YESCHFLT  >= 85 ) THEN YESCHFLT  = .; 
 IF (YESCHIMP  >= 85 ) THEN YESCHIMP  = .; 
 IF (YESCHINT  >= 85 ) THEN YESCHINT  = .; 
 IF (YESCHWRK  >= 85 ) THEN YESCHWRK  = .; 
 IF (YESLFHLP  >= 85 ) THEN YESLFHLP  = .; 
 IF (YESTSALC  >= 85 ) THEN YESTSALC  = .; 
 IF (YESTSCIG  >= 85 ) THEN YESTSCIG  = .; 
 IF (YESTSDNK  >= 85 ) THEN YESTSDNK  = .; 
 IF (YESTSMJ  >= 85 ) THEN YESTSMJ  = .; 
 IF (YETCGJOB  >= 85 ) THEN YETCGJOB  = .; 
 IF (YETLKBGF  >= 94 ) THEN YETLKBGF  = .; 
 IF (YETLKNON  >= 85 ) THEN YETLKNON  = .; 
 IF (YETLKOTA  >= 94 ) THEN YETLKOTA  = .; 
 IF (YETLKPAR  >= 85 ) THEN YETLKPAR  = .; 
 IF (YETLKSOP  >= 94 ) THEN YETLKSOP  = .; 
 IF (YEVIOPRV  >= 85 ) THEN YEVIOPRV  = .; 
 IF (YEYARGUP  >= 85 ) THEN YEYARGUP  = .; 
 IF (YEYATTAK  >= 85 ) THEN YEYATTAK  = .; 
 IF (YEYFGTGP  >= 85 ) THEN YEYFGTGP  = .; 
 IF (YEYFGTSW  >= 85 ) THEN YEYFGTSW  = .; 
 IF (YEYHGUN  >= 85 ) THEN YEYHGUN  = .; 
 IF (YEYSELL  >= 85 ) THEN YEYSELL  = .; 
 IF (YEYSTOLE  >= 85 ) THEN YEYSTOLE  = .; 
 IF (YOCOUNS  >= 94 ) THEN YOCOUNS  = .; 
 IF (YODPDISC  >= 85 ) THEN YODPDISC  = .; 




 IF (YODPPROB  >= 94 ) THEN YODPPROB  = .; 
 IF (YODPR2WK  >= 85 ) THEN YODPR2WK  = .; 
 IF (YODPREV  >= 85 ) THEN YODPREV  = .; 
 IF (YODSCEV  >= 94 ) THEN YODSCEV  = .; 
 IF (YODSLSIN  >= 94 ) THEN YODSLSIN  = .; 
 IF (YODSMMDE  >= 94 ) THEN YODSMMDE  = .; 
 IF (YOFAMDOC  >= 94 ) THEN YOFAMDOC  = .; 
 IF (YOHERBAL  >= 94 ) THEN YOHERBAL  = .; 
 IF (YOLOSEV  >= 94 ) THEN YOLOSEV  = .; 
 IF (YOLSI2WK  >= 94 ) THEN YOLSI2WK  = .; 
 IF (YONURSE  >= 94 ) THEN YONURSE  = .; 
 IF (YOOTHDOC  >= 94 ) THEN YOOTHDOC  = .; 
 IF (YOOTHHLP  >= 94 ) THEN YOOTHHLP  = .; 
 IF (YOOTHMHP  >= 94 ) THEN YOOTHMHP  = .; 
 IF (YOPB2WK  >= 85 ) THEN YOPB2WK  = .; 
 IF (YOPBAGE  >= 994 ) THEN YOPBAGE  = .; 
 IF (YOPBDLYA  >= 94 ) THEN YOPBDLYA  = .; 
 IF (YOPBINTF  >= 94 ) THEN YOPBINTF  = .; 
 IF (YOPBNUM  >= 9994 ) THEN YOPBNUM  = .; 
 IF (YOPBRMBR  >= 94 ) THEN YOPBRMBR  = .; 
 IF (YOPSDAYS  >= 985 ) THEN YOPSDAYS  = .; 
 IF (YOPSHMGT  >= 85 ) THEN YOPSHMGT  = .; 
 IF (YOPSRELS  >= 85 ) THEN YOPSRELS  = .; 
 IF (YOPSSOC  >= 85 ) THEN YOPSSOC  = .; 
 IF (YOPSWORK  >= 85 ) THEN YOPSWORK  = .; 
 IF (YOPSYCH  >= 94 ) THEN YOPSYCH  = .; 
 IF (YOPSYMD  >= 94 ) THEN YOPSYMD  = .; 
 IF (YORELIG  >= 94 ) THEN YORELIG  = .; 
 IF (YORX12MO  >= 85 ) THEN YORX12MO  = .; 
 IF (YORXHLP  >= 94 ) THEN YORXHLP  = .; 
 IF (YORXNOW  >= 97 ) THEN YORXNOW  = .; 
 IF (YOSEEDOC  >= 85 ) THEN YOSEEDOC  = .; 
 IF (YOSOCWRK  >= 94 ) THEN YOSOCWRK  = .; 
 IF (YOTMTHLP  >= 94 ) THEN YOTMTHLP  = .; 
 IF (YOTMTNOW  >= 97 ) THEN YOTMTNOW  = .; 
 IF (YOWRAGE  >= 994 ) THEN YOWRAGE  = .; 
 IF (YOWRCHR  >= 94 ) THEN YOWRCHR  = .; 
 IF (YOWRCONC  >= 94 ) THEN YOWRCONC  = .; 
 IF (YOWRDBTR  >= 94 ) THEN YOWRDBTR  = .; 
 IF (YOWRDCSN  >= 94 ) THEN YOWRDCSN  = .; 
 IF (YOWRDEPR  >= 94 ) THEN YOWRDEPR  = .; 
 IF (YOWRDIET  >= 94 ) THEN YOWRDIET  = .; 
 IF (YOWRDISC  >= 94 ) THEN YOWRDISC  = .; 
 IF (YOWRDLOT  >= 94 ) THEN YOWRDLOT  = .; 
 IF (YOWRDST  >= 94 ) THEN YOWRDST  = .; 
 IF (YOWRELES  >= 94 ) THEN YOWRELES  = .; 
 IF (YOWREMOR  >= 94 ) THEN YOWREMOR  = .; 
 IF (YOWRENRG  >= 94 ) THEN YOWRENRG  = .; 
 IF (YOWRGAIN  >= 94 ) THEN YOWRGAIN  = .; 
 IF (YOWRGNL2  >= 994 ) THEN YOWRGNL2  = .; 
 IF (YOWRGROW  >= 94 ) THEN YOWRGROW  = .; 
 IF (YOWRHRS  >= 85 ) THEN YOWRHRS  = .; 




 IF (YOWRJINO  >= 94 ) THEN YOWRJINO  = .; 
 IF (YOWRJITT  >= 94 ) THEN YOWRJITT  = .; 
 IF (YOWRLOSE  >= 94 ) THEN YOWRLOSE  = .; 
 IF (YOWRLSIN  >= 94 ) THEN YOWRLSIN  = .; 
 IF (YOWRLSL2  >= 994 ) THEN YOWRLSL2  = .; 
 IF (YOWRNOGD  >= 94 ) THEN YOWRNOGD  = .; 
 IF (YOWRPLSR  >= 94 ) THEN YOWRPLSR  = .; 
 IF (YOWRPREG  >= 98 ) THEN YOWRPREG  = .; 
 IF (YOWRPROB  >= 94 ) THEN YOWRPROB  = .; 
 IF (YOWRSATP  >= 94 ) THEN YOWRSATP  = .; 
 IF (YOWRSLEP  >= 94 ) THEN YOWRSLEP  = .; 
 IF (YOWRSLNO  >= 94 ) THEN YOWRSLNO  = .; 
 IF (YOWRSLOW  >= 94 ) THEN YOWRSLOW  = .; 
 IF (YOWRSMOR  >= 94 ) THEN YOWRSMOR  = .; 
 IF (YOWRSPLN  >= 94 ) THEN YOWRSPLN  = .; 
 IF (YOWRSTHK  >= 94 ) THEN YOWRSTHK  = .; 
 IF (YOWRTHOT  >= 94 ) THEN YOWRTHOT  = .; 
 IF (YOWRWRTH  >= 94 ) THEN YOWRWRTH  = .; 
 IF (YO_MDEA1  >= 94 ) THEN YO_MDEA1  = .; 
 IF (YO_MDEA2  >= 94 ) THEN YO_MDEA2  = .; 
 IF (YO_MDEA3  >= 94 ) THEN YO_MDEA3  = .; 
 IF (YO_MDEA4  >= 94 ) THEN YO_MDEA4  = .; 
 IF (YO_MDEA5  >= 94 ) THEN YO_MDEA5  = .; 
 IF (YO_MDEA6  >= 94 ) THEN YO_MDEA6  = .; 
 IF (YO_MDEA7  >= 94 ) THEN YO_MDEA7  = .; 
 IF (YO_MDEA8  >= 94 ) THEN YO_MDEA8  = .; 
 IF (YO_MDEA9  >= 94 ) THEN YO_MDEA9  = .; 
 IF (YUDYANGR  >= 94 ) THEN YUDYANGR  = .; 
 IF (YUDYBKRU  >= 94 ) THEN YUDYBKRU  = .; 
 IF (YUDYDEPR  >= 94 ) THEN YUDYDEPR  = .; 
 IF (YUDYEATP  >= 94 ) THEN YUDYEATP  = .; 
 IF (YUDYFEAR  >= 94 ) THEN YUDYFEAR  = .; 
 IF (YUDYFITE  >= 94 ) THEN YUDYFITE  = .; 
 IF (YUDYFMLY  >= 94 ) THEN YUDYFMLY  = .; 
 IF (YUDYFRND  >= 94 ) THEN YUDYFRND  = .; 
 IF (YUDYOTPP  >= 94 ) THEN YUDYOTPP  = .; 
 IF (YUDYSCHL  >= 85 ) THEN YUDYSCHL  = .; 
 IF (YUDYSOR  >= 94 ) THEN YUDYSOR  = .; 
 IF (YUDYSUIC  >= 85 ) THEN YUDYSUIC  = .; 
 IF (YUDYTXN2  >= 985 ) THEN YUDYTXN2  = .; 
 IF (YUDYTXYR  >= 85 ) THEN YUDYTXYR  = .; 
 IF (YUFCANGR  >= 94 ) THEN YUFCANGR  = .; 
 IF (YUFCARN2  >= 985 ) THEN YUFCARN2  = .; 
 IF (YUFCARYR  >= 85 ) THEN YUFCARYR  = .; 
 IF (YUFCBKRU  >= 94 ) THEN YUFCBKRU  = .; 
 IF (YUFCDEPR  >= 94 ) THEN YUFCDEPR  = .; 
 IF (YUFCEATP  >= 94 ) THEN YUFCEATP  = .; 
 IF (YUFCFEAR  >= 94 ) THEN YUFCFEAR  = .; 
 IF (YUFCFITE  >= 94 ) THEN YUFCFITE  = .; 
 IF (YUFCFMLY  >= 94 ) THEN YUFCFMLY  = .; 
 IF (YUFCFRND  >= 94 ) THEN YUFCFRND  = .; 
 IF (YUFCOTPP  >= 94 ) THEN YUFCOTPP  = .; 




 IF (YUFCSOR  >= 94 ) THEN YUFCSOR  = .; 
 IF (YUFCSUIC  >= 85 ) THEN YUFCSUIC  = .; 
 IF (YUFDANGR  >= 94 ) THEN YUFDANGR  = .; 
 IF (YUFDBKRU  >= 94 ) THEN YUFDBKRU  = .; 
 IF (YUFDDEPR  >= 85 ) THEN YUFDDEPR  = .; 
 IF (YUFDEATP  >= 94 ) THEN YUFDEATP  = .; 
 IF (YUFDFEAR  >= 94 ) THEN YUFDFEAR  = .; 
 IF (YUFDFITE  >= 94 ) THEN YUFDFITE  = .; 
 IF (YUFDFMLY  >= 94 ) THEN YUFDFMLY  = .; 
 IF (YUFDFRND  >= 94 ) THEN YUFDFRND  = .; 
 IF (YUFDOCN2  >= 985 ) THEN YUFDOCN2  = .; 
 IF (YUFDOCYR  >= 85 ) THEN YUFDOCYR  = .; 
 IF (YUFDOTPP  >= 94 ) THEN YUFDOTPP  = .; 
 IF (YUFDSCHL  >= 94 ) THEN YUFDSCHL  = .; 
 IF (YUFDSOR  >= 94 ) THEN YUFDSOR  = .; 
 IF (YUFDSUIC  >= 85 ) THEN YUFDSUIC  = .; 
 IF (YUHOANGR  >= 94 ) THEN YUHOANGR  = .; 
 IF (YUHOBKRU  >= 94 ) THEN YUHOBKRU  = .; 
 IF (YUHODEPR  >= 85 ) THEN YUHODEPR  = .; 
 IF (YUHOEATP  >= 94 ) THEN YUHOEATP  = .; 
 IF (YUHOFEAR  >= 94 ) THEN YUHOFEAR  = .; 
 IF (YUHOFITE  >= 94 ) THEN YUHOFITE  = .; 
 IF (YUHOFMLY  >= 94 ) THEN YUHOFMLY  = .; 
 IF (YUHOFRND  >= 94 ) THEN YUHOFRND  = .; 
 IF (YUHOOTPP  >= 94 ) THEN YUHOOTPP  = .; 
 IF (YUHOSCHL  >= 94 ) THEN YUHOSCHL  = .; 
 IF (YUHOSOR  >= 94 ) THEN YUHOSOR  = .; 
 IF (YUHOSPN2  >= 985 ) THEN YUHOSPN2  = .; 
 IF (YUHOSPYR  >= 85 ) THEN YUHOSPYR  = .; 
 IF (YUHOSUIC  >= 85 ) THEN YUHOSUIC  = .; 
 IF (YUIHANGR  >= 94 ) THEN YUIHANGR  = .; 
 IF (YUIHBKRU  >= 94 ) THEN YUIHBKRU  = .; 
 IF (YUIHDEPR  >= 94 ) THEN YUIHDEPR  = .; 
 IF (YUIHEATP  >= 94 ) THEN YUIHEATP  = .; 
 IF (YUIHFEAR  >= 94 ) THEN YUIHFEAR  = .; 
 IF (YUIHFITE  >= 94 ) THEN YUIHFITE  = .; 
 IF (YUIHFMLY  >= 94 ) THEN YUIHFMLY  = .; 
 IF (YUIHFRND  >= 94 ) THEN YUIHFRND  = .; 
 IF (YUIHOTPP  >= 94 ) THEN YUIHOTPP  = .; 
 IF (YUIHSCHL  >= 94 ) THEN YUIHSCHL  = .; 
 IF (YUIHSOR  >= 94 ) THEN YUIHSOR  = .; 
 IF (YUIHSUIC  >= 85 ) THEN YUIHSUIC  = .; 
 IF (YUIHTPN2  >= 985 ) THEN YUIHTPN2  = .; 
 IF (YUIHTPYR  >= 85 ) THEN YUIHTPYR  = .; 
 IF (YUJVDTN2  >= 985 ) THEN YUJVDTN2  = .; 
 IF (YUJVDTON  >= 85 ) THEN YUJVDTON  = .; 
 IF (YUJVDTYR  >= 85 ) THEN YUJVDTYR  = .; 
 IF (YUMHANGR  >= 94 ) THEN YUMHANGR  = .; 
 IF (YUMHBKRU  >= 94 ) THEN YUMHBKRU  = .; 
 IF (YUMHCRN2  >= 985 ) THEN YUMHCRN2  = .; 
 IF (YUMHCRYR  >= 85 ) THEN YUMHCRYR  = .; 
 IF (YUMHDEPR  >= 85 ) THEN YUMHDEPR  = .; 




 IF (YUMHFEAR  >= 94 ) THEN YUMHFEAR  = .; 
 IF (YUMHFITE  >= 94 ) THEN YUMHFITE  = .; 
 IF (YUMHFMLY  >= 94 ) THEN YUMHFMLY  = .; 
 IF (YUMHFRND  >= 94 ) THEN YUMHFRND  = .; 
 IF (YUMHOTPP  >= 94 ) THEN YUMHOTPP  = .; 
 IF (YUMHSCHL  >= 94 ) THEN YUMHSCHL  = .; 
 IF (YUMHSOR  >= 94 ) THEN YUMHSOR  = .; 
 IF (YUMHSUIC  >= 85 ) THEN YUMHSUIC  = .; 
 IF (YURSANGR  >= 94 ) THEN YURSANGR  = .; 
 IF (YURSBKRU  >= 94 ) THEN YURSBKRU  = .; 
 IF (YURSDEPR  >= 94 ) THEN YURSDEPR  = .; 
 IF (YURSEATP  >= 94 ) THEN YURSEATP  = .; 
 IF (YURSFEAR  >= 94 ) THEN YURSFEAR  = .; 
 IF (YURSFITE  >= 94 ) THEN YURSFITE  = .; 
 IF (YURSFMLY  >= 94 ) THEN YURSFMLY  = .; 
 IF (YURSFRND  >= 94 ) THEN YURSFRND  = .; 
 IF (YURSIDN2  >= 985 ) THEN YURSIDN2  = .; 
 IF (YURSIDYR  >= 85 ) THEN YURSIDYR  = .; 
 IF (YURSOTPP  >= 94 ) THEN YURSOTPP  = .; 
 IF (YURSSCHL  >= 94 ) THEN YURSSCHL  = .; 
 IF (YURSSOR  >= 94 ) THEN YURSSOR  = .; 
 IF (YURSSUIC  >= 85 ) THEN YURSSUIC  = .; 
 IF (YUSCEMYR  >= 85 ) THEN YUSCEMYR  = .; 
 IF (YUSCPGYR  >= 85 ) THEN YUSCPGYR  = .; 
 IF (YUSWANGR  >= 94 ) THEN YUSWANGR  = .; 
 IF (YUSWBKRU  >= 94 ) THEN YUSWBKRU  = .; 
 IF (YUSWDEPR  >= 94 ) THEN YUSWDEPR  = .; 
 IF (YUSWEATP  >= 94 ) THEN YUSWEATP  = .; 
 IF (YUSWFEAR  >= 94 ) THEN YUSWFEAR  = .; 
 IF (YUSWFITE  >= 94 ) THEN YUSWFITE  = .; 
 IF (YUSWFMLY  >= 94 ) THEN YUSWFMLY  = .; 
 IF (YUSWFRND  >= 94 ) THEN YUSWFRND  = .; 
 IF (YUSWOTPP  >= 94 ) THEN YUSWOTPP  = .; 
 IF (YUSWSCHL  >= 94 ) THEN YUSWSCHL  = .; 
 IF (YUSWSCYR  >= 85 ) THEN YUSWSCYR  = .; 
 IF (YUSWSOR  >= 94 ) THEN YUSWSOR  = .; 
 IF (YUSWSUIC  >= 85 ) THEN YUSWSUIC  = .; 
 IF (YUTPANGR  >= 94 ) THEN YUTPANGR  = .; 
 IF (YUTPBKRU  >= 94 ) THEN YUTPBKRU  = .; 
 IF (YUTPDEPR  >= 94 ) THEN YUTPDEPR  = .; 
 IF (YUTPEATP  >= 94 ) THEN YUTPEATP  = .; 
 IF (YUTPFEAR  >= 94 ) THEN YUTPFEAR  = .; 
 IF (YUTPFITE  >= 94 ) THEN YUTPFITE  = .; 
 IF (YUTPFMLY  >= 94 ) THEN YUTPFMLY  = .; 
 IF (YUTPFRND  >= 94 ) THEN YUTPFRND  = .; 
 IF (YUTPOTPP  >= 94 ) THEN YUTPOTPP  = .; 
 IF (YUTPSCHL  >= 94 ) THEN YUTPSCHL  = .; 
 IF (YUTPSOR  >= 94 ) THEN YUTPSOR  = .; 
 IF (YUTPSTN2  >= 985 ) THEN YUTPSTN2  = .; 
 IF (YUTPSTYR  >= 85 ) THEN YUTPSTYR  = .; 
 IF (YUTPSUIC  >= 85 ) THEN YUTPSUIC  = .; 
RUN ; 







DATA NSDUHr; SET NSDUH.dissr; *Age recode of AGE2 to AGE2r; 
 AGE2r = .; 
  IF (AGE2=1) or (AGE2=2) or (AGE2=3) or (AGE2=4) or (AGE2=5) or 
(AGE2=6) THEN AGE2r = 0; *12 to 17yo;  
  IF (AGE2=7) or (AGE2=8) or (AGE2=9) or (AGE2=10) or (AGE2=11) or 
(AGE2=12) THEN AGE2r = 1; *18 to 25yo; 
  IF (AGE2=13) or (AGE2=14) THEN AGE2r =2; *26 to 34yo; 
  IF (AGE2=15) THEN AGE2r =3; *35 to 49yo; 
  IF (AGE2=16) THEN AGE2r =4; *50 to 64yo; 
  IF (AGE2=17) THEN AGE2r =5; *65yo>; 
  If (AGE2=.) THEN AGE2r =.;  
  LABEL AGE2r = "Age (six categories)"; 
run; 
PROC FORMAT; *AGE2r formatting; 
value AGE2rlab 
      0 = '12-17 Years Old'   
      1 = '18-25 Years Old'   
      2 = '26-34 Years Old'   
      3 = '35-49 Years Old' 
   4 = '50-64 Years Old'  
   5 = '65 or Older'; 
RUN; 
DATA NSDUHr; *AGE2r seeting label; 
 SET NSDUHr; 
FORMAT AGE2r AGE2rlab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing AGE2 v AGE2r variable; 




PROC CONTENTS data=NSDUH.dissr varnum; *Data list; 
run; 
DATA NSDUHr; SET NSDUH.dissr; *Age recode of AGE2 to AGE4r; 
 AGE4r = .; 
  IF (AGE2=1) or (AGE2=2) or (AGE2=3) or (AGE2=4) or (AGE2=5) or 
(AGE2=6) THEN AGE4r = 0; *12 to 17yo;  
  IF (AGE2=7) or (AGE2=8) or (AGE2=9) or (AGE2=10) or (AGE2=11) or 
(AGE2=12) THEN AGE4r = 1; *18 to 25yo; 
  IF (AGE2=13) or (AGE2=14) THEN AGE4r =2; *26 to 34yo; 
  IF (AGE2=15) THEN AGE4r =3; *35 to 49yo; 
  IF (AGE2=16) or (AGE2=17) THEN AGE4r =4; *50yo>; 
  If (AGE2=.) THEN AGE4r =.;  
  LABEL AGE4r = "Age groups (5 categories)"; 
run; 
PROC FORMAT; *AGE4r formatting; 
value AGE4rlab 
      0 = '12-17 Years Old'   
      1 = '18-25 Years Old'   




      3 = '35-49 Years Old' 
   4 = '50 or Older'; 
RUN; 
DATA NSDUHr; *AGE4r seeting label; 
 SET NSDUHr; 
FORMAT AGE4r AGE4rlab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing AGE2 v AGE2r variable; 
TABLES AGE4r CATAG6 AGE4r*CATAG6; 
RUN; 
 
DATA NSDUHr; SET NSDUHr; *Employment recode to 8 cats; 
 EMPLOY8 = .; 
  IF (WRKSTATWK2=1)  THEN EMPLOY8 = 0; *Worked at full-time job, past 
week;  
  IF (WRKSTATWK2=2) THEN EMPLOY8 = 1; *Worked at part time job, past 
week; 
  IF (WRKSTATWK2=3) THEN EMPLOY8 =2; *Has job or volunteer worker, did 
not work past wk; 
  IF (WRKSTATWK2=4) OR (WRKSTATWK2=9) THEN EMPLOY8 =3; *Unemployed/No 
work; 
  IF (WRKSTATWK2=5) THEN EMPLOY8 =4; *Disabled; 
  IF (WRKSTATWK2=6) THEN EMPLOY8 =5; *Keeping house full-time; 
  IF (WRKSTATWK2=7) THEN EMPLOY8 =6; *In school/training; 
  IF (WRKSTATWK2=8) THEN EMPLOY8 =7; *Retired; 
  If (WRKSTATWK2=.) THEN EMPLOY8 =.;  
  LABEL EMPLOY8 = "Employment type (8 categories)"; 
run; 
PROC FORMAT; *EMPLOY8 formatting label; 
value EMPLOY8lab 
   0 = 'Worked at full-time job, past week'   
      1 = 'Worked at part time job, past week'   
      2 = 'Has job or volunteer worker, did not work past wk'   
      3 = 'Unemployed/on layoff, looking for work/No job, other reason'   
      4 = 'Disabled'   
      5 = 'Keeping house full-time'   
      6 = 'In school/training'   
      7 = 'Retired'; 
RUN; 
DATA NSDUHr; *EMPLOY8 setting label; 
 SET NSDUHr; 
FORMAT EMPLOY8 EMPLOY8lab.; 
RUN; 
DATA NSDUHr; SET NSDUHr; *Employment recode to 7 cats; 
 EMPLOY7 = .; 
  IF (WRKSTATWK2=1)  THEN EMPLOY7 = 0; *Worked at full-time job, past 
week;  
  IF (WRKSTATWK2=2) OR (WRKSTATWK2=3) THEN EMPLOY7 = 1; *Part time or 
some type of employment; 
  IF (WRKSTATWK2=4) OR (WRKSTATWK2=9) THEN EMPLOY7 =2; *Unemployed/No 
work; 
  IF (WRKSTATWK2=5) THEN EMPLOY7 =3; *Disabled; 




  IF (WRKSTATWK2=7) THEN EMPLOY7 =5; *In school/training; 
  IF (WRKSTATWK2=8) THEN EMPLOY7 =6; *Retired; 
  If (WRKSTATWK2=.) THEN EMPLOY7 =.;  
  LABEL EMPLOY7 = "Employment type (7 categories)"; 
run; 
PROC FORMAT; *EMPLOY7 formatting; 
value EMPLOY7lab 
   0 = 'Worked at full-time job, past week'   
      1 = 'Worked at part time job, past week/Has job or volunteer 
worker, did not work past wk'   
      2 = 'Unemployed/on layoff, looking for work/No job, other reason'   
      3 = 'Disabled'   
      4 = 'Keeping house full-time'   
      5 = 'In school/training'   
      6 = 'Retired'; 
RUN; 
DATA NSDUHr; *EMPLOY7 setting label; 
 SET NSDUHr; 
FORMAT EMPLOY7 EMPLOY7lab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing employment recodes; 




DATA NSDUHr; SET NSDUHr; *Employment recode to 6 cats; 
 EMPLOY6 = .; 
  IF (WRKSTATWK2=1)  THEN EMPLOY6 = 0; *Worked at full-time job, past 
week;  
  IF (WRKSTATWK2=2) OR (WRKSTATWK2=3) THEN EMPLOY6 = 1; *Part time or 
some type of employment; 
  IF (WRKSTATWK2=4) OR (WRKSTATWK2=9) THEN EMPLOY6 =2; *Unemployed/No 
work; 
  IF (WRKSTATWK2=5) THEN EMPLOY6 =3; *Disabled; 
  IF (WRKSTATWK2=6) OR (WRKSTATWK2=7) THEN EMPLOY6 =4; *Keeping house 
full-time and in school/training; 
  IF (WRKSTATWK2=8) THEN EMPLOY6 =5; *Retired; 
  If (WRKSTATWK2=.) THEN EMPLOY6 =.;  
  LABEL EMPLOY6 = "Employment type (6 categories)"; 
run; 
PROC FORMAT; *EMPLOY6 formatting; 
value EMPLOY6lab 
   0 = 'Worked at full-time job, past week'   
      1 = 'Worked at part time job, past week/Has job or volunteer 
worker, did not work past wk'   
      2 = 'Unemployed/on layoff, looking for work/No job, other reason'   
      3 = 'Disabled'   
      4 = 'Other (Keeping house full-time and In school/training)'   
      5 = 'Retired'; 
RUN; 
DATA NSDUHr; *EMPLOY6 setting label; 
 SET NSDUHr; 





PROC FREQ DATA=NSDUHr; *testing employment recodes; 
TABLES WRKSTATWK2 EMPLOY8 EMPLOY7 EMPLOY6 EMPLOY8*EMPLOY7 




DATA NSDUHr; SET NSDUHr; *Employment last week recode; 
  EMPLOYLW= .; 
  IF (WRKDPSTWK=1)  THEN EMPLOYLW = 1; *Yes;  
  IF (WRKDPSTWK=2) OR (WRKDPSTWK=4) THEN EMPLOYLW = 0; *No; 
  If (WRKDPSTWK=.) THEN EMPLOYLW =.;  
  LABEL EMPLOYLW = "Employed last week (2 categories)"; 
run; 
PROC FORMAT; *EMPLOYLW formatting; 
value EMPLOYLWlab 
   0 = 'No'   
      1 = 'Yes'; 
RUN; 
DATA NSDUHr; *EMPLOYLW setting label; 
 SET NSDUHr; 
FORMAT EMPLOYLW EMPLOYLWlab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing employment recodes; 




DATA NSDUHr; SET NSDUHr; *Ever BOOKED recode; 
  BOOKED1= .; 
  IF (BOOKED=2)  THEN BOOKED1 = 0; *No;  
  IF (BOOKED=1) OR (BOOKED=3) THEN BOOKED1 = 1; *Yes; 
  If (BOOKED=.) THEN BOOKED1 =.;  
  LABEL BOOKED1 = "Ever arrested and booked for breaking the law (2 
categories)"; 
run; 
PROC FORMAT; *BOOKED1 formatting; 
value BOOKED1lab 
   0 = 'No'   
      1 = 'Yes'; 
RUN; 
DATA NSDUHr; *BOOKED1 setting label; 
 SET NSDUHr; 
FORMAT BOOKED1 BOOKED1lab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing employment recodes; 
TABLES BOOKED BOOKED1 BOOKED*BOOKED1; 
RUN; 
 
DATA NSDUHr; SET NSDUHr; *NEWRACE2 recodes; 
race4r=.;  
IF (NEWRACE2=1) then race4r=1; 




IF (NEWRACE2=7) then race4r=3; 
IF (NEWRACE2=3) or (NEWRACE2=4) or (NEWRACE2=5) or (NEWRACE2=6) then 
race4r=4; 
IF (NEWRACE2=.) then race4r=.;  
 LABEL race4r="Race (4 categories)";  
run; 
PROC FORMAT; *NEWRACE2 formatting; 
value race4rlab 
   1 = 'White'   
      2 = 'Black' 
   3 = 'Hispanic' 
   4 = 'Other'; 
RUN; 
DATA NSDUHr; *NEWRACE2 setting label; 
 SET NSDUHr; 
FORMAT race4r race4rlab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing race recodes; 
TABLES NEWRACE2 race4r NEWRACE2*race4r; 
RUN; 
 
DATA NSDUHr; SET NSDUHr; *SEXIDENT recodes; 
sexidenr=.;  
IF (SEXIDENT=1) then sexidenr=1; 
IF (SEXIDENT=2) or (SEXIDENT=3) then sexidenr=2; 
IF (SEXIDENT=.) then sexidenr=.;  
 LABEL sexidenr="Sexual identity (2 categories)";  
run; 
PROC FORMAT; *sexidenr formatting; 
value sexidenrlab 
   1 = 'Heterosexual'   
      2 = 'Sexual minority (lesbian/gay/bi)'; 
RUN; 
DATA NSDUHr; *sexidenr setting label; 
 SET NSDUHr; 
FORMAT sexidenr sexidenrlab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing sexual identity recodes; 
TABLES SEXIDENT sexidenr SEXIDENT*sexidenr; 
RUN; 
 
DATA NSDUHr; SET NSDUHr; *HEALTH2 recodes; 
healthre=.;  
IF (HEALTH2=4) then healthre=1; 
IF (HEALTH2=3) then healthre=2; 
IF (HEALTH2=2) or (HEALTH2=1) then healthre=3; 
IF (HEALTH2=.) then healthre=.;  
 LABEL healthre="Overall health (3 categories)";  
run; 
PROC FORMAT; *healthre formatting; 
value healthrelab 
   1 = 'Poor/Fair'   




   3 = 'Very Good/Excellent'; 
RUN; 
DATA NSDUHr; *healthre setting label; 
 SET NSDUHr; 
FORMAT healthre healthrelab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing overall health recodes; 




DATA NSDUHr; SET NSDUHr; *INCOME recodes; 
incomere=.;  
IF (INCOME=1) then incomere=1; 
IF (INCOME=2) then incomere=2; 
IF (INCOME=3) or (INCOME=4) then incomere=3; 
IF (INCOME=.) then incomere=.;  
 LABEL incomere="Income (3 categories)";  
run; 
PROC FORMAT; *incomere formatting; 
value incomerelab 
   1 = 'Less than $20,000'   
      2 = '$20,000 to $49,999' 
   3 = '$50,000 or More'; 
RUN; 
DATA NSDUHr; *incomere setting label; 
 SET NSDUHr; 
FORMAT incomere incomerelab.; 
RUN; 
PROC FREQ DATA=NSDUHr; *testing oincome recodes; 





DATA NSDUHr; SET NSDUHr; *Other substance dependence or abuse recodes; 
Othdrug=.;  
IF (ABODCOC=0) or (UDPYINH=0) or (UDPYMTH=0) or (UDPYTRQ=0) or 
(UDPYSTM=0) or (UDPYHAL=0) or (UDPYSED=0)  then Othdrug=0; 
IF (ABODCOC=1) or (UDPYINH=1) or (UDPYMTH=1) or (UDPYTRQ=1) or 
(UDPYSTM=1) or (UDPYHAL=1) or (UDPYSED=1)  then Othdrug=1; 
IF (ABODCOC=.) or (UDPYINH=.) or (UDPYMTH=.) or (UDPYTRQ=.) or 
(UDPYSTM=.) or (UDPYHAL=.) or (UDPYSED=.)  then Othdrug=.;  
 LABEL Othdrug="Substance dependence/abuse (3 categories)";  
run; 
PROC FORMAT; *Othdrug formatting; 
value Othdruglab 
   0 = 'No'   
      1 = 'Yes'; 
RUN; 
DATA NSDUHr; *Othdrug setting label; 
 SET NSDUHr; 






ODS PDF file='NSDUH_2017_Descriptives_04112019.pdf'; 
OPTIONS ls=72; 
PROC SURVEYFREQ DATA=NSDUHr; *Descriptives; 
where AGE4r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
TABLES AGE4R IRSEX RACE4R SEXIDENR EDUHIGHCAT INCOMERE EMPLOYLW BOOKED1 
PRVHLTIN HEALTHRE PDEN10 COUTYP4 SPDYR SUICTHNK  
DNICNSP ABODALC ABODMRJ OTHDRUG; 
run; 




ODS PDF file='NSDUH_2017_Data_List.pdf'; 
OPTIONS ls=72; 
PROC CONTENTS data=NSDUHr varnum; *Data list of new set; 
run; 
ODS PDF close; 
 
 
PROC SURVEYFREQ DATA=NSDUHr; *Descriptives; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
TABLES IRSEX*UDPYOPI IRSEX*UDPYHRPNR; 
run; 
 
PROC SURVEYFREQ DATA=NSDUHr; *Descriptives; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
TABLES NEWRACE2*UDPYOPI NEWRACE2*UDPYHRPNR; 
run; 
 
*--------------------------------Descriptives and single entry---------
-------------------------------------------------; 
ODS PDF file='NSDUH_2017_Descriptives_SingleEntryModels_02132019.pdf'; 
OPTIONS ls=72; 
PROC SURVEYFREQ DATA=NSDUHr; *Descriptives; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
TABLES AGE2r AGE4r IRSEX NEWRACE2 SEXIDENT EDUHIGHCAT INCOME EMPLOY6 





DNICNSP ABODALC ABODMRJ ABODCOC UDPYINH UDPYMTH UDPYTRQ UDPYSTM UDPYHAL 
UDPYSED UDPYPSY UDPYOPI ; 
run; 
                                                                 
*--------------------------------single entry indicators and factors---
-------------------------------------------------; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with age categories; 
where AGE2r >= 1;                         
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C;                  
CLASS AGE2r (ref='65 or Older'); 
MODEL UDPYOPI (desc) = AGE2r / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with sex-gender categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS IRSEX (ref=last); 
MODEL UDPYOPI (desc) = IRSEX / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with income categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS INCOME (ref=last); 
MODEL UDPYOPI (desc) = INCOME / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with race/ethnicity categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS NEWRACE2 (ref='5 - NonHisp Asian'); 
MODEL UDPYOPI (desc) = NEWRACE2 / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with sexual identity 
categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS SEXIDENT (ref='1 - Heterosexual, that is, straight' ); 
MODEL UDPYOPI (desc) = SEXIDENT / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with employment categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 




MODEL UDPYOPI (desc) = WRKSTATWK2 / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with employment 7 categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS EMPLOY7 (ref='Worked at full-time job, past week'); 
MODEL UDPYOPI (desc) = EMPLOY7 / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with employment 8 categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS EMPLOY8 (ref='Keeping house full-time') ; 
MODEL UDPYOPI (desc) = EMPLOY8 / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with worked last week; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS WRKDPSTYR (ref='1 - Yes'); 
MODEL UDPYOPI (desc) = WRKDPSTYR / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with last week categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS EMPLOYLW (ref='Yes'); 
MODEL UDPYOPI (desc) = EMPLOYLW / expb clodds rsquare; 
RUN; 
 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with ever arrested categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS BOOKED1 (ref='No' ); 
MODEL UDPYOPI (desc) = BOOKED1 / expb clodds rsquare; 
RUN; 
 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with ever on probation 
categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS PROBATON (ref='2 - No' ); 








PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with overall health category; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS HEALTH2 (ref='1 - Excellent'); 
MODEL UDPYOPI (desc) = HEALTH2 / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with serious psychological 
distress indicator categories; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS SPDYR (ref='0 - No'); 
MODEL UDPYOPI (desc) = SPDYR / expb clodds rsquare; 
RUN; 
 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Best model with nic dep, ALC NOT SIG, 
marj, coke, inhalant, meth, trq, stm depabu; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS SUICTHNK (ref='2 - No'); 
MODEL UDPYOPI (desc) = SUICTHNK / expb clodds rsquare; 
RUN; 
 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with any health insurance; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS ANYHLTI2 (ref=last); 
MODEL UDPYOPI (desc) = ANYHLTI2 / expb clodds rsquare; 
RUN; 
 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with private health insurance; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS PRVHLTIN (ref=last); 
MODEL UDPYOPI (desc) = PRVHLTIN / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with private health insurance; 
where AGE2r >= 1; 
STRATA VESTR; 





CLASS PRVHLTIN (ref=first); 




PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with psychotherapeutic 
dependence or abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS PDEN10 (ref=last); 
MODEL UDPYOPI (desc) = PDEN10/ expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with psychotherapeutic 
dependence or abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS COUTYP4 (ref=last); 
MODEL UDPYOPI (desc) = COUTYP4/ expb clodds rsquare;; 
RUN; 
 
*----------------------------substance dependence and use--------------
--------------------------------; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with nicotine dependence using 
NDSS and FTND; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS DNICNSP (ref='0 - No'); 
MODEL UDPYOPI (desc) = DNICNSP / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with alcohol dependence or 
abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS ABODALC (ref='0 - No/Unknown'); 
MODEL UDPYOPI (desc) = ABODALC / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with marijuana dependence or 
abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS ABODMRJ (ref='0 - No/Unknown'); 





PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with cocaine dependence or 
abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS ABODCOC (ref='0 - No/Unknown'); 
MODEL UDPYOPI (desc) = ABODCOC / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with inhalant dependence or 
abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS UDPYINH (ref='0 - No'); 
MODEL UDPYOPI (desc) = UDPYINH / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with methamphetamine dependence 
or abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS UDPYMTH (ref='0 - No'); 
MODEL UDPYOPI (desc) = UDPYMTH / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with tranquilizer dependence or 
abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS UDPYTRQ (ref='0 - No') ; 
MODEL UDPYOPI (desc) = UDPYTRQ / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with stimulant dependence or 
abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS UDPYSTM (ref='0 - No'); 
MODEL UDPYOPI (desc) = UDPYSTM / expb clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with hallucinogen dependence or 
abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS UDPYHAL (ref=first); 





PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with sedative dependence or 
abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS UDPYSED (ref=first); 
MODEL UDPYOPI (desc) = UDPYSED / expb clodds rsquare;; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Model with psychotherapeutic 
dependence or abuse; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS UDPYPSY (ref=first); 
MODEL UDPYOPI (desc) = UDPYPSY / expb clodds rsquare;; 
RUN; 
ODS PDF close; 
 
 
*--------------------------------------Block entry method for sig 
model------------------------------------------; 
ODS PDF file='NSDUH_2017_PrelimFinalModels_BlockEntered_03152019.pdf'; 
OPTIONS ls=72; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Demo indicators; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS AGE2r (ref='65 or Older') IRSEX (ref=last) INCOME (ref=last) 
EMPLOY8 (ref='Keeping house full-time') PDEN10 (ref=last) 
NEWRACE2 (ref='5 - NonHisp Asian') EDUHIGHCAT (ref='4 - College 
graduate') SEXIDENT (ref='1 - Heterosexual, that is, straight'); 
MODEL UDPYOPI (desc) = AGE2r IRSEX NEWRACE2 SEXIDENT EDUHIGHCAT INCOME 
PDEN10 EMPLOY8 / expb clodds rsquare; 
RUN; 
 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Demo indicators; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS AGE2r (ref='65 or Older') IRSEX (ref=last) INCOME (ref=last) 
EMPLOY8 (ref='Keeping house full-time') PDEN10 (ref=last) 
NEWRACE2 (ref='5 - NonHisp Asian') EDUHIGHCAT (ref='4 - College 
graduate') SEXIDENT (ref='1 - Heterosexual, that is, straight' ) 
BOOKED1 (ref='No'); 
MODEL UDPYOPI (desc) = AGE2r IRSEX NEWRACE2 SEXIDENT EDUHIGHCAT INCOME 






PROC SURVEYLOGISTIC DATA=NSDUHr; *Health and health insurance 
indicators; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS AGE2r (ref='65 or Older') IRSEX (ref=last) INCOME (ref=last) 
EMPLOY8 (ref='Keeping house full-time') PDEN10 (ref=last) 
NEWRACE2 (ref='5 - NonHisp Asian') EDUHIGHCAT (ref='4 - College 
graduate') SEXIDENT (ref='1 - Heterosexual, that is, straight' ) 
HEALTH2 (ref='1 - Excellent') SPDYR (ref='0 - No') SUICTHNK (ref='2 - 
No') PRVHLTIN (ref=first); 
MODEL UDPYOPI (desc) = AGE2r IRSEX NEWRACE2 SEXIDENT EDUHIGHCAT INCOME 




PROC SURVEYLOGISTIC DATA=NSDUHr; *all single entry sig substance 
dependence and/or abuse var FULL MODEL FINAL; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS AGE2r (ref='65 or Older') IRSEX (ref=last) INCOME (ref=last) 
EMPLOY8 (ref='Keeping house full-time')  
NEWRACE2 (ref='5 - NonHisp Asian') EDUHIGHCAT (ref='4 - College 
graduate') SEXIDENT (ref='1 - Heterosexual, that is, straight' ) 
HEALTH2 (ref='1 - Excellent') SPDYR (ref='0 - No') SUICTHNK (ref='2 - 
No') PRVHLTIN (ref=first) PDEN10 (ref=last) 
DNICNSP (ref='0 - No') ABODALC (ref='0 - No/Unknown')ABODMRJ (ref='0 - 
No/Unknown') ABODCOC (ref='0 - No/Unknown') 
UDPYINH (ref='0 - No') UDPYMTH (ref='0 - No') UDPYTRQ (ref='0 - No') 
UDPYSTM (ref='0 - No'); 
MODEL UDPYOPI (desc) = AGE2r IRSEX NEWRACE2 SEXIDENT EDUHIGHCAT INCOME 
PDEN10 EMPLOY8 BOOKED1 HEALTH2 SPDYR SUICTHNK PRVHLTIN  
DNICNSP ABODALC ABODMRJ ABODCOC UDPYINH UDPYMTH UDPYTRQ UDPYSTM / expb 
clodds rsquare; 
RUN; 






*------------------Employment and sexual identity removed--------------
-----; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Demo indicators; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS AGE2r (ref='65 or Older') IRSEX (ref=last) INCOME (ref=last) 




EDUHIGHCAT (ref='4 - College graduate'); 
MODEL UDPYOPI (desc) = AGE2r IRSEX INCOME NEWRACE2 EDUHIGHCAT / expb 
clodds rsquare; 
RUN; 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Health indicators; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS AGE2r (ref='65 or Older') IRSEX (ref=last) INCOME (ref=last) 
NEWRACE2 (ref='5 - NonHisp Asian') EDUHIGHCAT (ref='4 - College 
graduate')  
HEALTH2 (ref='1 - Excellent') SPDYR (ref='0 - No') SUICTHNK (ref='2 - 
No') ; 
MODEL UDPYOPI (desc) = AGE2r IRSEX INCOME NEWRACE2 EDUHIGHCAT HEALTH2 
SPDYR SUICTHNK / expb clodds rsquare; 
RUN; 
 
PROC SURVEYLOGISTIC DATA=NSDUHr; *Best model all single entry sig 
substance dependence and/or abuse var; 
where AGE2r >= 1; 
STRATA VESTR; 
CLUSTER VEREP;  
WEIGHT ANALWT_C; 
CLASS AGE2r (ref='65 or Older') IRSEX (ref=last) INCOME (ref=last) 
NEWRACE2 (ref='5 - NonHisp Asian') EDUHIGHCAT (ref='4 - College 
graduate') 
HEALTH2 (ref='1 - Excellent') SPDYR (ref='0 - No') SUICTHNK (ref='2 - 
No')  DNICNSP (ref='0 - No') ABODALC (ref='0 - No/Unknown') 
ABODMRJ (ref='0 - No/Unknown') ABODCOC (ref='0 - No/Unknown') UDPYINH 
(ref='0 - No') UDPYMTH (ref='0 - No') UDPYTRQ (ref='0 - No') 
UDPYSTM (ref='0 - No') ; 
MODEL UDPYOPI (desc) = AGE2r IRSEX INCOME NEWRACE2 EDUHIGHCAT HEALTH2 
SPDYR SUICTHNK DNICNSP ABODALC  
ABODMRJ ABODCOC UDPYINH UDPYMTH UDPYTRQ UDPYSTM / expb clodds rsquare; 
RUN; 





SAS 9.4 SYNTAX AND COMMAND PROCEDURE FOR CONVERTING DATA TO 
USE IN MPLUS 8.2  
 
DATA NSDUHdm; set NSDUHd; *setting array up for LCA in Mplus; 
ARRAY miss (21)  
AGE4R IRSEX RACE4R SEXIDENR EDUHIGHCAT INCOMERE EMPLOYLW BOOKED1 
PRVHLTIN HEALTHRE PDEN10 COUTYP4 SPDYR SUICTHNK  
DNICNSP ABODALC ABODMRJ OTHDRUG UDPYOPI UDPYHRPNR INCOME; 
   do i=1 to 21; 
      if miss {i}= . then miss {i}=999; 
   end; 
   drop i; 
 
keep QUESTID2 ANALWT_C VEREP VESTR AGE4R IRSEX RACE4R SEXIDENR 
EDUHIGHCAT INCOMERE EMPLOYLW BOOKED1 PRVHLTIN HEALTHRE PDEN10 COUTYP4  




ODS PDF file='NSDUH_2017_Data_List_LCA_deletedCases_0415A.pdf'; 
OPTIONS ls=72; 
PROC CONTENTS data=NSDUHdm varnum;  
*Data list of new set with deleted cases; 
run; 
ODS PDF close; 
 
*--------------------------Export for Mplus --------------------------; 
proc export data=NSDUHdm 
outfile='C:\Users\famon\OneDrive\Docs\StatsProjects\NSDUH\2017\NSDUH201








MPLUS 8.2 SYNTAX AND COMMAND PROCEDURES FOR PERSON-
CENTERED APPROACH IN CHAPTER IV: ONE CLASS MODEL 
 
TITLE: Opioid risk indicators and profiles 1-class solution 
 
DATA: FILE IS "C:\...\NSDUH2017_filename.csv"; 
 
VARIABLE: NAMES ARE QUESTID2, DNICNSP, ABODALC, ABODMRJ, 
UDPYOPI, UDPYHRPR, SUICTHNK, SPDYR, IRSEX, EDUHI4, EDUHI3, 
PRVHLTIN, PDEN10, COUTYP4, ANALWT, VESTR, VEREP, AGE4r, 
EMPLOYLW, BOOKED1, race4r, sexidenr, healthre, incomere, Othdrug, INCOME; 
 
USEVARIABLES ARE AGE4r IRSEX race4r INCOME EDUHI4 SPDYR SUICTHNK  
healthre sexidenr EMPLOYLW BOOKED1 PRVHLTIN PDEN10 UDPYHRPR; 
USEOBSERVATIONS = (UDPYOPI == 1); 
 
CLASSES = c(1); 
        
Categorical = AGE4r IRSEX race4r INCOME EDUHI4 SPDYR SUICTHNK  
healthre sexidenr EMPLOYLW BOOKED1 PRVHLTIN PDEN10 UDPYHRPR; 
 
IDVAR IS QUESTID2; 
WEIGHT IS ANALWT; 
CLUSTER IS VEREP; 
STRATIFICATION IS VESTR; 
 
Missing is all (999); 
 
ANALYSIS: 
type = mixture complex missing; 
starts = 1000 100; 
stiterations = 50; 
 








MPLUS 8.2 SYNTAX AND COMMAND PROCEDURES FOR PERSON-
CENTERED APPROACH IN CHAPTER IV: MORE THAN ONE CLASS MODELS 
 
TITLE: Opioid risk indicators and profiles x-class solution 
 
DATA: FILE IS "C:\...\NSDUH2017_filename.csv"; 
 
VARIABLE: NAMES ARE QUESTID2, DNICNSP, ABODALC, ABODMRJ, 
UDPYOPI, UDPYHRPR, SUICTHNK, SPDYR, IRSEX, EDUHI4, EDUHI3, 
PRVHLTIN, PDEN10, COUTYP4, ANALWT, VESTR, VEREP, AGE4r, 
EMPLOYLW, BOOKED1, race4r, sexidenr, healthre, incomere, Othdrug, INCOME; 
 
USEVARIABLES ARE AGE4r IRSEX race4r INCOME EDUHI4 SPDYR SUICTHNK  
healthre sexidenr EMPLOYLW BOOKED1 PRVHLTIN PDEN10 UDPYHRPR; 
USEOBSERVATIONS = (UDPYOPI == 1); 
 
CLASSES = c(x);  
!x=n+1where n is any positive number one or greater for number of desired classes; 
        
Categorical = AGE4r IRSEX race4r income EDUHI4 SPDYR SUICTHNK  
healthre sexidenr EMPLOYLW BOOKED1 PRVHLTIN PDEN10 UDPYHRPR; 
 
IDVAR IS QUESTID2; 
WEIGHT IS ANALWT; 
CLUSTER IS VEREP; 
STRATIFICATION IS VESTR; 
 
Missing is all (999); 
 




type = mixture complex missing; 
starts = 1000 100; 
stiterations = 50; 
 
 
OUTPUT:  SAMP stand cint tech11; 
